data_2mfv_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2mfv _Structure_validation_residue.Date_analyzed 2016-10-08 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.371 0 CA-C-O 116.573 -2.237 . . . . 42.210000000000001 116.846 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.26 175.36 34.71 Favored Glycine 0 C--N 1.363 2.072 1 CA-C-N 124.782 4.291 . . . . 72.340000000000003 112.099 -170.691 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.53 49.53 3.22 Favored 'Trans proline' 0 C--N 1.352 0.717 0 CA-C-N 122.479 3.139 . . . . 74.219999999999999 115.659 -178.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . 0.419 ' N ' ' O ' ' A' ' 11' ' ' GLY . 37.8 mt -155.56 -156.16 0.62 Allowed 'General case' 0 C--N 1.358 0.965 0 CA-C-O 115.436 -2.221 . . . . 70.129999999999995 106.832 -177.04 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.03 105.49 9.61 Favored 'General case' 0 C--N 1.352 0.685 0 CA-C-N 122.06 2.209 . . . . 52.109999999999999 111.102 -175.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.14 -36.66 0.02 OUTLIER Glycine 0 C--N 1.373 2.632 0 N-CA-C 118.406 2.122 . . . . 74.340000000000003 118.406 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -116.31 177.4 4.7 Favored 'General case' 0 C--N 1.349 0.584 0 N-CA-C 105.474 -2.047 . . . . 75.040000000000006 105.474 176.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 7.4 tt0 -58.67 -32.48 69.14 Favored 'General case' 0 C--N 1.348 0.536 0 CA-C-O 117.931 -1.033 . . . . 73.540000000000006 111.816 179.275 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 6.1 mmt -109.63 57.49 0.61 Allowed 'General case' 0 C--N 1.359 0.986 0 CA-C-N 119.924 1.238 . . . . 60.439999999999998 111.655 -172.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 67.88 108.16 0.02 OUTLIER Glycine 0 C--N 1.358 1.767 0 CA-C-O 115.998 -2.557 . . . . 73.430000000000007 109.962 177.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -107.91 -174.18 22.09 Favored Glycine 0 C--N 1.354 1.572 0 CA-C-N 121.505 2.653 . . . . 60.340000000000003 111.198 -170.319 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 8.7 tt -96.42 22.66 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.735 0 CA-C-N 120.412 2.106 . . . . 75.340000000000003 111.022 176.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -124.56 125.69 44.6 Favored 'General case' 0 C--N 1.365 1.271 0 CA-C-N 121.171 1.805 . . . . 70.109999999999999 111.138 -174.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 7.0 t . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 75.019999999999996 111.091 -179.985 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 1.636 0 N-CA-C 120.158 2.823 . . . . 55.409999999999997 120.158 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -156.48 174.22 34.25 Favored Glycine 0 C--N 1.348 1.218 1 CA-C-N 124.817 4.308 . . . . 74.319999999999993 111.191 -173.437 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -79.94 44.55 1.74 Allowed 'Trans proline' 0 C--N 1.369 1.636 0 CA-C-N 122.054 2.927 . . . . 71.209999999999994 115.017 -177.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . 0.44 ' N ' ' O ' ' A' ' 11' ' ' GLY . 43.3 mt -148.96 -154.5 0.56 Allowed 'General case' 0 C--N 1.354 0.788 0 N-CA-C 106.477 -1.675 . . . . 73.040000000000006 106.477 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.97 88.58 2.91 Favored 'General case' 0 C--N 1.362 1.142 0 C-N-CA 125.91 1.684 . . . . 72.420000000000002 111.151 -176.558 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -138.31 -14.78 0.7 Allowed Glycine 0 CA--C 1.528 0.845 0 O-C-N 118.724 -2.485 . . . . 71.450000000000003 117.305 171.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -129.39 175.67 8.57 Favored 'General case' 0 C--N 1.359 0.984 0 CA-C-N 121.372 2.586 . . . . 75.200000000000003 106.236 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -58.57 -36.95 74.75 Favored 'General case' 0 C--O 1.219 -0.546 0 CA-C-O 117.807 -1.092 . . . . 73.349999999999994 110.944 178.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 78.3 mtm -109.16 66.83 0.64 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 119.551 1.069 . . . . 72.540000000000006 111.396 -175.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 60.67 91.13 0.02 OUTLIER Glycine 0 C--N 1.352 1.448 0 CA-C-O 116.599 -2.223 . . . . 73.099999999999994 110.041 173.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.44 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -92.22 -174.34 42.09 Favored Glycine 0 C--O 1.201 -1.948 0 CA-C-O 116.204 -2.442 . . . . 74.319999999999993 115.091 -177.263 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.8 tt -96.84 24.06 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.371 1.538 0 CA-C-N 118.645 1.222 . . . . 74.319999999999993 111.257 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.4 p -120.57 124.44 45.32 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-N 120.744 1.611 . . . . 73.230000000000004 111.151 -174.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 15.4 t . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.244 -0.435 . . . . 75.329999999999998 111.153 179.978 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 1.782 0 N-CA-C 119.205 2.442 . . . . 61.200000000000003 119.205 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -158.72 175.25 35.78 Favored Glycine 0 C--N 1.354 1.571 1 CA-C-N 125.813 4.807 . . . . 74.319999999999993 109.764 -174.026 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -80.31 45.18 1.9 Allowed 'Trans proline' 0 C--N 1.351 0.71 0 CA-C-N 121.097 2.449 . . . . 74.200000000000003 115.504 -176.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . 0.441 ' N ' ' O ' ' A' ' 11' ' ' GLY . 47.6 mt -149.95 -154.48 0.56 Allowed 'General case' 0 C--N 1.36 1.022 0 CA-C-O 116.467 -1.73 . . . . 74.140000000000001 107.017 -179.019 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.97 88.86 2.96 Favored 'General case' 0 C--N 1.354 0.778 0 C-N-CA 125.674 1.59 . . . . 73.140000000000001 111.108 -176.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -138.8 -14.58 0.66 Allowed Glycine 0 CA--C 1.529 0.909 0 O-C-N 118.698 -2.501 . . . . 63.299999999999997 117.271 171.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -129.13 174.96 9.09 Favored 'General case' 0 C--N 1.352 0.69 0 CA-C-N 121.04 2.42 . . . . 72.420000000000002 105.74 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -58.65 -35.13 72.04 Favored 'General case' 0 C--O 1.219 -0.525 0 CA-C-O 117.682 -1.151 . . . . 71.230000000000004 110.731 179.306 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 3.6 mmt -109.76 63.23 0.6 Allowed 'General case' 0 C--N 1.355 0.816 0 CA-C-N 119.419 1.008 . . . . 70.239999999999995 111.656 -174.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.67 91.17 0.02 OUTLIER Glycine 0 C--N 1.352 1.421 0 CA-C-O 116.567 -2.241 . . . . 62.310000000000002 110.093 175.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.441 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -92.87 -175.06 41.21 Favored Glycine 0 N--CA 1.491 2.34 0 CA-C-O 115.617 -2.768 . . . . 65.200000000000003 115.052 -177.006 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 12.1 tt -96.13 24.38 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.844 0 CA-C-N 120.124 1.962 . . . . 75.200000000000003 111.051 -179.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.4 p -120.66 124.59 45.59 Favored 'General case' 0 C--N 1.359 1.01 0 CA-C-N 121.346 1.885 . . . . 64.25 111.132 -175.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.5 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.249 -0.432 . . . . 71.040000000000006 111.139 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.703 0 CA-C-O 116.506 -2.274 . . . . 64.319999999999993 117.844 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -145.03 178.63 22.69 Favored Glycine 0 C--N 1.368 2.359 0 CA-C-N 123.347 3.574 . . . . 64.340000000000003 110.995 -174.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -79.38 44.62 1.74 Allowed 'Trans proline' 0 C--N 1.357 1.011 0 CA-C-N 121.78 2.79 . . . . 74.040000000000006 116.375 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . 0.452 ' N ' ' O ' ' A' ' 11' ' ' GLY . 39.3 mt -149.24 -156.34 0.71 Allowed 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 106.381 -1.711 . . . . 73.209999999999994 106.381 -176.203 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.19 100.92 7.1 Favored 'General case' 0 C--N 1.353 0.721 0 C-N-CA 125.079 1.352 . . . . 73.530000000000001 111.095 -176.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -149.53 -32.04 0.05 OUTLIER Glycine 0 C--N 1.347 1.151 0 O-C-N 119.299 -2.125 . . . . 51.020000000000003 116.776 178.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -119.67 179.22 4.3 Favored 'General case' 0 C--N 1.357 0.904 0 N-CA-C 104.743 -2.318 . . . . 72.239999999999995 104.743 178.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -64.12 -29.82 70.93 Favored 'General case' 0 C--N 1.349 0.558 0 CA-C-O 117.382 -1.294 . . . . 74.120000000000005 111.664 178.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 66.3 mmm -110.6 59.29 0.61 Allowed 'General case' 0 C--N 1.357 0.92 0 CA-C-N 119.597 1.089 . . . . 73.230000000000004 110.555 -176.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 65.99 98.74 0.02 OUTLIER Glycine 0 C--N 1.354 1.56 0 CA-C-O 117.978 -1.456 . . . . 75.109999999999999 110.428 174.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.452 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -94.2 -177.58 38.98 Favored Glycine 0 CA--C 1.491 -1.447 0 CA-C-O 115.598 -2.779 . . . . 63.299999999999997 113.183 -171.549 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.7 tt -97.58 24.85 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.992 0 CA-C-N 120.726 2.263 . . . . 73.439999999999998 111.289 175.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.2 p -124.16 125.83 45.12 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.593 1.088 . . . . 65.239999999999995 111.113 -176.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.181 -0.463 . . . . 72.310000000000002 111.121 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.172 0 N-CA-C 120.027 2.771 . . . . 70.109999999999999 120.027 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -150.56 178.68 27.85 Favored Glycine 0 C--N 1.366 2.204 0 CA-C-N 124.069 3.935 . . . . 75.510000000000005 112.598 -175.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -81.29 49.62 3.27 Favored 'Trans proline' 0 N--CA 1.449 -1.118 1 CA-C-N 124.298 4.049 . . . . 74.420000000000002 116.208 -178.046 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . 0.449 ' N ' ' O ' ' A' ' 11' ' ' GLY . 59.6 mt -154.01 -157.17 0.75 Allowed 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 116.703 -1.617 . . . . 74.230000000000004 106.91 -176.206 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.13 104.71 9.36 Favored 'General case' 0 C--N 1.358 0.976 0 CA-C-N 121.612 2.005 . . . . 71.530000000000001 111.095 -176.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.15 -35.78 0.02 OUTLIER Glycine 0 C--N 1.369 2.367 0 N-CA-C 117.599 1.8 . . . . 74.510000000000005 117.599 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -116.02 177.38 4.7 Favored 'General case' 0 C--N 1.354 0.799 0 N-CA-C 105.755 -1.942 . . . . 74.010000000000005 105.755 175.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -57.17 -33.51 67.52 Favored 'General case' 0 C--N 1.35 0.589 0 CA-C-O 117.926 -1.035 . . . . 53.310000000000002 111.424 178.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 1.8 mmm -110.15 60.72 0.6 Allowed 'General case' 0 C--N 1.354 0.776 0 CA-C-N 119.044 0.838 . . . . 73.310000000000002 112.352 -174.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.53 102.84 0.02 OUTLIER Glycine 0 C--N 1.355 1.631 0 N-CA-C 108.991 -1.644 . . . . 73.109999999999999 108.991 174.36 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -100.9 -174.2 29.19 Favored Glycine 0 C--O 1.207 -1.561 0 CA-C-O 115.912 -2.605 . . . . 73.420000000000002 112.941 -170.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 8.1 tt -96.99 22.48 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.364 1.209 0 CA-C-N 120.012 1.906 . . . . 72.230000000000004 111.669 175.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.4 p -124.48 125.75 44.75 Favored 'General case' 0 C--N 1.364 1.222 0 CA-C-N 120.079 1.308 . . . . 75.549999999999997 111.152 -174.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.1 t . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 71.140000000000001 111.112 -179.956 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.557 2.672 0 CA-C-O 115.318 -2.935 . . . . 71.120000000000005 118.803 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.53 173.12 42.59 Favored Glycine 0 C--N 1.379 2.927 0 CA-C-N 124.147 3.973 . . . . 65.340000000000003 111.039 -172.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -81.89 50.58 3.52 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 CA-C-N 122.573 3.186 . . . . 73.109999999999999 115.64 -176.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 71.9 mt -155.61 -156.77 0.67 Allowed 'General case' 0 C--O 1.211 -0.938 0 CA-C-O 115.785 -2.055 . . . . 75.540000000000006 106.362 -177.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.0 91.31 3.41 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 121.798 2.09 . . . . 63.399999999999999 111.093 -176.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -141.87 -14.95 0.39 Allowed Glycine 0 C--N 1.353 1.498 0 O-C-N 119.064 -2.273 . . . . 63.43 118.422 169.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -128.24 175.02 8.78 Favored 'General case' 0 C--N 1.353 0.748 0 CA-C-N 121.466 2.633 . . . . 61.329999999999998 104.441 178.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -62.49 -30.62 71.4 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 116.886 -1.531 . . . . 74.209999999999994 110.57 -177.029 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 44.0 mtm -111.98 65.26 0.63 Allowed 'General case' 0 C--N 1.359 1.02 0 CA-C-N 120.622 1.555 . . . . 75.219999999999999 112.007 -177.22 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.71 96.66 0.01 OUTLIER Glycine 0 C--N 1.357 1.736 0 CA-C-O 116.346 -2.363 . . . . 72.409999999999997 109.365 174.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.62 -172.87 28.13 Favored Glycine 0 C--N 1.364 2.135 0 CA-C-O 114.722 -3.265 . . . . 72.420000000000002 113.858 -174.197 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.5 tt -96.96 25.26 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.361 1.105 0 CA-C-N 120.305 2.052 . . . . 75.319999999999993 111.233 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -122.11 124.56 44.19 Favored 'General case' 0 C--N 1.366 1.301 0 CA-C-N 122.138 2.244 . . . . 65.420000000000002 111.123 -174.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.194 -0.457 . . . . 75.319999999999993 111.156 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.554 2.477 0 CA-C-O 115.442 -2.865 . . . . 73.430000000000007 118.881 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.71 173.11 42.7 Favored Glycine 0 C--N 1.377 2.84 0 CA-C-N 124.144 3.972 . . . . 74.140000000000001 111.205 -171.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -82.69 49.62 3.14 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 CA-C-N 122.639 3.22 . . . . 74.299999999999997 115.828 -176.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.9 mt -154.44 -154.89 0.54 Allowed 'General case' 0 C--N 1.357 0.929 0 CA-C-O 115.744 -2.074 . . . . 71.209999999999994 106.317 -178.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.84 89.88 3.11 Favored 'General case' 0 C--N 1.358 0.969 0 CA-C-N 121.782 2.083 . . . . 62.020000000000003 111.108 -175.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.02 -14.6 0.56 Allowed Glycine 0 C--N 1.353 1.503 0 O-C-N 118.84 -2.413 . . . . 55.509999999999998 117.936 170.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -129.64 173.45 10.6 Favored 'General case' 0 C--N 1.355 0.83 0 CA-C-N 121.705 2.753 . . . . 74.0 104.999 179.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -56.84 -35.07 68.4 Favored 'General case' 0 C--O 1.217 -0.622 0 CA-C-O 117.282 -1.342 . . . . 72.530000000000001 111.132 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 7.7 mmt -110.28 64.0 0.61 Allowed 'General case' 0 C--N 1.36 1.042 0 CA-C-N 120.456 1.48 . . . . 71.540000000000006 111.598 -173.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.12 96.82 0.01 OUTLIER Glycine 0 C--N 1.356 1.66 0 CA-C-O 116.42 -2.322 . . . . 63.539999999999999 109.439 175.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.84 -173.86 27.96 Favored Glycine 0 C--N 1.364 2.087 0 CA-C-O 115.14 -3.033 . . . . 73.209999999999994 113.721 -174.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.9 tt -96.3 25.43 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.051 0 CA-C-N 120.245 2.023 . . . . 73.519999999999996 111.281 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -121.38 124.43 44.51 Favored 'General case' 0 C--N 1.364 1.233 0 CA-C-N 122.018 2.19 . . . . 54.329999999999998 111.162 -175.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.2 m . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.455 . . . . 70.209999999999994 111.145 179.99 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.556 2.655 0 CA-C-O 115.298 -2.946 . . . . 61.200000000000003 118.832 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.01 173.07 42.88 Favored Glycine 0 C--N 1.379 2.928 0 CA-C-N 124.08 3.94 . . . . 63.100000000000001 111.15 -172.043 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -82.61 50.21 3.33 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 CA-C-N 122.665 3.233 . . . . 72.150000000000006 115.71 -175.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.5 mt -154.9 -155.35 0.57 Allowed 'General case' 0 C--N 1.357 0.902 0 CA-C-O 115.891 -2.004 . . . . 74.099999999999994 106.266 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.61 89.84 3.11 Favored 'General case' 0 C--N 1.359 1.019 0 CA-C-N 121.687 2.039 . . . . 72.140000000000001 111.103 -175.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.2 -14.19 0.56 Allowed Glycine 0 C--N 1.355 1.609 0 O-C-N 118.944 -2.347 . . . . 73.319999999999993 117.947 170.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -130.39 174.66 9.64 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 121.708 2.754 . . . . 70.030000000000001 104.996 178.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -61.61 -30.59 70.79 Favored 'General case' 0 C--O 1.218 -0.567 0 CA-C-O 116.923 -1.513 . . . . 72.040000000000006 110.722 -177.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 8.1 mmt -112.01 64.8 0.63 Allowed 'General case' 0 C--N 1.359 1.003 0 CA-C-N 120.598 1.545 . . . . 75.510000000000005 111.561 -176.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 60.87 96.95 0.01 OUTLIER Glycine 0 C--N 1.356 1.674 0 CA-C-O 116.516 -2.269 . . . . 42.200000000000003 109.752 174.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -102.24 -173.82 27.45 Favored Glycine 0 C--N 1.364 2.107 0 CA-C-O 115.062 -3.077 . . . . 74.129999999999995 113.799 -174.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.7 tt -96.14 24.96 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.053 0 CA-C-N 120.261 2.031 . . . . 71.310000000000002 111.475 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -121.24 124.8 45.54 Favored 'General case' 0 C--N 1.365 1.24 0 CA-C-N 121.913 2.142 . . . . 73.349999999999994 111.167 -175.084 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.9 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 72.120000000000005 111.115 -179.988 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.556 2.648 0 CA-C-O 115.264 -2.965 . . . . 55.509999999999998 118.753 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.88 172.82 42.75 Favored Glycine 0 C--N 1.379 2.934 0 CA-C-N 124.085 3.942 . . . . 75.340000000000003 111.125 -172.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -82.09 50.07 3.34 Favored 'Trans proline' 0 N--CA 1.454 -0.839 0 CA-C-N 122.581 3.191 . . . . 73.040000000000006 115.908 -176.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.8 mt -154.64 -154.95 0.54 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-O 115.918 -1.992 . . . . 72.120000000000005 106.114 -178.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.93 91.18 3.33 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 121.731 2.06 . . . . 74.230000000000004 111.143 -175.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -141.33 -15.37 0.43 Allowed Glycine 0 C--N 1.353 1.484 0 O-C-N 119.039 -2.288 . . . . 61.109999999999999 118.209 170.248 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -128.36 174.01 9.69 Favored 'General case' 0 C--N 1.354 0.771 0 CA-C-N 121.47 2.635 . . . . 75.540000000000006 104.739 179.063 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -58.77 -33.7 70.6 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-O 116.905 -1.522 . . . . 74.010000000000005 110.886 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 33.4 mmm -111.24 65.09 0.62 Allowed 'General case' 0 C--N 1.359 1.009 0 CA-C-N 120.885 1.675 . . . . 75.129999999999995 111.751 -174.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.42 97.04 0.01 OUTLIER Glycine 0 C--N 1.358 1.769 0 CA-C-O 116.26 -2.411 . . . . 74.400000000000006 109.569 174.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -102.34 -173.88 27.33 Favored Glycine 0 C--N 1.364 2.133 0 CA-C-O 114.978 -3.123 . . . . 74.310000000000002 113.682 -174.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.4 tt -96.24 25.13 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.362 1.111 0 CA-C-N 120.279 2.039 . . . . 74.200000000000003 111.291 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.67 124.62 44.7 Favored 'General case' 0 C--N 1.365 1.247 0 CA-C-N 121.907 2.14 . . . . 63.219999999999999 111.174 -174.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.253 -0.43 . . . . 75.049999999999997 111.113 -179.929 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 1.414 0 CA-C-O 116.708 -2.162 . . . . 73.400000000000006 117.815 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.27 171.94 37.4 Favored Glycine 0 C--N 1.36 1.88 0 CA-C-N 123.808 3.804 . . . . 74.439999999999998 111.459 -170.25 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -79.84 45.33 1.92 Allowed 'Trans proline' 0 C--N 1.354 0.845 0 CA-C-N 122.395 3.098 . . . . 72.310000000000002 116.185 -178.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . 0.413 ' N ' ' O ' ' A' ' 11' ' ' GLY . 48.3 mt -150.69 -155.16 0.6 Allowed 'General case' 0 C--N 1.352 0.677 0 N-CA-C 106.015 -1.846 . . . . 73.329999999999998 106.015 -176.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.6 90.87 3.29 Favored 'General case' 0 C--N 1.359 1.02 0 C-N-CA 125.689 1.596 . . . . 74.420000000000002 111.149 -176.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.54 -17.69 0.42 Allowed Glycine 0 C--N 1.349 1.252 0 O-C-N 118.544 -2.597 . . . . 65.230000000000004 116.774 172.52 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -127.92 177.71 6.67 Favored 'General case' 0 C--N 1.36 1.031 0 CA-C-N 121.571 2.685 . . . . 71.129999999999995 104.481 179.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -63.51 -32.07 73.41 Favored 'General case' 0 C--O 1.219 -0.552 0 CA-C-O 117.062 -1.447 . . . . 73.530000000000001 110.937 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 15.9 mtt -110.6 64.53 0.61 Allowed 'General case' 0 C--N 1.361 1.099 0 CA-C-N 120.435 1.471 . . . . 73.439999999999998 111.942 -177.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 63.15 96.76 0.01 OUTLIER Glycine 0 C--N 1.356 1.686 0 CA-C-O 115.958 -2.579 . . . . 55.32 109.059 174.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.413 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -99.4 -174.04 31.19 Favored Glycine 0 N--CA 1.488 2.147 0 CA-C-O 115.509 -2.828 . . . . 75.25 113.301 -175.331 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.1 tt -97.21 25.46 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.022 0 CA-C-N 119.869 1.834 . . . . 70.439999999999998 111.002 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.52 124.79 45.25 Favored 'General case' 0 C--N 1.363 1.176 0 CA-C-N 121.149 1.795 . . . . 61.25 111.123 -175.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 64.299999999999997 111.139 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.141 0 CA-C-O 116.095 -2.503 . . . . 63.420000000000002 119.231 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -149.4 177.05 27.84 Favored Glycine 0 C--N 1.366 2.244 0 CA-C-N 123.074 3.437 . . . . 75.209999999999994 110.915 -174.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -80.19 46.88 2.36 Favored 'Trans proline' 0 C--N 1.349 0.588 0 CA-C-N 122.272 3.036 . . . . 72.209999999999994 115.267 -178.174 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . 0.497 ' N ' ' O ' ' A' ' 11' ' ' GLY . 54.9 mt -150.81 -156.08 0.68 Allowed 'General case' 0 C--N 1.349 0.544 0 CA-C-O 117.032 -1.461 . . . . 73.430000000000007 108.092 -178.036 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -122.54 102.94 8.37 Favored 'General case' 0 C--N 1.369 1.453 0 CA-C-N 121.042 1.747 . . . . 71.310000000000002 111.089 -177.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -153.3 -33.9 0.03 OUTLIER Glycine 0 C--N 1.349 1.304 0 N-CA-C 117.622 1.809 . . . . 53.109999999999999 117.622 179.479 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -116.11 177.64 4.61 Favored 'General case' 0 C--N 1.351 0.66 0 CA-C-N 119.141 1.47 . . . . 74.120000000000005 107.524 174.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -60.29 -31.44 70.25 Favored 'General case' 0 C--N 1.349 0.544 0 CA-C-O 117.816 -1.088 . . . . 63.299999999999997 110.93 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 31.4 mmm -110.05 58.45 0.61 Allowed 'General case' 0 C--N 1.359 1.004 0 CA-C-N 119.389 0.995 . . . . 74.219999999999999 111.969 -173.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.09 101.14 0.02 OUTLIER Glycine 0 C--N 1.356 1.655 0 CA-C-O 117.08 -1.956 . . . . 75.150000000000006 110.86 177.036 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.497 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -96.32 -176.07 35.94 Favored Glycine 0 CA--C 1.486 -1.766 0 CA-C-O 116.203 -2.443 . . . . 61.229999999999997 114.066 -172.311 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.5 tt -97.17 22.62 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.749 0 CA-C-N 120.211 2.006 . . . . 75.109999999999999 111.389 174.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.0 p -124.14 128.19 48.89 Favored 'General case' 0 C--N 1.362 1.132 0 CA-C-N 120.348 1.431 . . . . 73.319999999999993 111.137 -175.402 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 86.8 m . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 73.340000000000003 111.121 -179.974 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.555 2.565 0 CA-C-O 115.466 -2.852 . . . . 73.329999999999998 118.899 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.71 173.15 42.7 Favored Glycine 0 C--N 1.378 2.9 0 CA-C-N 124.032 3.916 . . . . 73.030000000000001 111.158 -172.03 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -82.6 50.0 3.26 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 CA-C-N 122.519 3.16 . . . . 73.299999999999997 115.791 -176.116 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 61.5 mt -154.6 -155.08 0.55 Allowed 'General case' 0 C--N 1.357 0.917 0 CA-C-O 115.852 -2.023 . . . . 75.5 106.205 -178.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.89 90.02 3.13 Favored 'General case' 0 C--N 1.359 1.007 0 CA-C-N 121.81 2.096 . . . . 75.140000000000001 111.061 -175.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.2 -14.79 0.54 Allowed Glycine 0 C--N 1.353 1.482 0 O-C-N 118.816 -2.427 . . . . 72.530000000000001 117.927 170.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -129.5 173.51 10.51 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-N 121.708 2.754 . . . . 75.319999999999993 104.921 179.188 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -56.15 -35.77 67.54 Favored 'General case' 0 C--O 1.218 -0.582 0 CA-C-O 117.018 -1.468 . . . . 74.5 110.723 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -110.55 64.02 0.61 Allowed 'General case' 0 C--N 1.36 1.054 0 CA-C-N 120.692 1.587 . . . . 74.140000000000001 112.47 -173.098 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.91 96.45 0.01 OUTLIER Glycine 0 C--N 1.356 1.692 0 CA-C-O 116.349 -2.362 . . . . 71.140000000000001 108.795 175.567 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.62 -173.9 28.25 Favored Glycine 0 C--N 1.363 2.068 0 CA-C-O 115.079 -3.067 . . . . 65.140000000000001 113.557 -174.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.5 tt -96.12 25.39 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.361 1.104 0 CA-C-N 120.192 1.996 . . . . 65.239999999999995 111.271 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.63 124.3 44.0 Favored 'General case' 0 C--N 1.364 1.238 0 CA-C-N 122.03 2.196 . . . . 73.230000000000004 111.112 -175.269 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 73.310000000000002 111.15 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 1.536 0 CA-C-O 116.544 -2.253 . . . . 65.109999999999999 117.875 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.46 171.88 37.55 Favored Glycine 0 C--N 1.359 1.815 0 CA-C-N 123.891 3.846 . . . . 75.120000000000005 111.398 -169.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -80.2 45.75 2.05 Favored 'Trans proline' 0 C--N 1.353 0.786 0 CA-C-N 122.298 3.049 . . . . 74.329999999999998 116.304 -177.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . 0.419 ' N ' ' O ' ' A' ' 11' ' ' GLY . 56.9 mt -150.71 -154.01 0.52 Allowed 'General case' 0 C--N 1.352 0.711 0 N-CA-C 105.848 -1.908 . . . . 75.420000000000002 105.848 -178.472 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -126.26 90.21 3.14 Favored 'General case' 0 C--N 1.361 1.069 0 C-N-CA 126.044 1.738 . . . . 73.209999999999994 111.131 -176.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -139.81 -17.61 0.48 Allowed Glycine 0 C--N 1.349 1.254 0 O-C-N 118.487 -2.633 . . . . 70.439999999999998 116.627 172.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -127.7 176.98 7.12 Favored 'General case' 0 C--N 1.359 1.003 0 CA-C-N 121.64 2.72 . . . . 61.539999999999999 104.967 179.528 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -59.06 -35.96 74.23 Favored 'General case' 0 C--O 1.22 -0.46 0 CA-C-O 117.67 -1.157 . . . . 72.019999999999996 111.04 179.578 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 4.9 mmt -110.16 63.2 0.6 Allowed 'General case' 0 C--N 1.36 1.051 0 CA-C-N 119.86 1.209 . . . . 73.420000000000002 110.861 -173.321 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 62.81 96.61 0.01 OUTLIER Glycine 0 C--N 1.356 1.647 0 CA-C-O 116.073 -2.515 . . . . 74.430000000000007 109.63 175.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -99.38 -174.4 31.27 Favored Glycine 0 N--CA 1.49 2.239 0 CA-C-O 115.942 -2.588 . . . . 63.119999999999997 113.422 -176.036 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.0 tt -97.11 25.39 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.985 0 CA-C-N 119.73 1.765 . . . . 75.430000000000007 111.085 179.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.9 p -120.87 124.57 45.32 Favored 'General case' 0 C--N 1.363 1.174 0 CA-C-N 120.861 1.664 . . . . 75.340000000000003 111.149 -176.073 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 13.7 t . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 71.209999999999994 111.162 179.998 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.059 0 CA-C-O 116.268 -2.407 . . . . 74.230000000000004 117.296 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -148.92 174.97 28.39 Favored Glycine 0 C--N 1.35 1.309 0 CA-C-N 123.358 3.579 . . . . 70.409999999999997 111.926 -170.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_endo -79.35 44.27 1.66 Allowed 'Trans proline' 0 C--N 1.362 1.282 0 CA-C-N 121.616 2.708 . . . . 72.140000000000001 116.046 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . 0.465 ' N ' ' O ' ' A' ' 11' ' ' GLY . 34.2 mt -150.41 -156.3 0.71 Allowed 'General case' 0 C--O 1.218 -0.589 0 N-CA-C 105.89 -1.893 . . . . 72.120000000000005 105.89 -175.732 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.49 101.53 7.38 Favored 'General case' 0 C--N 1.355 0.828 0 C-N-CA 125.219 1.407 . . . . 62.039999999999999 111.14 -176.289 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -150.11 -33.93 0.04 OUTLIER Glycine 0 C--N 1.351 1.416 0 O-C-N 120.087 -1.633 . . . . 61.210000000000001 117.166 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -118.71 -179.43 3.8 Favored 'General case' 0 C--N 1.353 0.725 0 N-CA-C 104.503 -2.406 . . . . 74.340000000000003 104.503 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.79 -30.11 71.11 Favored 'General case' 0 C--N 1.347 0.471 0 CA-C-O 117.575 -1.203 . . . . 75.420000000000002 111.558 179.735 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 94.5 mtp -111.02 59.32 0.61 Allowed 'General case' 0 C--N 1.359 1.018 0 CA-C-N 119.866 1.212 . . . . 73.430000000000007 110.863 -176.133 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.49 103.89 0.02 OUTLIER Glycine 0 C--N 1.353 1.524 0 CA-C-O 117.464 -1.742 . . . . 63.420000000000002 109.969 176.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.465 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -100.34 -176.53 30.15 Favored Glycine 0 CA--C 1.491 -1.468 0 CA-C-O 115.877 -2.624 . . . . 70.400000000000006 112.362 -172.594 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.6 tt -97.39 24.07 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.853 0 CA-C-N 120.343 2.071 . . . . 75.230000000000004 111.469 176.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -123.58 125.68 45.29 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 119.675 1.125 . . . . 75.340000000000003 111.157 -176.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 15.1 t . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 73.519999999999996 111.173 179.983 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.838 0 CA-C-O 114.936 -3.147 . . . . 71.230000000000004 118.198 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -152.62 175.45 31.2 Favored Glycine 0 C--N 1.35 1.313 0 CA-C-N 123.461 3.631 . . . . 63.520000000000003 111.5 -172.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -80.53 46.68 2.32 Favored 'Trans proline' 0 C--N 1.364 1.391 0 CA-C-N 120.911 2.356 . . . . 75.120000000000005 114.731 -178.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' LEU . . . . . 0.459 ' N ' ' O ' ' A' ' 11' ' ' GLY . 37.5 mt -151.31 -156.55 0.72 Allowed 'General case' 0 C--N 1.352 0.684 0 N-CA-C 106.819 -1.549 . . . . 74.140000000000001 106.819 -177.713 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.18 102.6 8.04 Favored 'General case' 0 C--N 1.362 1.13 0 CA-C-N 120.776 1.625 . . . . 75.140000000000001 111.066 -176.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -151.77 -34.71 0.03 OUTLIER Glycine 0 C--N 1.357 1.737 0 CA-C-O 117.177 -1.901 . . . . 62.43 116.915 179.236 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -117.46 178.05 4.52 Favored 'General case' 0 CA--C 1.506 -0.712 0 N-CA-C 105.792 -1.929 . . . . 71.230000000000004 105.792 177.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -61.18 -30.9 70.69 Favored 'General case' 0 C--O 1.22 -0.482 0 CA-C-O 117.662 -1.161 . . . . 72.25 111.415 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 20.9 mmt -110.33 58.51 0.61 Allowed 'General case' 0 C--N 1.359 0.991 0 CA-C-N 119.647 1.112 . . . . 75.109999999999999 113.021 -176.14 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 65.97 106.53 0.01 OUTLIER Glycine 0 C--N 1.353 1.528 0 CA-C-O 117.213 -1.881 . . . . 73.540000000000006 109.986 178.063 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -102.68 -174.78 26.98 Favored Glycine 0 CA--C 1.489 -1.593 0 CA-C-O 116.138 -2.479 . . . . 74.519999999999996 112.368 -172.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.4 tt -96.99 22.77 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.846 0 CA-C-N 120.256 2.028 . . . . 74.239999999999995 111.192 175.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -124.32 125.77 44.9 Favored 'General case' 0 C--N 1.359 0.981 0 CA-C-N 120.888 1.676 . . . . 74.439999999999998 111.153 -175.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.257 0 CA-C-N 116.217 -0.447 . . . . 73.140000000000001 111.141 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.371 0 CA-C-O 116.573 -2.237 . . . . 42.210000000000001 116.846 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.26 175.36 34.71 Favored Glycine 0 C--N 1.363 2.072 1 CA-C-N 124.782 4.291 . . . . 72.340000000000003 112.099 -170.691 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.53 49.53 3.22 Favored 'Trans proline' 0 C--N 1.352 0.717 0 CA-C-N 122.479 3.139 . . . . 74.219999999999999 115.659 -178.327 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.419 ' N ' ' O ' ' A' ' 11' ' ' GLY . 37.8 mt -155.56 -156.16 0.62 Allowed 'General case' 0 C--N 1.358 0.965 0 CA-C-O 115.436 -2.221 . . . . 70.129999999999995 106.832 -177.04 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.03 105.49 9.61 Favored 'General case' 0 C--N 1.352 0.685 0 CA-C-N 122.06 2.209 . . . . 52.109999999999999 111.102 -175.778 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.14 -36.66 0.02 OUTLIER Glycine 0 C--N 1.373 2.632 0 N-CA-C 118.406 2.122 . . . . 74.340000000000003 118.406 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -116.31 177.4 4.7 Favored 'General case' 0 C--N 1.349 0.584 0 N-CA-C 105.474 -2.047 . . . . 75.040000000000006 105.474 176.075 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 7.4 tt0 -58.67 -32.48 69.14 Favored 'General case' 0 C--N 1.348 0.536 0 CA-C-O 117.931 -1.033 . . . . 73.540000000000006 111.816 179.275 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 6.1 mmt -109.63 57.49 0.61 Allowed 'General case' 0 C--N 1.359 0.986 0 CA-C-N 119.924 1.238 . . . . 60.439999999999998 111.655 -172.59 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 67.88 108.16 0.02 OUTLIER Glycine 0 C--N 1.358 1.767 0 CA-C-O 115.998 -2.557 . . . . 73.430000000000007 109.962 177.869 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -107.91 -174.18 22.09 Favored Glycine 0 C--N 1.354 1.572 0 CA-C-N 121.505 2.653 . . . . 60.340000000000003 111.198 -170.319 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 8.7 tt -96.42 22.66 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.735 0 CA-C-N 120.412 2.106 . . . . 75.340000000000003 111.022 176.577 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -124.56 125.69 44.6 Favored 'General case' 0 C--N 1.365 1.271 0 CA-C-N 121.171 1.805 . . . . 70.109999999999999 111.138 -174.653 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 7.0 t . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 75.019999999999996 111.091 -179.985 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 1.636 0 N-CA-C 120.158 2.823 . . . . 55.409999999999997 120.158 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -156.48 174.22 34.25 Favored Glycine 0 C--N 1.348 1.218 1 CA-C-N 124.817 4.308 . . . . 74.319999999999993 111.191 -173.437 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -79.94 44.55 1.74 Allowed 'Trans proline' 0 C--N 1.369 1.636 0 CA-C-N 122.054 2.927 . . . . 71.209999999999994 115.017 -177.36 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.44 ' N ' ' O ' ' A' ' 11' ' ' GLY . 43.3 mt -148.96 -154.5 0.56 Allowed 'General case' 0 C--N 1.354 0.788 0 N-CA-C 106.477 -1.675 . . . . 73.040000000000006 106.477 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.97 88.58 2.91 Favored 'General case' 0 C--N 1.362 1.142 0 C-N-CA 125.91 1.684 . . . . 72.420000000000002 111.151 -176.558 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -138.31 -14.78 0.7 Allowed Glycine 0 CA--C 1.528 0.845 0 O-C-N 118.724 -2.485 . . . . 71.450000000000003 117.305 171.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -129.39 175.67 8.57 Favored 'General case' 0 C--N 1.359 0.984 0 CA-C-N 121.372 2.586 . . . . 75.200000000000003 106.236 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -58.57 -36.95 74.75 Favored 'General case' 0 C--O 1.219 -0.546 0 CA-C-O 117.807 -1.092 . . . . 73.349999999999994 110.944 178.798 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 78.3 mtm -109.16 66.83 0.64 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 119.551 1.069 . . . . 72.540000000000006 111.396 -175.753 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 60.67 91.13 0.02 OUTLIER Glycine 0 C--N 1.352 1.448 0 CA-C-O 116.599 -2.223 . . . . 73.099999999999994 110.041 173.239 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.44 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -92.22 -174.34 42.09 Favored Glycine 0 C--O 1.201 -1.948 0 CA-C-O 116.204 -2.442 . . . . 74.319999999999993 115.091 -177.263 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.8 tt -96.84 24.06 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.371 1.538 0 CA-C-N 118.645 1.222 . . . . 74.319999999999993 111.257 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.4 p -120.57 124.44 45.32 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-N 120.744 1.611 . . . . 73.230000000000004 111.151 -174.86 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 15.4 t . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.244 -0.435 . . . . 75.329999999999998 111.153 179.978 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 1.782 0 N-CA-C 119.205 2.442 . . . . 61.200000000000003 119.205 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -158.72 175.25 35.78 Favored Glycine 0 C--N 1.354 1.571 1 CA-C-N 125.813 4.807 . . . . 74.319999999999993 109.764 -174.026 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -80.31 45.18 1.9 Allowed 'Trans proline' 0 C--N 1.351 0.71 0 CA-C-N 121.097 2.449 . . . . 74.200000000000003 115.504 -176.902 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.441 ' N ' ' O ' ' A' ' 11' ' ' GLY . 47.6 mt -149.95 -154.48 0.56 Allowed 'General case' 0 C--N 1.36 1.022 0 CA-C-O 116.467 -1.73 . . . . 74.140000000000001 107.017 -179.019 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.97 88.86 2.96 Favored 'General case' 0 C--N 1.354 0.778 0 C-N-CA 125.674 1.59 . . . . 73.140000000000001 111.108 -176.203 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -138.8 -14.58 0.66 Allowed Glycine 0 CA--C 1.529 0.909 0 O-C-N 118.698 -2.501 . . . . 63.299999999999997 117.271 171.343 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -129.13 174.96 9.09 Favored 'General case' 0 C--N 1.352 0.69 0 CA-C-N 121.04 2.42 . . . . 72.420000000000002 105.74 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -58.65 -35.13 72.04 Favored 'General case' 0 C--O 1.219 -0.525 0 CA-C-O 117.682 -1.151 . . . . 71.230000000000004 110.731 179.306 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 3.6 mmt -109.76 63.23 0.6 Allowed 'General case' 0 C--N 1.355 0.816 0 CA-C-N 119.419 1.008 . . . . 70.239999999999995 111.656 -174.077 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.67 91.17 0.02 OUTLIER Glycine 0 C--N 1.352 1.421 0 CA-C-O 116.567 -2.241 . . . . 62.310000000000002 110.093 175.71 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.441 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -92.87 -175.06 41.21 Favored Glycine 0 N--CA 1.491 2.34 0 CA-C-O 115.617 -2.768 . . . . 65.200000000000003 115.052 -177.006 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 12.1 tt -96.13 24.38 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.844 0 CA-C-N 120.124 1.962 . . . . 75.200000000000003 111.051 -179.481 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.4 p -120.66 124.59 45.59 Favored 'General case' 0 C--N 1.359 1.01 0 CA-C-N 121.346 1.885 . . . . 64.25 111.132 -175.328 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.5 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.249 -0.432 . . . . 71.040000000000006 111.139 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.703 0 CA-C-O 116.506 -2.274 . . . . 64.319999999999993 117.844 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -145.03 178.63 22.69 Favored Glycine 0 C--N 1.368 2.359 0 CA-C-N 123.347 3.574 . . . . 64.340000000000003 110.995 -174.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -79.38 44.62 1.74 Allowed 'Trans proline' 0 C--N 1.357 1.011 0 CA-C-N 121.78 2.79 . . . . 74.040000000000006 116.375 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.452 ' N ' ' O ' ' A' ' 11' ' ' GLY . 39.3 mt -149.24 -156.34 0.71 Allowed 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 106.381 -1.711 . . . . 73.209999999999994 106.381 -176.203 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.19 100.92 7.1 Favored 'General case' 0 C--N 1.353 0.721 0 C-N-CA 125.079 1.352 . . . . 73.530000000000001 111.095 -176.758 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -149.53 -32.04 0.05 OUTLIER Glycine 0 C--N 1.347 1.151 0 O-C-N 119.299 -2.125 . . . . 51.020000000000003 116.776 178.939 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -119.67 179.22 4.3 Favored 'General case' 0 C--N 1.357 0.904 0 N-CA-C 104.743 -2.318 . . . . 72.239999999999995 104.743 178.864 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -64.12 -29.82 70.93 Favored 'General case' 0 C--N 1.349 0.558 0 CA-C-O 117.382 -1.294 . . . . 74.120000000000005 111.664 178.777 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 66.3 mmm -110.6 59.29 0.61 Allowed 'General case' 0 C--N 1.357 0.92 0 CA-C-N 119.597 1.089 . . . . 73.230000000000004 110.555 -176.345 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 65.99 98.74 0.02 OUTLIER Glycine 0 C--N 1.354 1.56 0 CA-C-O 117.978 -1.456 . . . . 75.109999999999999 110.428 174.83 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.452 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -94.2 -177.58 38.98 Favored Glycine 0 CA--C 1.491 -1.447 0 CA-C-O 115.598 -2.779 . . . . 63.299999999999997 113.183 -171.549 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.7 tt -97.58 24.85 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.992 0 CA-C-N 120.726 2.263 . . . . 73.439999999999998 111.289 175.63 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.2 p -124.16 125.83 45.12 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.593 1.088 . . . . 65.239999999999995 111.113 -176.431 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.181 -0.463 . . . . 72.310000000000002 111.121 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.172 0 N-CA-C 120.027 2.771 . . . . 70.109999999999999 120.027 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -150.56 178.68 27.85 Favored Glycine 0 C--N 1.366 2.204 0 CA-C-N 124.069 3.935 . . . . 75.510000000000005 112.598 -175.598 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -81.29 49.62 3.27 Favored 'Trans proline' 0 N--CA 1.449 -1.118 1 CA-C-N 124.298 4.049 . . . . 74.420000000000002 116.208 -178.046 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.449 ' N ' ' O ' ' A' ' 11' ' ' GLY . 59.6 mt -154.01 -157.17 0.75 Allowed 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 116.703 -1.617 . . . . 74.230000000000004 106.91 -176.206 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.13 104.71 9.36 Favored 'General case' 0 C--N 1.358 0.976 0 CA-C-N 121.612 2.005 . . . . 71.530000000000001 111.095 -176.433 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.15 -35.78 0.02 OUTLIER Glycine 0 C--N 1.369 2.367 0 N-CA-C 117.599 1.8 . . . . 74.510000000000005 117.599 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -116.02 177.38 4.7 Favored 'General case' 0 C--N 1.354 0.799 0 N-CA-C 105.755 -1.942 . . . . 74.010000000000005 105.755 175.211 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -57.17 -33.51 67.52 Favored 'General case' 0 C--N 1.35 0.589 0 CA-C-O 117.926 -1.035 . . . . 53.310000000000002 111.424 178.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 1.8 mmm -110.15 60.72 0.6 Allowed 'General case' 0 C--N 1.354 0.776 0 CA-C-N 119.044 0.838 . . . . 73.310000000000002 112.352 -174.225 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.53 102.84 0.02 OUTLIER Glycine 0 C--N 1.355 1.631 0 N-CA-C 108.991 -1.644 . . . . 73.109999999999999 108.991 174.36 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -100.9 -174.2 29.19 Favored Glycine 0 C--O 1.207 -1.561 0 CA-C-O 115.912 -2.605 . . . . 73.420000000000002 112.941 -170.954 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 8.1 tt -96.99 22.48 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.364 1.209 0 CA-C-N 120.012 1.906 . . . . 72.230000000000004 111.669 175.388 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.4 p -124.48 125.75 44.75 Favored 'General case' 0 C--N 1.364 1.222 0 CA-C-N 120.079 1.308 . . . . 75.549999999999997 111.152 -174.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.1 t . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 71.140000000000001 111.112 -179.956 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.557 2.672 0 CA-C-O 115.318 -2.935 . . . . 71.120000000000005 118.803 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.53 173.12 42.59 Favored Glycine 0 C--N 1.379 2.927 0 CA-C-N 124.147 3.973 . . . . 65.340000000000003 111.039 -172.481 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -81.89 50.58 3.52 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 CA-C-N 122.573 3.186 . . . . 73.109999999999999 115.64 -176.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 71.9 mt -155.61 -156.77 0.67 Allowed 'General case' 0 C--O 1.211 -0.938 0 CA-C-O 115.785 -2.055 . . . . 75.540000000000006 106.362 -177.457 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.0 91.31 3.41 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 121.798 2.09 . . . . 63.399999999999999 111.093 -176.133 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -141.87 -14.95 0.39 Allowed Glycine 0 C--N 1.353 1.498 0 O-C-N 119.064 -2.273 . . . . 63.43 118.422 169.881 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.0 pt-20 -128.24 175.02 8.78 Favored 'General case' 0 C--N 1.353 0.748 0 CA-C-N 121.466 2.633 . . . . 61.329999999999998 104.441 178.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -62.49 -30.62 71.4 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 116.886 -1.531 . . . . 74.209999999999994 110.57 -177.029 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 44.0 mtm -111.98 65.26 0.63 Allowed 'General case' 0 C--N 1.359 1.02 0 CA-C-N 120.622 1.555 . . . . 75.219999999999999 112.007 -177.22 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.71 96.66 0.01 OUTLIER Glycine 0 C--N 1.357 1.736 0 CA-C-O 116.346 -2.363 . . . . 72.409999999999997 109.365 174.338 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.62 -172.87 28.13 Favored Glycine 0 C--N 1.364 2.135 0 CA-C-O 114.722 -3.265 . . . . 72.420000000000002 113.858 -174.197 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.5 tt -96.96 25.26 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.361 1.105 0 CA-C-N 120.305 2.052 . . . . 75.319999999999993 111.233 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -122.11 124.56 44.19 Favored 'General case' 0 C--N 1.366 1.301 0 CA-C-N 122.138 2.244 . . . . 65.420000000000002 111.123 -174.757 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.194 -0.457 . . . . 75.319999999999993 111.156 179.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.554 2.477 0 CA-C-O 115.442 -2.865 . . . . 73.430000000000007 118.881 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.71 173.11 42.7 Favored Glycine 0 C--N 1.377 2.84 0 CA-C-N 124.144 3.972 . . . . 74.140000000000001 111.205 -171.941 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -82.69 49.62 3.14 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 CA-C-N 122.639 3.22 . . . . 74.299999999999997 115.828 -176.041 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.9 mt -154.44 -154.89 0.54 Allowed 'General case' 0 C--N 1.357 0.929 0 CA-C-O 115.744 -2.074 . . . . 71.209999999999994 106.317 -178.821 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.84 89.88 3.11 Favored 'General case' 0 C--N 1.358 0.969 0 CA-C-N 121.782 2.083 . . . . 62.020000000000003 111.108 -175.532 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.02 -14.6 0.56 Allowed Glycine 0 C--N 1.353 1.503 0 O-C-N 118.84 -2.413 . . . . 55.509999999999998 117.936 170.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -129.64 173.45 10.6 Favored 'General case' 0 C--N 1.355 0.83 0 CA-C-N 121.705 2.753 . . . . 74.0 104.999 179.192 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -56.84 -35.07 68.4 Favored 'General case' 0 C--O 1.217 -0.622 0 CA-C-O 117.282 -1.342 . . . . 72.530000000000001 111.132 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 7.7 mmt -110.28 64.0 0.61 Allowed 'General case' 0 C--N 1.36 1.042 0 CA-C-N 120.456 1.48 . . . . 71.540000000000006 111.598 -173.348 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.12 96.82 0.01 OUTLIER Glycine 0 C--N 1.356 1.66 0 CA-C-O 116.42 -2.322 . . . . 63.539999999999999 109.439 175.633 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.84 -173.86 27.96 Favored Glycine 0 C--N 1.364 2.087 0 CA-C-O 115.14 -3.033 . . . . 73.209999999999994 113.721 -174.933 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.9 tt -96.3 25.43 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.051 0 CA-C-N 120.245 2.023 . . . . 73.519999999999996 111.281 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -121.38 124.43 44.51 Favored 'General case' 0 C--N 1.364 1.233 0 CA-C-N 122.018 2.19 . . . . 54.329999999999998 111.162 -175.512 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.2 m . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.455 . . . . 70.209999999999994 111.145 179.99 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.556 2.655 0 CA-C-O 115.298 -2.946 . . . . 61.200000000000003 118.832 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.01 173.07 42.88 Favored Glycine 0 C--N 1.379 2.928 0 CA-C-N 124.08 3.94 . . . . 63.100000000000001 111.15 -172.043 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -82.61 50.21 3.33 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 CA-C-N 122.665 3.233 . . . . 72.150000000000006 115.71 -175.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.5 mt -154.9 -155.35 0.57 Allowed 'General case' 0 C--N 1.357 0.902 0 CA-C-O 115.891 -2.004 . . . . 74.099999999999994 106.266 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.61 89.84 3.11 Favored 'General case' 0 C--N 1.359 1.019 0 CA-C-N 121.687 2.039 . . . . 72.140000000000001 111.103 -175.719 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.2 -14.19 0.56 Allowed Glycine 0 C--N 1.355 1.609 0 O-C-N 118.944 -2.347 . . . . 73.319999999999993 117.947 170.978 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 10.1 pt-20 -130.39 174.66 9.64 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 121.708 2.754 . . . . 70.030000000000001 104.996 178.876 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -61.61 -30.59 70.79 Favored 'General case' 0 C--O 1.218 -0.567 0 CA-C-O 116.923 -1.513 . . . . 72.040000000000006 110.722 -177.551 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 8.1 mmt -112.01 64.8 0.63 Allowed 'General case' 0 C--N 1.359 1.003 0 CA-C-N 120.598 1.545 . . . . 75.510000000000005 111.561 -176.757 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 60.87 96.95 0.01 OUTLIER Glycine 0 C--N 1.356 1.674 0 CA-C-O 116.516 -2.269 . . . . 42.200000000000003 109.752 174.713 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -102.24 -173.82 27.45 Favored Glycine 0 C--N 1.364 2.107 0 CA-C-O 115.062 -3.077 . . . . 74.129999999999995 113.799 -174.485 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.7 tt -96.14 24.96 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.053 0 CA-C-N 120.261 2.031 . . . . 71.310000000000002 111.475 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -121.24 124.8 45.54 Favored 'General case' 0 C--N 1.365 1.24 0 CA-C-N 121.913 2.142 . . . . 73.349999999999994 111.167 -175.084 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.9 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 72.120000000000005 111.115 -179.988 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.556 2.648 0 CA-C-O 115.264 -2.965 . . . . 55.509999999999998 118.753 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.88 172.82 42.75 Favored Glycine 0 C--N 1.379 2.934 0 CA-C-N 124.085 3.942 . . . . 75.340000000000003 111.125 -172.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -82.09 50.07 3.34 Favored 'Trans proline' 0 N--CA 1.454 -0.839 0 CA-C-N 122.581 3.191 . . . . 73.040000000000006 115.908 -176.221 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.8 mt -154.64 -154.95 0.54 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-O 115.918 -1.992 . . . . 72.120000000000005 106.114 -178.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.93 91.18 3.33 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 121.731 2.06 . . . . 74.230000000000004 111.143 -175.797 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -141.33 -15.37 0.43 Allowed Glycine 0 C--N 1.353 1.484 0 O-C-N 119.039 -2.288 . . . . 61.109999999999999 118.209 170.248 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -128.36 174.01 9.69 Favored 'General case' 0 C--N 1.354 0.771 0 CA-C-N 121.47 2.635 . . . . 75.540000000000006 104.739 179.063 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -58.77 -33.7 70.6 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-O 116.905 -1.522 . . . . 74.010000000000005 110.886 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 33.4 mmm -111.24 65.09 0.62 Allowed 'General case' 0 C--N 1.359 1.009 0 CA-C-N 120.885 1.675 . . . . 75.129999999999995 111.751 -174.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.42 97.04 0.01 OUTLIER Glycine 0 C--N 1.358 1.769 0 CA-C-O 116.26 -2.411 . . . . 74.400000000000006 109.569 174.936 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -102.34 -173.88 27.33 Favored Glycine 0 C--N 1.364 2.133 0 CA-C-O 114.978 -3.123 . . . . 74.310000000000002 113.682 -174.152 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.4 tt -96.24 25.13 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.362 1.111 0 CA-C-N 120.279 2.039 . . . . 74.200000000000003 111.291 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.67 124.62 44.7 Favored 'General case' 0 C--N 1.365 1.247 0 CA-C-N 121.907 2.14 . . . . 63.219999999999999 111.174 -174.961 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.253 -0.43 . . . . 75.049999999999997 111.113 -179.929 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 1.414 0 CA-C-O 116.708 -2.162 . . . . 73.400000000000006 117.815 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.27 171.94 37.4 Favored Glycine 0 C--N 1.36 1.88 0 CA-C-N 123.808 3.804 . . . . 74.439999999999998 111.459 -170.25 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -79.84 45.33 1.92 Allowed 'Trans proline' 0 C--N 1.354 0.845 0 CA-C-N 122.395 3.098 . . . . 72.310000000000002 116.185 -178.029 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.413 ' N ' ' O ' ' A' ' 11' ' ' GLY . 48.3 mt -150.69 -155.16 0.6 Allowed 'General case' 0 C--N 1.352 0.677 0 N-CA-C 106.015 -1.846 . . . . 73.329999999999998 106.015 -176.949 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.6 90.87 3.29 Favored 'General case' 0 C--N 1.359 1.02 0 C-N-CA 125.689 1.596 . . . . 74.420000000000002 111.149 -176.719 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.54 -17.69 0.42 Allowed Glycine 0 C--N 1.349 1.252 0 O-C-N 118.544 -2.597 . . . . 65.230000000000004 116.774 172.52 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -127.92 177.71 6.67 Favored 'General case' 0 C--N 1.36 1.031 0 CA-C-N 121.571 2.685 . . . . 71.129999999999995 104.481 179.596 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -63.51 -32.07 73.41 Favored 'General case' 0 C--O 1.219 -0.552 0 CA-C-O 117.062 -1.447 . . . . 73.530000000000001 110.937 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 15.9 mtt -110.6 64.53 0.61 Allowed 'General case' 0 C--N 1.361 1.099 0 CA-C-N 120.435 1.471 . . . . 73.439999999999998 111.942 -177.776 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 63.15 96.76 0.01 OUTLIER Glycine 0 C--N 1.356 1.686 0 CA-C-O 115.958 -2.579 . . . . 55.32 109.059 174.66 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.413 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -99.4 -174.04 31.19 Favored Glycine 0 N--CA 1.488 2.147 0 CA-C-O 115.509 -2.828 . . . . 75.25 113.301 -175.331 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.1 tt -97.21 25.46 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.022 0 CA-C-N 119.869 1.834 . . . . 70.439999999999998 111.002 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.52 124.79 45.25 Favored 'General case' 0 C--N 1.363 1.176 0 CA-C-N 121.149 1.795 . . . . 61.25 111.123 -175.581 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 64.299999999999997 111.139 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.141 0 CA-C-O 116.095 -2.503 . . . . 63.420000000000002 119.231 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -149.4 177.05 27.84 Favored Glycine 0 C--N 1.366 2.244 0 CA-C-N 123.074 3.437 . . . . 75.209999999999994 110.915 -174.222 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -80.19 46.88 2.36 Favored 'Trans proline' 0 C--N 1.349 0.588 0 CA-C-N 122.272 3.036 . . . . 72.209999999999994 115.267 -178.174 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.497 ' N ' ' O ' ' A' ' 11' ' ' GLY . 54.9 mt -150.81 -156.08 0.68 Allowed 'General case' 0 C--N 1.349 0.544 0 CA-C-O 117.032 -1.461 . . . . 73.430000000000007 108.092 -178.036 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -122.54 102.94 8.37 Favored 'General case' 0 C--N 1.369 1.453 0 CA-C-N 121.042 1.747 . . . . 71.310000000000002 111.089 -177.221 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -153.3 -33.9 0.03 OUTLIER Glycine 0 C--N 1.349 1.304 0 N-CA-C 117.622 1.809 . . . . 53.109999999999999 117.622 179.479 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -116.11 177.64 4.61 Favored 'General case' 0 C--N 1.351 0.66 0 CA-C-N 119.141 1.47 . . . . 74.120000000000005 107.524 174.966 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -60.29 -31.44 70.25 Favored 'General case' 0 C--N 1.349 0.544 0 CA-C-O 117.816 -1.088 . . . . 63.299999999999997 110.93 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 31.4 mmm -110.05 58.45 0.61 Allowed 'General case' 0 C--N 1.359 1.004 0 CA-C-N 119.389 0.995 . . . . 74.219999999999999 111.969 -173.677 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.09 101.14 0.02 OUTLIER Glycine 0 C--N 1.356 1.655 0 CA-C-O 117.08 -1.956 . . . . 75.150000000000006 110.86 177.036 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.497 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -96.32 -176.07 35.94 Favored Glycine 0 CA--C 1.486 -1.766 0 CA-C-O 116.203 -2.443 . . . . 61.229999999999997 114.066 -172.311 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.5 tt -97.17 22.62 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.749 0 CA-C-N 120.211 2.006 . . . . 75.109999999999999 111.389 174.768 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.0 p -124.14 128.19 48.89 Favored 'General case' 0 C--N 1.362 1.132 0 CA-C-N 120.348 1.431 . . . . 73.319999999999993 111.137 -175.402 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 86.8 m . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 73.340000000000003 111.121 -179.974 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.555 2.565 0 CA-C-O 115.466 -2.852 . . . . 73.329999999999998 118.899 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.71 173.15 42.7 Favored Glycine 0 C--N 1.378 2.9 0 CA-C-N 124.032 3.916 . . . . 73.030000000000001 111.158 -172.03 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -82.6 50.0 3.26 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 CA-C-N 122.519 3.16 . . . . 73.299999999999997 115.791 -176.116 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 61.5 mt -154.6 -155.08 0.55 Allowed 'General case' 0 C--N 1.357 0.917 0 CA-C-O 115.852 -2.023 . . . . 75.5 106.205 -178.785 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.89 90.02 3.13 Favored 'General case' 0 C--N 1.359 1.007 0 CA-C-N 121.81 2.096 . . . . 75.140000000000001 111.061 -175.69 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.2 -14.79 0.54 Allowed Glycine 0 C--N 1.353 1.482 0 O-C-N 118.816 -2.427 . . . . 72.530000000000001 117.927 170.729 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.9 pt-20 -129.5 173.51 10.51 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-N 121.708 2.754 . . . . 75.319999999999993 104.921 179.188 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -56.15 -35.77 67.54 Favored 'General case' 0 C--O 1.218 -0.582 0 CA-C-O 117.018 -1.468 . . . . 74.5 110.723 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -110.55 64.02 0.61 Allowed 'General case' 0 C--N 1.36 1.054 0 CA-C-N 120.692 1.587 . . . . 74.140000000000001 112.47 -173.098 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.91 96.45 0.01 OUTLIER Glycine 0 C--N 1.356 1.692 0 CA-C-O 116.349 -2.362 . . . . 71.140000000000001 108.795 175.567 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . . . . . . . . . . . -101.62 -173.9 28.25 Favored Glycine 0 C--N 1.363 2.068 0 CA-C-O 115.079 -3.067 . . . . 65.140000000000001 113.557 -174.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.5 tt -96.12 25.39 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.361 1.104 0 CA-C-N 120.192 1.996 . . . . 65.239999999999995 111.271 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.63 124.3 44.0 Favored 'General case' 0 C--N 1.364 1.238 0 CA-C-N 122.03 2.196 . . . . 73.230000000000004 111.112 -175.269 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 73.310000000000002 111.15 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 1.536 0 CA-C-O 116.544 -2.253 . . . . 65.109999999999999 117.875 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.46 171.88 37.55 Favored Glycine 0 C--N 1.359 1.815 0 CA-C-N 123.891 3.846 . . . . 75.120000000000005 111.398 -169.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -80.2 45.75 2.05 Favored 'Trans proline' 0 C--N 1.353 0.786 0 CA-C-N 122.298 3.049 . . . . 74.329999999999998 116.304 -177.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.419 ' N ' ' O ' ' A' ' 11' ' ' GLY . 56.9 mt -150.71 -154.01 0.52 Allowed 'General case' 0 C--N 1.352 0.711 0 N-CA-C 105.848 -1.908 . . . . 75.420000000000002 105.848 -178.472 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -126.26 90.21 3.14 Favored 'General case' 0 C--N 1.361 1.069 0 C-N-CA 126.044 1.738 . . . . 73.209999999999994 111.131 -176.077 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -139.81 -17.61 0.48 Allowed Glycine 0 C--N 1.349 1.254 0 O-C-N 118.487 -2.633 . . . . 70.439999999999998 116.627 172.608 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.6 pt-20 -127.7 176.98 7.12 Favored 'General case' 0 C--N 1.359 1.003 0 CA-C-N 121.64 2.72 . . . . 61.539999999999999 104.967 179.528 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -59.06 -35.96 74.23 Favored 'General case' 0 C--O 1.22 -0.46 0 CA-C-O 117.67 -1.157 . . . . 72.019999999999996 111.04 179.578 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 4.9 mmt -110.16 63.2 0.6 Allowed 'General case' 0 C--N 1.36 1.051 0 CA-C-N 119.86 1.209 . . . . 73.420000000000002 110.861 -173.321 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 62.81 96.61 0.01 OUTLIER Glycine 0 C--N 1.356 1.647 0 CA-C-O 116.073 -2.515 . . . . 74.430000000000007 109.63 175.807 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -99.38 -174.4 31.27 Favored Glycine 0 N--CA 1.49 2.239 0 CA-C-O 115.942 -2.588 . . . . 63.119999999999997 113.422 -176.036 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.0 tt -97.11 25.39 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.985 0 CA-C-N 119.73 1.765 . . . . 75.430000000000007 111.085 179.689 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.9 p -120.87 124.57 45.32 Favored 'General case' 0 C--N 1.363 1.174 0 CA-C-N 120.861 1.664 . . . . 75.340000000000003 111.149 -176.073 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 13.7 t . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 71.209999999999994 111.162 179.998 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.059 0 CA-C-O 116.268 -2.407 . . . . 74.230000000000004 117.296 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -148.92 174.97 28.39 Favored Glycine 0 C--N 1.35 1.309 0 CA-C-N 123.358 3.579 . . . . 70.409999999999997 111.926 -170.716 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_endo -79.35 44.27 1.66 Allowed 'Trans proline' 0 C--N 1.362 1.282 0 CA-C-N 121.616 2.708 . . . . 72.140000000000001 116.046 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.465 ' N ' ' O ' ' A' ' 11' ' ' GLY . 34.2 mt -150.41 -156.3 0.71 Allowed 'General case' 0 C--O 1.218 -0.589 0 N-CA-C 105.89 -1.893 . . . . 72.120000000000005 105.89 -175.732 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.49 101.53 7.38 Favored 'General case' 0 C--N 1.355 0.828 0 C-N-CA 125.219 1.407 . . . . 62.039999999999999 111.14 -176.289 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -150.11 -33.93 0.04 OUTLIER Glycine 0 C--N 1.351 1.416 0 O-C-N 120.087 -1.633 . . . . 61.210000000000001 117.166 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -118.71 -179.43 3.8 Favored 'General case' 0 C--N 1.353 0.725 0 N-CA-C 104.503 -2.406 . . . . 74.340000000000003 104.503 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.79 -30.11 71.11 Favored 'General case' 0 C--N 1.347 0.471 0 CA-C-O 117.575 -1.203 . . . . 75.420000000000002 111.558 179.735 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 94.5 mtp -111.02 59.32 0.61 Allowed 'General case' 0 C--N 1.359 1.018 0 CA-C-N 119.866 1.212 . . . . 73.430000000000007 110.863 -176.133 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.49 103.89 0.02 OUTLIER Glycine 0 C--N 1.353 1.524 0 CA-C-O 117.464 -1.742 . . . . 63.420000000000002 109.969 176.28 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.465 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -100.34 -176.53 30.15 Favored Glycine 0 CA--C 1.491 -1.468 0 CA-C-O 115.877 -2.624 . . . . 70.400000000000006 112.362 -172.594 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.6 tt -97.39 24.07 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.853 0 CA-C-N 120.343 2.071 . . . . 75.230000000000004 111.469 176.533 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -123.58 125.68 45.29 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 119.675 1.125 . . . . 75.340000000000003 111.157 -176.041 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 15.1 t . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 73.519999999999996 111.173 179.983 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.838 0 CA-C-O 114.936 -3.147 . . . . 71.230000000000004 118.198 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -152.62 175.45 31.2 Favored Glycine 0 C--N 1.35 1.313 0 CA-C-N 123.461 3.631 . . . . 63.520000000000003 111.5 -172.949 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -80.53 46.68 2.32 Favored 'Trans proline' 0 C--N 1.364 1.391 0 CA-C-N 120.911 2.356 . . . . 75.120000000000005 114.731 -178.357 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' LEU . . . . . 0.459 ' N ' ' O ' ' A' ' 11' ' ' GLY . 37.5 mt -151.31 -156.55 0.72 Allowed 'General case' 0 C--N 1.352 0.684 0 N-CA-C 106.819 -1.549 . . . . 74.140000000000001 106.819 -177.713 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.18 102.6 8.04 Favored 'General case' 0 C--N 1.362 1.13 0 CA-C-N 120.776 1.625 . . . . 75.140000000000001 111.066 -176.904 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -151.77 -34.71 0.03 OUTLIER Glycine 0 C--N 1.357 1.737 0 CA-C-O 117.177 -1.901 . . . . 62.43 116.915 179.236 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -117.46 178.05 4.52 Favored 'General case' 0 CA--C 1.506 -0.712 0 N-CA-C 105.792 -1.929 . . . . 71.230000000000004 105.792 177.774 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -61.18 -30.9 70.69 Favored 'General case' 0 C--O 1.22 -0.482 0 CA-C-O 117.662 -1.161 . . . . 72.25 111.415 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 20.9 mmt -110.33 58.51 0.61 Allowed 'General case' 0 C--N 1.359 0.991 0 CA-C-N 119.647 1.112 . . . . 75.109999999999999 113.021 -176.14 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 65.97 106.53 0.01 OUTLIER Glycine 0 C--N 1.353 1.528 0 CA-C-O 117.213 -1.881 . . . . 73.540000000000006 109.986 178.063 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -102.68 -174.78 26.98 Favored Glycine 0 CA--C 1.489 -1.593 0 CA-C-O 116.138 -2.479 . . . . 74.519999999999996 112.368 -172.376 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.4 tt -96.99 22.77 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.846 0 CA-C-N 120.256 2.028 . . . . 74.239999999999995 111.192 175.79 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -124.32 125.77 44.9 Favored 'General case' 0 C--N 1.359 0.981 0 CA-C-N 120.888 1.676 . . . . 74.439999999999998 111.153 -175.259 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.257 0 CA-C-N 116.217 -0.447 . . . . 73.140000000000001 111.141 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.371 0 CA-C-O 116.573 -2.237 . . . . 42.21 116.846 . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.26 175.36 34.71 Favored Glycine 0 C--N 1.363 2.072 1 CA-C-N 124.782 4.291 . . . . 72.34 112.099 -170.691 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.53 49.53 3.22 Favored 'Trans proline' 0 C--N 1.352 0.717 0 CA-C-N 122.479 3.139 . . . . 72.22 115.659 -178.327 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.419 ' N ' ' O ' ' A' ' 11' ' ' GLY . 37.8 mt -155.56 -156.16 0.62 Allowed 'General case' 0 C--N 1.358 0.965 0 CA-C-O 115.436 -2.221 . . . . 70.13 106.832 -177.04 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.03 105.49 9.61 Favored 'General case' 0 C--N 1.352 0.685 0 CA-C-N 122.06 2.209 . . . . 52.11 111.102 -175.778 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.14 -36.66 0.02 OUTLIER Glycine 0 C--N 1.373 2.632 0 N-CA-C 118.406 2.122 . . . . 43.32 118.406 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -116.31 177.4 4.7 Favored 'General case' 0 C--N 1.349 0.584 0 N-CA-C 105.474 -2.047 . . . . 75.04 105.474 176.075 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 7.4 tt0 -58.67 -32.48 69.14 Favored 'General case' 0 C--N 1.348 0.536 0 CA-C-O 117.931 -1.033 . . . . 50.44 111.816 179.275 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 6.1 mmt -109.63 57.49 0.61 Allowed 'General case' 0 C--N 1.359 0.986 0 CA-C-N 119.924 1.238 . . . . 60.44 111.655 -172.59 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 67.88 108.16 0.02 OUTLIER Glycine 0 C--N 1.358 1.767 0 CA-C-O 115.998 -2.557 . . . . 73.43 109.962 177.869 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -107.91 -174.18 22.09 Favored Glycine 0 C--N 1.354 1.572 0 CA-C-N 121.505 2.653 . . . . 53.14 111.198 -170.319 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 8.7 tt -96.42 22.66 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.735 0 CA-C-N 120.412 2.106 . . . . 75.34 111.022 176.577 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -124.56 125.69 44.6 Favored 'General case' 0 C--N 1.365 1.271 0 CA-C-N 121.171 1.805 . . . . 64.54 111.138 -174.653 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 7.0 t . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 64.51 111.091 -179.985 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 1.636 0 N-CA-C 120.158 2.823 . . . . 55.41 120.158 . . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -156.48 174.22 34.25 Favored Glycine 0 C--N 1.348 1.218 1 CA-C-N 124.817 4.308 . . . . 51.43 111.191 -173.437 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -79.94 44.55 1.74 Allowed 'Trans proline' 0 C--N 1.369 1.636 0 CA-C-N 122.054 2.927 . . . . 62.35 115.017 -177.36 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.44 ' N ' ' O ' ' A' ' 11' ' ' GLY . 43.3 mt -148.96 -154.5 0.56 Allowed 'General case' 0 C--N 1.354 0.788 0 N-CA-C 106.477 -1.675 . . . . 65.01 106.477 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.97 88.58 2.91 Favored 'General case' 0 C--N 1.362 1.142 0 C-N-CA 125.91 1.684 . . . . 72.41 111.151 -176.558 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -138.31 -14.78 0.7 Allowed Glycine 0 CA--C 1.528 0.845 0 O-C-N 118.724 -2.485 . . . . 71.45 117.305 171.715 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -129.39 175.67 8.57 Favored 'General case' 0 C--N 1.359 0.984 0 CA-C-N 121.372 2.586 . . . . 75.2 106.236 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -58.57 -36.95 74.75 Favored 'General case' 0 C--O 1.219 -0.546 0 CA-C-O 117.807 -1.092 . . . . 73.35 110.944 178.798 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 78.3 mtm -109.16 66.83 0.64 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 119.551 1.069 . . . . 63.21 111.396 -175.753 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 60.67 91.13 0.02 OUTLIER Glycine 0 C--N 1.352 1.448 0 CA-C-O 116.599 -2.223 . . . . 62.31 110.041 173.239 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.44 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -92.22 -174.34 42.09 Favored Glycine 0 C--O 1.201 -1.948 0 CA-C-O 116.204 -2.442 . . . . 74.32 115.091 -177.263 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.8 tt -96.84 24.06 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.371 1.538 0 CA-C-N 118.645 1.222 . . . . 73.31 111.257 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.4 p -120.57 124.44 45.32 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-N 120.744 1.611 . . . . 70.22 111.151 -174.86 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 15.4 t . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.244 -0.435 . . . . 75.33 111.153 179.978 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 1.782 0 N-CA-C 119.205 2.442 . . . . 61.2 119.205 . . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -158.72 175.25 35.78 Favored Glycine 0 C--N 1.354 1.571 1 CA-C-N 125.813 4.807 . . . . 74.32 109.764 -174.026 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -80.31 45.18 1.9 Allowed 'Trans proline' 0 C--N 1.351 0.71 0 CA-C-N 121.097 2.449 . . . . 74.2 115.504 -176.902 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.441 ' N ' ' O ' ' A' ' 11' ' ' GLY . 47.6 mt -149.95 -154.48 0.56 Allowed 'General case' 0 C--N 1.36 1.022 0 CA-C-O 116.467 -1.73 . . . . 74.14 107.017 -179.019 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.97 88.86 2.96 Favored 'General case' 0 C--N 1.354 0.778 0 C-N-CA 125.674 1.59 . . . . 62.22 111.108 -176.203 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -138.8 -14.58 0.66 Allowed Glycine 0 CA--C 1.529 0.909 0 O-C-N 118.698 -2.501 . . . . 63.3 117.271 171.343 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -129.13 174.96 9.09 Favored 'General case' 0 C--N 1.352 0.69 0 CA-C-N 121.04 2.42 . . . . 53.32 105.74 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -58.65 -35.13 72.04 Favored 'General case' 0 C--O 1.219 -0.525 0 CA-C-O 117.682 -1.151 . . . . 71.23 110.731 179.306 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 3.6 mmt -109.76 63.23 0.6 Allowed 'General case' 0 C--N 1.355 0.816 0 CA-C-N 119.419 1.008 . . . . 70.24 111.656 -174.077 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.67 91.17 0.02 OUTLIER Glycine 0 C--N 1.352 1.421 0 CA-C-O 116.567 -2.241 . . . . 62.31 110.093 175.71 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.441 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -92.87 -175.06 41.21 Favored Glycine 0 N--CA 1.491 2.34 0 CA-C-O 115.617 -2.768 . . . . 65.2 115.052 -177.006 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 12.1 tt -96.13 24.38 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.844 0 CA-C-N 120.124 1.962 . . . . 64.21 111.051 -179.481 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.4 p -120.66 124.59 45.59 Favored 'General case' 0 C--N 1.359 1.01 0 CA-C-N 121.346 1.885 . . . . 61.21 111.132 -175.328 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.5 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.249 -0.432 . . . . 71.04 111.139 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.703 0 CA-C-O 116.506 -2.274 . . . . 24.15 117.844 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -145.03 178.63 22.69 Favored Glycine 0 C--N 1.368 2.359 0 CA-C-N 123.347 3.574 . . . . 64.02 110.995 -174.826 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -79.38 44.62 1.74 Allowed 'Trans proline' 0 C--N 1.357 1.011 0 CA-C-N 121.78 2.79 . . . . 70.04 116.375 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.732 HD22 HG23 ' A' ' 14' ' ' THR . 39.3 mt -149.24 -156.34 0.71 Allowed 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 106.381 -1.711 . . . . 72.42 106.381 -176.203 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.19 100.92 7.1 Favored 'General case' 0 C--N 1.353 0.721 0 C-N-CA 125.079 1.352 . . . . 71.22 111.095 -176.758 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -149.53 -32.04 0.05 OUTLIER Glycine 0 C--N 1.347 1.151 0 O-C-N 119.299 -2.125 . . . . 51.02 116.776 178.939 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -119.67 179.22 4.3 Favored 'General case' 0 C--N 1.357 0.904 0 N-CA-C 104.743 -2.318 . . . . 64.51 104.743 178.864 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -64.12 -29.82 70.93 Favored 'General case' 0 C--N 1.349 0.558 0 CA-C-O 117.382 -1.294 . . . . 65.42 111.664 178.777 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 66.3 mmm -110.6 59.29 0.61 Allowed 'General case' 0 C--N 1.357 0.92 0 CA-C-N 119.597 1.089 . . . . 73.23 110.555 -176.345 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 65.99 98.74 0.02 OUTLIER Glycine 0 C--N 1.354 1.56 0 CA-C-O 117.978 -1.456 . . . . 64.44 110.428 174.83 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.452 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -94.2 -177.58 38.98 Favored Glycine 0 CA--C 1.491 -1.447 0 CA-C-O 115.598 -2.779 . . . . 63.3 113.183 -171.549 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.7 tt -97.58 24.85 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.992 0 CA-C-N 120.726 2.263 . . . . 65.31 111.289 175.63 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.2 p -124.16 125.83 45.12 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.593 1.088 . . . . 45.35 111.113 -176.431 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.732 HG23 HD22 ' A' ' 4' ' ' LEU . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.181 -0.463 . . . . 70.0 111.121 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.172 0 N-CA-C 120.027 2.771 . . . . 70.11 120.027 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -150.56 178.68 27.85 Favored Glycine 0 C--N 1.366 2.204 0 CA-C-N 124.069 3.935 . . . . 31.15 112.598 -175.598 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -81.29 49.62 3.27 Favored 'Trans proline' 0 N--CA 1.449 -1.118 1 CA-C-N 124.298 4.049 . . . . 74.42 116.208 -178.046 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.449 ' N ' ' O ' ' A' ' 11' ' ' GLY . 59.6 mt -154.01 -157.17 0.75 Allowed 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 116.703 -1.617 . . . . 51.43 106.91 -176.206 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.13 104.71 9.36 Favored 'General case' 0 C--N 1.358 0.976 0 CA-C-N 121.612 2.005 . . . . 71.53 111.095 -176.433 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.15 -35.78 0.02 OUTLIER Glycine 0 C--N 1.369 2.367 0 N-CA-C 117.599 1.8 . . . . 74.51 117.599 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -116.02 177.38 4.7 Favored 'General case' 0 C--N 1.354 0.799 0 N-CA-C 105.755 -1.942 . . . . 74.01 105.755 175.211 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -57.17 -33.51 67.52 Favored 'General case' 0 C--N 1.35 0.589 0 CA-C-O 117.926 -1.035 . . . . 42.44 111.424 178.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 1.8 mmm -110.15 60.72 0.6 Allowed 'General case' 0 C--N 1.354 0.776 0 CA-C-N 119.044 0.838 . . . . 72.3 112.352 -174.225 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.53 102.84 0.02 OUTLIER Glycine 0 C--N 1.355 1.631 0 N-CA-C 108.991 -1.644 . . . . 73.11 108.991 174.36 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -100.9 -174.2 29.19 Favored Glycine 0 C--O 1.207 -1.561 0 CA-C-O 115.912 -2.605 . . . . 73.42 112.941 -170.954 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 8.1 tt -96.99 22.48 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.364 1.209 0 CA-C-N 120.012 1.906 . . . . 64.44 111.669 175.388 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.4 p -124.48 125.75 44.75 Favored 'General case' 0 C--N 1.364 1.222 0 CA-C-N 120.079 1.308 . . . . 75.55 111.152 -174.62 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.1 t . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 71.14 111.112 -179.956 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.557 2.672 0 CA-C-O 115.318 -2.935 . . . . 62.53 118.803 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.53 173.12 42.59 Favored Glycine 0 C--N 1.379 2.927 0 CA-C-N 124.147 3.973 . . . . 61.25 111.039 -172.481 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -81.89 50.58 3.52 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 CA-C-N 122.573 3.186 . . . . 73.11 115.64 -176.356 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.648 HD22 HG23 ' A' ' 14' ' ' THR . 71.9 mt -155.61 -156.77 0.67 Allowed 'General case' 0 C--O 1.211 -0.938 0 CA-C-O 115.785 -2.055 . . . . 75.45 106.362 -177.457 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.0 91.31 3.41 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 121.798 2.09 . . . . 63.4 111.093 -176.133 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -141.87 -14.95 0.39 Allowed Glycine 0 C--N 1.353 1.498 0 O-C-N 119.064 -2.273 . . . . 52.5 118.422 169.881 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.419 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 10.0 pt-20 -128.24 175.02 8.78 Favored 'General case' 0 C--N 1.353 0.748 0 CA-C-N 121.466 2.633 . . . . 61.33 104.441 178.788 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -62.49 -30.62 71.4 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 116.886 -1.531 . . . . 74.21 110.57 -177.029 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 44.0 mtm -111.98 65.26 0.63 Allowed 'General case' 0 C--N 1.359 1.02 0 CA-C-N 120.622 1.555 . . . . 74.52 112.007 -177.22 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.71 96.66 0.01 OUTLIER Glycine 0 C--N 1.357 1.736 0 CA-C-O 116.346 -2.363 . . . . 72.41 109.365 174.338 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.419 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -101.62 -172.87 28.13 Favored Glycine 0 C--N 1.364 2.135 0 CA-C-O 114.722 -3.265 . . . . 72.42 113.858 -174.197 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.5 tt -96.96 25.26 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.361 1.105 0 CA-C-N 120.305 2.052 . . . . 75.32 111.233 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -122.11 124.56 44.19 Favored 'General case' 0 C--N 1.366 1.301 0 CA-C-N 122.138 2.244 . . . . 65.42 111.123 -174.757 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.648 HG23 HD22 ' A' ' 4' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.194 -0.457 . . . . 63.33 111.156 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.554 2.477 0 CA-C-O 115.442 -2.865 . . . . 55.25 118.881 . . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.71 173.11 42.7 Favored Glycine 0 C--N 1.377 2.84 0 CA-C-N 124.144 3.972 . . . . 74.14 111.205 -171.941 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -82.69 49.62 3.14 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 CA-C-N 122.639 3.22 . . . . 70.14 115.828 -176.041 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.9 mt -154.44 -154.89 0.54 Allowed 'General case' 0 C--N 1.357 0.929 0 CA-C-O 115.744 -2.074 . . . . 64.32 106.317 -178.821 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.84 89.88 3.11 Favored 'General case' 0 C--N 1.358 0.969 0 CA-C-N 121.782 2.083 . . . . 62.02 111.108 -175.532 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.02 -14.6 0.56 Allowed Glycine 0 C--N 1.353 1.503 0 O-C-N 118.84 -2.413 . . . . 55.51 117.936 170.569 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.414 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 9.0 pt-20 -129.64 173.45 10.6 Favored 'General case' 0 C--N 1.355 0.83 0 CA-C-N 121.705 2.753 . . . . 74.0 104.999 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -56.84 -35.07 68.4 Favored 'General case' 0 C--O 1.217 -0.622 0 CA-C-O 117.282 -1.342 . . . . 72.53 111.132 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 7.7 mmt -110.28 64.0 0.61 Allowed 'General case' 0 C--N 1.36 1.042 0 CA-C-N 120.456 1.48 . . . . 71.54 111.598 -173.348 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.12 96.82 0.01 OUTLIER Glycine 0 C--N 1.356 1.66 0 CA-C-O 116.42 -2.322 . . . . 63.54 109.439 175.633 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.414 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -101.84 -173.86 27.96 Favored Glycine 0 C--N 1.364 2.087 0 CA-C-O 115.14 -3.033 . . . . 73.21 113.721 -174.933 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.9 tt -96.3 25.43 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.051 0 CA-C-N 120.245 2.023 . . . . 52.51 111.281 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -121.38 124.43 44.51 Favored 'General case' 0 C--N 1.364 1.233 0 CA-C-N 122.018 2.19 . . . . 52.32 111.162 -175.512 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.2 m . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.455 . . . . 53.32 111.145 179.99 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.556 2.655 0 CA-C-O 115.298 -2.946 . . . . 61.2 118.832 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.01 173.07 42.88 Favored Glycine 0 C--N 1.379 2.928 0 CA-C-N 124.08 3.94 . . . . 63.1 111.15 -172.043 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -82.61 50.21 3.33 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 CA-C-N 122.665 3.233 . . . . 63.14 115.71 -175.93 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.5 mt -154.9 -155.35 0.57 Allowed 'General case' 0 C--N 1.357 0.902 0 CA-C-O 115.891 -2.004 . . . . 73.11 106.266 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.61 89.84 3.11 Favored 'General case' 0 C--N 1.359 1.019 0 CA-C-N 121.687 2.039 . . . . 70.51 111.103 -175.719 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.2 -14.19 0.56 Allowed Glycine 0 C--N 1.355 1.609 0 O-C-N 118.944 -2.347 . . . . 73.32 117.947 170.978 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.419 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 10.1 pt-20 -130.39 174.66 9.64 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 121.708 2.754 . . . . 63.52 104.996 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -61.61 -30.59 70.79 Favored 'General case' 0 C--O 1.218 -0.567 0 CA-C-O 116.923 -1.513 . . . . 72.04 110.722 -177.551 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 8.1 mmt -112.01 64.8 0.63 Allowed 'General case' 0 C--N 1.359 1.003 0 CA-C-N 120.598 1.545 . . . . 63.33 111.561 -176.757 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 60.87 96.95 0.01 OUTLIER Glycine 0 C--N 1.356 1.674 0 CA-C-O 116.516 -2.269 . . . . 31.33 109.752 174.713 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.419 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -102.24 -173.82 27.45 Favored Glycine 0 C--N 1.364 2.107 0 CA-C-O 115.062 -3.077 . . . . 74.13 113.799 -174.485 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.7 tt -96.14 24.96 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.053 0 CA-C-N 120.261 2.031 . . . . 54.45 111.475 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -121.24 124.8 45.54 Favored 'General case' 0 C--N 1.365 1.24 0 CA-C-N 121.913 2.142 . . . . 71.5 111.167 -175.084 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.9 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 53.42 111.115 -179.988 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.556 2.648 0 CA-C-O 115.264 -2.965 . . . . 52.21 118.753 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.88 172.82 42.75 Favored Glycine 0 C--N 1.379 2.934 0 CA-C-N 124.085 3.942 . . . . 54.31 111.125 -172.244 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -82.09 50.07 3.34 Favored 'Trans proline' 0 N--CA 1.454 -0.839 0 CA-C-N 122.581 3.191 . . . . 73.04 115.908 -176.221 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.8 mt -154.64 -154.95 0.54 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-O 115.918 -1.992 . . . . 45.1 106.114 -178.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.93 91.18 3.33 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 121.731 2.06 . . . . 74.23 111.143 -175.797 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -141.33 -15.37 0.43 Allowed Glycine 0 C--N 1.353 1.484 0 O-C-N 119.039 -2.288 . . . . 61.11 118.209 170.248 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.415 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 9.3 pt-20 -128.36 174.01 9.69 Favored 'General case' 0 C--N 1.354 0.771 0 CA-C-N 121.47 2.635 . . . . 75.54 104.739 179.063 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -58.77 -33.7 70.6 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-O 116.905 -1.522 . . . . 74.01 110.886 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 33.4 mmm -111.24 65.09 0.62 Allowed 'General case' 0 C--N 1.359 1.009 0 CA-C-N 120.885 1.675 . . . . 64.12 111.751 -174.965 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.42 97.04 0.01 OUTLIER Glycine 0 C--N 1.358 1.769 0 CA-C-O 116.26 -2.411 . . . . 64.24 109.569 174.936 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.415 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -102.34 -173.88 27.33 Favored Glycine 0 C--N 1.364 2.133 0 CA-C-O 114.978 -3.123 . . . . 74.31 113.682 -174.152 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.4 tt -96.24 25.13 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.362 1.111 0 CA-C-N 120.279 2.039 . . . . 72.54 111.291 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.67 124.62 44.7 Favored 'General case' 0 C--N 1.365 1.247 0 CA-C-N 121.907 2.14 . . . . 54.1 111.174 -174.961 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.253 -0.43 . . . . 75.05 111.113 -179.929 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 1.414 0 CA-C-O 116.708 -2.162 . . . . 73.4 117.815 . . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.27 171.94 37.4 Favored Glycine 0 C--N 1.36 1.88 0 CA-C-N 123.808 3.804 . . . . 74.44 111.459 -170.25 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -79.84 45.33 1.92 Allowed 'Trans proline' 0 C--N 1.354 0.845 0 CA-C-N 122.395 3.098 . . . . 71.42 116.185 -178.029 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.622 HD22 HG23 ' A' ' 14' ' ' THR . 48.3 mt -150.69 -155.16 0.6 Allowed 'General case' 0 C--N 1.352 0.677 0 N-CA-C 106.015 -1.846 . . . . 73.33 106.015 -176.949 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.6 90.87 3.29 Favored 'General case' 0 C--N 1.359 1.02 0 C-N-CA 125.689 1.596 . . . . 74.42 111.149 -176.719 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.54 -17.69 0.42 Allowed Glycine 0 C--N 1.349 1.252 0 O-C-N 118.544 -2.597 . . . . 65.23 116.774 172.52 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.43 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 8.2 pt-20 -127.92 177.71 6.67 Favored 'General case' 0 C--N 1.36 1.031 0 CA-C-N 121.571 2.685 . . . . 71.13 104.481 179.596 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -63.51 -32.07 73.41 Favored 'General case' 0 C--O 1.219 -0.552 0 CA-C-O 117.062 -1.447 . . . . 73.53 110.937 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 15.9 mtt -110.6 64.53 0.61 Allowed 'General case' 0 C--N 1.361 1.099 0 CA-C-N 120.435 1.471 . . . . 63.04 111.942 -177.776 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 63.15 96.76 0.01 OUTLIER Glycine 0 C--N 1.356 1.686 0 CA-C-O 115.958 -2.579 . . . . 54.13 109.059 174.66 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.43 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -99.4 -174.04 31.19 Favored Glycine 0 N--CA 1.488 2.147 0 CA-C-O 115.509 -2.828 . . . . 75.25 113.301 -175.331 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.1 tt -97.21 25.46 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.022 0 CA-C-N 119.869 1.834 . . . . 64.24 111.002 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.52 124.79 45.25 Favored 'General case' 0 C--N 1.363 1.176 0 CA-C-N 121.149 1.795 . . . . 61.25 111.123 -175.581 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.622 HG23 HD22 ' A' ' 4' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 53.05 111.139 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.141 0 CA-C-O 116.095 -2.503 . . . . 63.42 119.231 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -149.4 177.05 27.84 Favored Glycine 0 C--N 1.366 2.244 0 CA-C-N 123.074 3.437 . . . . 75.21 110.915 -174.222 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -80.19 46.88 2.36 Favored 'Trans proline' 0 C--N 1.349 0.588 0 CA-C-N 122.272 3.036 . . . . 54.13 115.267 -178.174 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.497 ' N ' ' O ' ' A' ' 11' ' ' GLY . 54.9 mt -150.81 -156.08 0.68 Allowed 'General case' 0 C--N 1.349 0.544 0 CA-C-O 117.032 -1.461 . . . . 71.44 108.092 -178.036 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -122.54 102.94 8.37 Favored 'General case' 0 C--N 1.369 1.453 0 CA-C-N 121.042 1.747 . . . . 71.31 111.089 -177.221 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -153.3 -33.9 0.03 OUTLIER Glycine 0 C--N 1.349 1.304 0 N-CA-C 117.622 1.809 . . . . 53.11 117.622 179.479 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -116.11 177.64 4.61 Favored 'General case' 0 C--N 1.351 0.66 0 CA-C-N 119.141 1.47 . . . . 74.12 107.524 174.966 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -60.29 -31.44 70.25 Favored 'General case' 0 C--N 1.349 0.544 0 CA-C-O 117.816 -1.088 . . . . 63.3 110.93 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 31.4 mmm -110.05 58.45 0.61 Allowed 'General case' 0 C--N 1.359 1.004 0 CA-C-N 119.389 0.995 . . . . 71.44 111.969 -173.677 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.09 101.14 0.02 OUTLIER Glycine 0 C--N 1.356 1.655 0 CA-C-O 117.08 -1.956 . . . . 75.15 110.86 177.036 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.497 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -96.32 -176.07 35.94 Favored Glycine 0 CA--C 1.486 -1.766 0 CA-C-O 116.203 -2.443 . . . . 61.23 114.066 -172.311 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.5 tt -97.17 22.62 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.749 0 CA-C-N 120.211 2.006 . . . . 75.11 111.389 174.768 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.0 p -124.14 128.19 48.89 Favored 'General case' 0 C--N 1.362 1.132 0 CA-C-N 120.348 1.431 . . . . 73.32 111.137 -175.402 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 86.8 m . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 73.34 111.121 -179.974 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.555 2.565 0 CA-C-O 115.466 -2.852 . . . . 64.34 118.899 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.71 173.15 42.7 Favored Glycine 0 C--N 1.378 2.9 0 CA-C-N 124.032 3.916 . . . . 64.33 111.158 -172.03 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -82.6 50.0 3.26 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 CA-C-N 122.519 3.16 . . . . 64.43 115.791 -176.116 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 61.5 mt -154.6 -155.08 0.55 Allowed 'General case' 0 C--N 1.357 0.917 0 CA-C-O 115.852 -2.023 . . . . 74.32 106.205 -178.785 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.89 90.02 3.13 Favored 'General case' 0 C--N 1.359 1.007 0 CA-C-N 121.81 2.096 . . . . 64.31 111.061 -175.69 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.2 -14.79 0.54 Allowed Glycine 0 C--N 1.353 1.482 0 O-C-N 118.816 -2.427 . . . . 72.53 117.927 170.729 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.415 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 8.9 pt-20 -129.5 173.51 10.51 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-N 121.708 2.754 . . . . 75.32 104.921 179.188 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -56.15 -35.77 67.54 Favored 'General case' 0 C--O 1.218 -0.582 0 CA-C-O 117.018 -1.468 . . . . 74.5 110.723 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -110.55 64.02 0.61 Allowed 'General case' 0 C--N 1.36 1.054 0 CA-C-N 120.692 1.587 . . . . 73.13 112.47 -173.098 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.91 96.45 0.01 OUTLIER Glycine 0 C--N 1.356 1.692 0 CA-C-O 116.349 -2.362 . . . . 53.22 108.795 175.567 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.415 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -101.62 -173.9 28.25 Favored Glycine 0 C--N 1.363 2.068 0 CA-C-O 115.079 -3.067 . . . . 41.32 113.557 -174.686 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.5 tt -96.12 25.39 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.361 1.104 0 CA-C-N 120.192 1.996 . . . . 60.13 111.271 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.63 124.3 44.0 Favored 'General case' 0 C--N 1.364 1.238 0 CA-C-N 122.03 2.196 . . . . 73.23 111.112 -175.269 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 73.31 111.15 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 1.536 0 CA-C-O 116.544 -2.253 . . . . 65.11 117.875 . . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.46 171.88 37.55 Favored Glycine 0 C--N 1.359 1.815 0 CA-C-N 123.891 3.846 . . . . 75.12 111.398 -169.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -80.2 45.75 2.05 Favored 'Trans proline' 0 C--N 1.353 0.786 0 CA-C-N 122.298 3.049 . . . . 74.33 116.304 -177.989 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.419 ' N ' ' O ' ' A' ' 11' ' ' GLY . 56.9 mt -150.71 -154.01 0.52 Allowed 'General case' 0 C--N 1.352 0.711 0 N-CA-C 105.848 -1.908 . . . . 75.42 105.848 -178.472 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -126.26 90.21 3.14 Favored 'General case' 0 C--N 1.361 1.069 0 C-N-CA 126.044 1.738 . . . . 73.12 111.131 -176.077 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -139.81 -17.61 0.48 Allowed Glycine 0 C--N 1.349 1.254 0 O-C-N 118.487 -2.633 . . . . 70.44 116.627 172.608 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 7' ' ' GLU . . . . . 0.424 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 8.6 pt-20 -127.7 176.98 7.12 Favored 'General case' 0 C--N 1.359 1.003 0 CA-C-N 121.64 2.72 . . . . 54.52 104.967 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -59.06 -35.96 74.23 Favored 'General case' 0 C--O 1.22 -0.46 0 CA-C-O 117.67 -1.157 . . . . 72.02 111.04 179.578 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 4.9 mmt -110.16 63.2 0.6 Allowed 'General case' 0 C--N 1.36 1.051 0 CA-C-N 119.86 1.209 . . . . 73.42 110.861 -173.321 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 62.81 96.61 0.01 OUTLIER Glycine 0 C--N 1.356 1.647 0 CA-C-O 116.073 -2.515 . . . . 52.01 109.63 175.807 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.424 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -99.38 -174.4 31.27 Favored Glycine 0 N--CA 1.49 2.239 0 CA-C-O 115.942 -2.588 . . . . 63.12 113.422 -176.036 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.0 tt -97.11 25.39 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.985 0 CA-C-N 119.73 1.765 . . . . 75.43 111.085 179.689 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.9 p -120.87 124.57 45.32 Favored 'General case' 0 C--N 1.363 1.174 0 CA-C-N 120.861 1.664 . . . . 64.45 111.149 -176.073 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 13.7 t . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 70.33 111.162 179.998 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.059 0 CA-C-O 116.268 -2.407 . . . . 74.23 117.296 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -148.92 174.97 28.39 Favored Glycine 0 C--N 1.35 1.309 0 CA-C-N 123.358 3.579 . . . . 45.22 111.926 -170.716 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_endo -79.35 44.27 1.66 Allowed 'Trans proline' 0 C--N 1.362 1.282 0 CA-C-N 121.616 2.708 . . . . 64.44 116.046 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.465 ' N ' ' O ' ' A' ' 11' ' ' GLY . 34.2 mt -150.41 -156.3 0.71 Allowed 'General case' 0 C--O 1.218 -0.589 0 N-CA-C 105.89 -1.893 . . . . 63.05 105.89 -175.732 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.49 101.53 7.38 Favored 'General case' 0 C--N 1.355 0.828 0 C-N-CA 125.219 1.407 . . . . 60.21 111.14 -176.289 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -150.11 -33.93 0.04 OUTLIER Glycine 0 C--N 1.351 1.416 0 O-C-N 120.087 -1.633 . . . . 60.1 117.166 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -118.71 -179.43 3.8 Favored 'General case' 0 C--N 1.353 0.725 0 N-CA-C 104.503 -2.406 . . . . 74.34 104.503 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.79 -30.11 71.11 Favored 'General case' 0 C--N 1.347 0.471 0 CA-C-O 117.575 -1.203 . . . . 75.42 111.558 179.735 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 94.5 mtp -111.02 59.32 0.61 Allowed 'General case' 0 C--N 1.359 1.018 0 CA-C-N 119.866 1.212 . . . . 65.3 110.863 -176.133 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.49 103.89 0.02 OUTLIER Glycine 0 C--N 1.353 1.524 0 CA-C-O 117.464 -1.742 . . . . 63.42 109.969 176.28 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.465 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -100.34 -176.53 30.15 Favored Glycine 0 CA--C 1.491 -1.468 0 CA-C-O 115.877 -2.624 . . . . 70.4 112.362 -172.594 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.6 tt -97.39 24.07 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.853 0 CA-C-N 120.343 2.071 . . . . 71.4 111.469 176.533 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -123.58 125.68 45.29 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 119.675 1.125 . . . . 75.34 111.157 -176.041 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 15.1 t . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 73.52 111.173 179.983 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.838 0 CA-C-O 114.936 -3.147 . . . . 51.44 118.198 . . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -152.62 175.45 31.2 Favored Glycine 0 C--N 1.35 1.313 0 CA-C-N 123.461 3.631 . . . . 63.21 111.5 -172.949 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -80.53 46.68 2.32 Favored 'Trans proline' 0 C--N 1.364 1.391 0 CA-C-N 120.911 2.356 . . . . 75.12 114.731 -178.357 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 4' ' ' LEU . . . . . 0.626 HD22 HG23 ' A' ' 14' ' ' THR . 37.5 mt -151.31 -156.55 0.72 Allowed 'General case' 0 C--N 1.352 0.684 0 N-CA-C 106.819 -1.549 . . . . 74.14 106.819 -177.713 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.18 102.6 8.04 Favored 'General case' 0 C--N 1.362 1.13 0 CA-C-N 120.776 1.625 . . . . 75.14 111.066 -176.904 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -151.77 -34.71 0.03 OUTLIER Glycine 0 C--N 1.357 1.737 0 CA-C-O 117.177 -1.901 . . . . 61.23 116.915 179.236 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -117.46 178.05 4.52 Favored 'General case' 0 CA--C 1.506 -0.712 0 N-CA-C 105.792 -1.929 . . . . 63.11 105.792 177.774 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -61.18 -30.9 70.69 Favored 'General case' 0 C--O 1.22 -0.482 0 CA-C-O 117.662 -1.161 . . . . 72.25 111.415 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 20.9 mmt -110.33 58.51 0.61 Allowed 'General case' 0 C--N 1.359 0.991 0 CA-C-N 119.647 1.112 . . . . 73.35 113.021 -176.14 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 65.97 106.53 0.01 OUTLIER Glycine 0 C--N 1.353 1.528 0 CA-C-O 117.213 -1.881 . . . . 73.54 109.986 178.063 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -102.68 -174.78 26.98 Favored Glycine 0 CA--C 1.489 -1.593 0 CA-C-O 116.138 -2.479 . . . . 73.54 112.368 -172.376 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.4 tt -96.99 22.77 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.846 0 CA-C-N 120.256 2.028 . . . . 64.15 111.192 175.79 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -124.32 125.77 44.9 Favored 'General case' 0 C--N 1.359 0.981 0 CA-C-N 120.888 1.676 . . . . 74.44 111.153 -175.259 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' THR . . . . . 0.626 HG23 HD22 ' A' ' 4' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.257 0 CA-C-N 116.217 -0.447 . . . . 73.14 111.141 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.371 0 CA-C-O 116.573 -2.237 . . . . 42.21 116.846 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.26 175.36 34.71 Favored Glycine 0 C--N 1.363 2.072 1 CA-C-N 124.782 4.291 . . . . 72.34 112.099 -170.691 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.53 49.53 3.22 Favored 'Trans proline' 0 C--N 1.352 0.717 0 CA-C-N 122.479 3.139 . . . . 72.22 115.659 -178.327 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.419 ' N ' ' O ' ' A' ' 11' ' ' GLY . 37.8 mt -155.56 -156.16 0.62 Allowed 'General case' 0 C--N 1.358 0.965 0 CA-C-O 115.436 -2.221 . . . . 70.13 106.832 -177.04 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.03 105.49 9.61 Favored 'General case' 0 C--N 1.352 0.685 0 CA-C-N 122.06 2.209 . . . . 52.11 111.102 -175.778 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.14 -36.66 0.02 OUTLIER Glycine 0 C--N 1.373 2.632 0 N-CA-C 118.406 2.122 . . . . 43.32 118.406 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -116.31 177.4 4.7 Favored 'General case' 0 C--N 1.349 0.584 0 N-CA-C 105.474 -2.047 . . . . 75.04 105.474 176.075 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 7.4 tt0 -58.67 -32.48 69.14 Favored 'General case' 0 C--N 1.348 0.536 0 CA-C-O 117.931 -1.033 . . . . 50.44 111.816 179.275 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 6.1 mmt -109.63 57.49 0.61 Allowed 'General case' 0 C--N 1.359 0.986 0 CA-C-N 119.924 1.238 . . . . 60.44 111.655 -172.59 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 67.88 108.16 0.02 OUTLIER Glycine 0 C--N 1.358 1.767 0 CA-C-O 115.998 -2.557 . . . . 73.43 109.962 177.869 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -107.91 -174.18 22.09 Favored Glycine 0 C--N 1.354 1.572 0 CA-C-N 121.505 2.653 . . . . 53.14 111.198 -170.319 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 8.7 tt -96.42 22.66 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.735 0 CA-C-N 120.412 2.106 . . . . 75.34 111.022 176.577 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -124.56 125.69 44.6 Favored 'General case' 0 C--N 1.365 1.271 0 CA-C-N 121.171 1.805 . . . . 64.54 111.138 -174.653 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 7.0 t . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 64.51 111.091 -179.985 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 1.636 0 N-CA-C 120.158 2.823 . . . . 55.41 120.158 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -156.48 174.22 34.25 Favored Glycine 0 C--N 1.348 1.218 1 CA-C-N 124.817 4.308 . . . . 51.43 111.191 -173.437 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -79.94 44.55 1.74 Allowed 'Trans proline' 0 C--N 1.369 1.636 0 CA-C-N 122.054 2.927 . . . . 62.35 115.017 -177.36 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.44 ' N ' ' O ' ' A' ' 11' ' ' GLY . 43.3 mt -148.96 -154.5 0.56 Allowed 'General case' 0 C--N 1.354 0.788 0 N-CA-C 106.477 -1.675 . . . . 65.01 106.477 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.97 88.58 2.91 Favored 'General case' 0 C--N 1.362 1.142 0 C-N-CA 125.91 1.684 . . . . 72.41 111.151 -176.558 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -138.31 -14.78 0.7 Allowed Glycine 0 CA--C 1.528 0.845 0 O-C-N 118.724 -2.485 . . . . 71.45 117.305 171.715 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -129.39 175.67 8.57 Favored 'General case' 0 C--N 1.359 0.984 0 CA-C-N 121.372 2.586 . . . . 75.2 106.236 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -58.57 -36.95 74.75 Favored 'General case' 0 C--O 1.219 -0.546 0 CA-C-O 117.807 -1.092 . . . . 73.35 110.944 178.798 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 78.3 mtm -109.16 66.83 0.64 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 119.551 1.069 . . . . 63.21 111.396 -175.753 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 60.67 91.13 0.02 OUTLIER Glycine 0 C--N 1.352 1.448 0 CA-C-O 116.599 -2.223 . . . . 62.31 110.041 173.239 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.44 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -92.22 -174.34 42.09 Favored Glycine 0 C--O 1.201 -1.948 0 CA-C-O 116.204 -2.442 . . . . 74.32 115.091 -177.263 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.8 tt -96.84 24.06 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.371 1.538 0 CA-C-N 118.645 1.222 . . . . 73.31 111.257 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.4 p -120.57 124.44 45.32 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-N 120.744 1.611 . . . . 70.22 111.151 -174.86 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 15.4 t . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.244 -0.435 . . . . 75.33 111.153 179.978 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 1.782 0 N-CA-C 119.205 2.442 . . . . 61.2 119.205 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -158.72 175.25 35.78 Favored Glycine 0 C--N 1.354 1.571 1 CA-C-N 125.813 4.807 . . . . 74.32 109.764 -174.026 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -80.31 45.18 1.9 Allowed 'Trans proline' 0 C--N 1.351 0.71 0 CA-C-N 121.097 2.449 . . . . 74.2 115.504 -176.902 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.441 ' N ' ' O ' ' A' ' 11' ' ' GLY . 47.6 mt -149.95 -154.48 0.56 Allowed 'General case' 0 C--N 1.36 1.022 0 CA-C-O 116.467 -1.73 . . . . 74.14 107.017 -179.019 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.97 88.86 2.96 Favored 'General case' 0 C--N 1.354 0.778 0 C-N-CA 125.674 1.59 . . . . 62.22 111.108 -176.203 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -138.8 -14.58 0.66 Allowed Glycine 0 CA--C 1.529 0.909 0 O-C-N 118.698 -2.501 . . . . 63.3 117.271 171.343 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -129.13 174.96 9.09 Favored 'General case' 0 C--N 1.352 0.69 0 CA-C-N 121.04 2.42 . . . . 53.32 105.74 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -58.65 -35.13 72.04 Favored 'General case' 0 C--O 1.219 -0.525 0 CA-C-O 117.682 -1.151 . . . . 71.23 110.731 179.306 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 3.6 mmt -109.76 63.23 0.6 Allowed 'General case' 0 C--N 1.355 0.816 0 CA-C-N 119.419 1.008 . . . . 70.24 111.656 -174.077 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.67 91.17 0.02 OUTLIER Glycine 0 C--N 1.352 1.421 0 CA-C-O 116.567 -2.241 . . . . 62.31 110.093 175.71 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.441 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -92.87 -175.06 41.21 Favored Glycine 0 N--CA 1.491 2.34 0 CA-C-O 115.617 -2.768 . . . . 65.2 115.052 -177.006 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 12.1 tt -96.13 24.38 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.844 0 CA-C-N 120.124 1.962 . . . . 64.21 111.051 -179.481 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.4 p -120.66 124.59 45.59 Favored 'General case' 0 C--N 1.359 1.01 0 CA-C-N 121.346 1.885 . . . . 61.21 111.132 -175.328 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.5 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.249 -0.432 . . . . 71.04 111.139 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.703 0 CA-C-O 116.506 -2.274 . . . . 24.15 117.844 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -145.03 178.63 22.69 Favored Glycine 0 C--N 1.368 2.359 0 CA-C-N 123.347 3.574 . . . . 64.02 110.995 -174.826 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -79.38 44.62 1.74 Allowed 'Trans proline' 0 C--N 1.357 1.011 0 CA-C-N 121.78 2.79 . . . . 70.04 116.375 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.732 HD22 HG23 ' A' ' 14' ' ' THR . 39.3 mt -149.24 -156.34 0.71 Allowed 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 106.381 -1.711 . . . . 72.42 106.381 -176.203 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.19 100.92 7.1 Favored 'General case' 0 C--N 1.353 0.721 0 C-N-CA 125.079 1.352 . . . . 71.22 111.095 -176.758 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -149.53 -32.04 0.05 OUTLIER Glycine 0 C--N 1.347 1.151 0 O-C-N 119.299 -2.125 . . . . 51.02 116.776 178.939 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -119.67 179.22 4.3 Favored 'General case' 0 C--N 1.357 0.904 0 N-CA-C 104.743 -2.318 . . . . 64.51 104.743 178.864 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -64.12 -29.82 70.93 Favored 'General case' 0 C--N 1.349 0.558 0 CA-C-O 117.382 -1.294 . . . . 65.42 111.664 178.777 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 66.3 mmm -110.6 59.29 0.61 Allowed 'General case' 0 C--N 1.357 0.92 0 CA-C-N 119.597 1.089 . . . . 73.23 110.555 -176.345 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 65.99 98.74 0.02 OUTLIER Glycine 0 C--N 1.354 1.56 0 CA-C-O 117.978 -1.456 . . . . 64.44 110.428 174.83 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.452 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -94.2 -177.58 38.98 Favored Glycine 0 CA--C 1.491 -1.447 0 CA-C-O 115.598 -2.779 . . . . 63.3 113.183 -171.549 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.7 tt -97.58 24.85 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.992 0 CA-C-N 120.726 2.263 . . . . 65.31 111.289 175.63 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.2 p -124.16 125.83 45.12 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.593 1.088 . . . . 45.35 111.113 -176.431 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.732 HG23 HD22 ' A' ' 4' ' ' LEU . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.181 -0.463 . . . . 70.0 111.121 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.172 0 N-CA-C 120.027 2.771 . . . . 70.11 120.027 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -150.56 178.68 27.85 Favored Glycine 0 C--N 1.366 2.204 0 CA-C-N 124.069 3.935 . . . . 31.15 112.598 -175.598 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -81.29 49.62 3.27 Favored 'Trans proline' 0 N--CA 1.449 -1.118 1 CA-C-N 124.298 4.049 . . . . 74.42 116.208 -178.046 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.449 ' N ' ' O ' ' A' ' 11' ' ' GLY . 59.6 mt -154.01 -157.17 0.75 Allowed 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 116.703 -1.617 . . . . 51.43 106.91 -176.206 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.13 104.71 9.36 Favored 'General case' 0 C--N 1.358 0.976 0 CA-C-N 121.612 2.005 . . . . 71.53 111.095 -176.433 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.15 -35.78 0.02 OUTLIER Glycine 0 C--N 1.369 2.367 0 N-CA-C 117.599 1.8 . . . . 74.51 117.599 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -116.02 177.38 4.7 Favored 'General case' 0 C--N 1.354 0.799 0 N-CA-C 105.755 -1.942 . . . . 74.01 105.755 175.211 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -57.17 -33.51 67.52 Favored 'General case' 0 C--N 1.35 0.589 0 CA-C-O 117.926 -1.035 . . . . 42.44 111.424 178.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 1.8 mmm -110.15 60.72 0.6 Allowed 'General case' 0 C--N 1.354 0.776 0 CA-C-N 119.044 0.838 . . . . 72.3 112.352 -174.225 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.53 102.84 0.02 OUTLIER Glycine 0 C--N 1.355 1.631 0 N-CA-C 108.991 -1.644 . . . . 73.11 108.991 174.36 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -100.9 -174.2 29.19 Favored Glycine 0 C--O 1.207 -1.561 0 CA-C-O 115.912 -2.605 . . . . 73.42 112.941 -170.954 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 8.1 tt -96.99 22.48 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.364 1.209 0 CA-C-N 120.012 1.906 . . . . 64.44 111.669 175.388 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.4 p -124.48 125.75 44.75 Favored 'General case' 0 C--N 1.364 1.222 0 CA-C-N 120.079 1.308 . . . . 75.55 111.152 -174.62 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.1 t . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 71.14 111.112 -179.956 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.557 2.672 0 CA-C-O 115.318 -2.935 . . . . 62.53 118.803 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.53 173.12 42.59 Favored Glycine 0 C--N 1.379 2.927 0 CA-C-N 124.147 3.973 . . . . 61.25 111.039 -172.481 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -81.89 50.58 3.52 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 CA-C-N 122.573 3.186 . . . . 73.11 115.64 -176.356 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.648 HD22 HG23 ' A' ' 14' ' ' THR . 71.9 mt -155.61 -156.77 0.67 Allowed 'General case' 0 C--O 1.211 -0.938 0 CA-C-O 115.785 -2.055 . . . . 75.45 106.362 -177.457 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.0 91.31 3.41 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 121.798 2.09 . . . . 63.4 111.093 -176.133 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -141.87 -14.95 0.39 Allowed Glycine 0 C--N 1.353 1.498 0 O-C-N 119.064 -2.273 . . . . 52.5 118.422 169.881 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.419 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 10.0 pt-20 -128.24 175.02 8.78 Favored 'General case' 0 C--N 1.353 0.748 0 CA-C-N 121.466 2.633 . . . . 61.33 104.441 178.788 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -62.49 -30.62 71.4 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 116.886 -1.531 . . . . 74.21 110.57 -177.029 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 44.0 mtm -111.98 65.26 0.63 Allowed 'General case' 0 C--N 1.359 1.02 0 CA-C-N 120.622 1.555 . . . . 74.52 112.007 -177.22 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.71 96.66 0.01 OUTLIER Glycine 0 C--N 1.357 1.736 0 CA-C-O 116.346 -2.363 . . . . 72.41 109.365 174.338 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.419 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -101.62 -172.87 28.13 Favored Glycine 0 C--N 1.364 2.135 0 CA-C-O 114.722 -3.265 . . . . 72.42 113.858 -174.197 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.5 tt -96.96 25.26 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.361 1.105 0 CA-C-N 120.305 2.052 . . . . 75.32 111.233 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -122.11 124.56 44.19 Favored 'General case' 0 C--N 1.366 1.301 0 CA-C-N 122.138 2.244 . . . . 65.42 111.123 -174.757 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.648 HG23 HD22 ' A' ' 4' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.194 -0.457 . . . . 63.33 111.156 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.554 2.477 0 CA-C-O 115.442 -2.865 . . . . 55.25 118.881 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.71 173.11 42.7 Favored Glycine 0 C--N 1.377 2.84 0 CA-C-N 124.144 3.972 . . . . 74.14 111.205 -171.941 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -82.69 49.62 3.14 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 CA-C-N 122.639 3.22 . . . . 70.14 115.828 -176.041 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.9 mt -154.44 -154.89 0.54 Allowed 'General case' 0 C--N 1.357 0.929 0 CA-C-O 115.744 -2.074 . . . . 64.32 106.317 -178.821 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.84 89.88 3.11 Favored 'General case' 0 C--N 1.358 0.969 0 CA-C-N 121.782 2.083 . . . . 62.02 111.108 -175.532 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.02 -14.6 0.56 Allowed Glycine 0 C--N 1.353 1.503 0 O-C-N 118.84 -2.413 . . . . 55.51 117.936 170.569 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.414 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 9.0 pt-20 -129.64 173.45 10.6 Favored 'General case' 0 C--N 1.355 0.83 0 CA-C-N 121.705 2.753 . . . . 74.0 104.999 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -56.84 -35.07 68.4 Favored 'General case' 0 C--O 1.217 -0.622 0 CA-C-O 117.282 -1.342 . . . . 72.53 111.132 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 7.7 mmt -110.28 64.0 0.61 Allowed 'General case' 0 C--N 1.36 1.042 0 CA-C-N 120.456 1.48 . . . . 71.54 111.598 -173.348 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.12 96.82 0.01 OUTLIER Glycine 0 C--N 1.356 1.66 0 CA-C-O 116.42 -2.322 . . . . 63.54 109.439 175.633 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.414 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -101.84 -173.86 27.96 Favored Glycine 0 C--N 1.364 2.087 0 CA-C-O 115.14 -3.033 . . . . 73.21 113.721 -174.933 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.9 tt -96.3 25.43 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.051 0 CA-C-N 120.245 2.023 . . . . 52.51 111.281 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -121.38 124.43 44.51 Favored 'General case' 0 C--N 1.364 1.233 0 CA-C-N 122.018 2.19 . . . . 52.32 111.162 -175.512 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.2 m . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.455 . . . . 53.32 111.145 179.99 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.556 2.655 0 CA-C-O 115.298 -2.946 . . . . 61.2 118.832 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.01 173.07 42.88 Favored Glycine 0 C--N 1.379 2.928 0 CA-C-N 124.08 3.94 . . . . 63.1 111.15 -172.043 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -82.61 50.21 3.33 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 CA-C-N 122.665 3.233 . . . . 63.14 115.71 -175.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.5 mt -154.9 -155.35 0.57 Allowed 'General case' 0 C--N 1.357 0.902 0 CA-C-O 115.891 -2.004 . . . . 73.11 106.266 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.61 89.84 3.11 Favored 'General case' 0 C--N 1.359 1.019 0 CA-C-N 121.687 2.039 . . . . 70.51 111.103 -175.719 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.2 -14.19 0.56 Allowed Glycine 0 C--N 1.355 1.609 0 O-C-N 118.944 -2.347 . . . . 73.32 117.947 170.978 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.419 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 10.1 pt-20 -130.39 174.66 9.64 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 121.708 2.754 . . . . 63.52 104.996 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -61.61 -30.59 70.79 Favored 'General case' 0 C--O 1.218 -0.567 0 CA-C-O 116.923 -1.513 . . . . 72.04 110.722 -177.551 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 8.1 mmt -112.01 64.8 0.63 Allowed 'General case' 0 C--N 1.359 1.003 0 CA-C-N 120.598 1.545 . . . . 63.33 111.561 -176.757 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 60.87 96.95 0.01 OUTLIER Glycine 0 C--N 1.356 1.674 0 CA-C-O 116.516 -2.269 . . . . 31.33 109.752 174.713 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.419 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -102.24 -173.82 27.45 Favored Glycine 0 C--N 1.364 2.107 0 CA-C-O 115.062 -3.077 . . . . 74.13 113.799 -174.485 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.7 tt -96.14 24.96 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.053 0 CA-C-N 120.261 2.031 . . . . 54.45 111.475 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -121.24 124.8 45.54 Favored 'General case' 0 C--N 1.365 1.24 0 CA-C-N 121.913 2.142 . . . . 71.5 111.167 -175.084 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.9 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 53.42 111.115 -179.988 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.556 2.648 0 CA-C-O 115.264 -2.965 . . . . 52.21 118.753 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.88 172.82 42.75 Favored Glycine 0 C--N 1.379 2.934 0 CA-C-N 124.085 3.942 . . . . 54.31 111.125 -172.244 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -82.09 50.07 3.34 Favored 'Trans proline' 0 N--CA 1.454 -0.839 0 CA-C-N 122.581 3.191 . . . . 73.04 115.908 -176.221 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.8 mt -154.64 -154.95 0.54 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-O 115.918 -1.992 . . . . 45.1 106.114 -178.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.93 91.18 3.33 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 121.731 2.06 . . . . 74.23 111.143 -175.797 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -141.33 -15.37 0.43 Allowed Glycine 0 C--N 1.353 1.484 0 O-C-N 119.039 -2.288 . . . . 61.11 118.209 170.248 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.415 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 9.3 pt-20 -128.36 174.01 9.69 Favored 'General case' 0 C--N 1.354 0.771 0 CA-C-N 121.47 2.635 . . . . 75.54 104.739 179.063 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -58.77 -33.7 70.6 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-O 116.905 -1.522 . . . . 74.01 110.886 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 33.4 mmm -111.24 65.09 0.62 Allowed 'General case' 0 C--N 1.359 1.009 0 CA-C-N 120.885 1.675 . . . . 64.12 111.751 -174.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.42 97.04 0.01 OUTLIER Glycine 0 C--N 1.358 1.769 0 CA-C-O 116.26 -2.411 . . . . 64.24 109.569 174.936 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.415 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -102.34 -173.88 27.33 Favored Glycine 0 C--N 1.364 2.133 0 CA-C-O 114.978 -3.123 . . . . 74.31 113.682 -174.152 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.4 tt -96.24 25.13 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.362 1.111 0 CA-C-N 120.279 2.039 . . . . 72.54 111.291 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.67 124.62 44.7 Favored 'General case' 0 C--N 1.365 1.247 0 CA-C-N 121.907 2.14 . . . . 54.1 111.174 -174.961 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.253 -0.43 . . . . 75.05 111.113 -179.929 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 1.414 0 CA-C-O 116.708 -2.162 . . . . 73.4 117.815 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.27 171.94 37.4 Favored Glycine 0 C--N 1.36 1.88 0 CA-C-N 123.808 3.804 . . . . 74.44 111.459 -170.25 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -79.84 45.33 1.92 Allowed 'Trans proline' 0 C--N 1.354 0.845 0 CA-C-N 122.395 3.098 . . . . 71.42 116.185 -178.029 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.622 HD22 HG23 ' A' ' 14' ' ' THR . 48.3 mt -150.69 -155.16 0.6 Allowed 'General case' 0 C--N 1.352 0.677 0 N-CA-C 106.015 -1.846 . . . . 73.33 106.015 -176.949 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.6 90.87 3.29 Favored 'General case' 0 C--N 1.359 1.02 0 C-N-CA 125.689 1.596 . . . . 74.42 111.149 -176.719 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.54 -17.69 0.42 Allowed Glycine 0 C--N 1.349 1.252 0 O-C-N 118.544 -2.597 . . . . 65.23 116.774 172.52 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.43 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 8.2 pt-20 -127.92 177.71 6.67 Favored 'General case' 0 C--N 1.36 1.031 0 CA-C-N 121.571 2.685 . . . . 71.13 104.481 179.596 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -63.51 -32.07 73.41 Favored 'General case' 0 C--O 1.219 -0.552 0 CA-C-O 117.062 -1.447 . . . . 73.53 110.937 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 15.9 mtt -110.6 64.53 0.61 Allowed 'General case' 0 C--N 1.361 1.099 0 CA-C-N 120.435 1.471 . . . . 63.04 111.942 -177.776 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 63.15 96.76 0.01 OUTLIER Glycine 0 C--N 1.356 1.686 0 CA-C-O 115.958 -2.579 . . . . 54.13 109.059 174.66 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.43 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -99.4 -174.04 31.19 Favored Glycine 0 N--CA 1.488 2.147 0 CA-C-O 115.509 -2.828 . . . . 75.25 113.301 -175.331 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.1 tt -97.21 25.46 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.022 0 CA-C-N 119.869 1.834 . . . . 64.24 111.002 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.52 124.79 45.25 Favored 'General case' 0 C--N 1.363 1.176 0 CA-C-N 121.149 1.795 . . . . 61.25 111.123 -175.581 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.622 HG23 HD22 ' A' ' 4' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 53.05 111.139 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.141 0 CA-C-O 116.095 -2.503 . . . . 63.42 119.231 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -149.4 177.05 27.84 Favored Glycine 0 C--N 1.366 2.244 0 CA-C-N 123.074 3.437 . . . . 75.21 110.915 -174.222 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -80.19 46.88 2.36 Favored 'Trans proline' 0 C--N 1.349 0.588 0 CA-C-N 122.272 3.036 . . . . 54.13 115.267 -178.174 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.497 ' N ' ' O ' ' A' ' 11' ' ' GLY . 54.9 mt -150.81 -156.08 0.68 Allowed 'General case' 0 C--N 1.349 0.544 0 CA-C-O 117.032 -1.461 . . . . 71.44 108.092 -178.036 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -122.54 102.94 8.37 Favored 'General case' 0 C--N 1.369 1.453 0 CA-C-N 121.042 1.747 . . . . 71.31 111.089 -177.221 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -153.3 -33.9 0.03 OUTLIER Glycine 0 C--N 1.349 1.304 0 N-CA-C 117.622 1.809 . . . . 53.11 117.622 179.479 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -116.11 177.64 4.61 Favored 'General case' 0 C--N 1.351 0.66 0 CA-C-N 119.141 1.47 . . . . 74.12 107.524 174.966 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -60.29 -31.44 70.25 Favored 'General case' 0 C--N 1.349 0.544 0 CA-C-O 117.816 -1.088 . . . . 63.3 110.93 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 31.4 mmm -110.05 58.45 0.61 Allowed 'General case' 0 C--N 1.359 1.004 0 CA-C-N 119.389 0.995 . . . . 71.44 111.969 -173.677 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.09 101.14 0.02 OUTLIER Glycine 0 C--N 1.356 1.655 0 CA-C-O 117.08 -1.956 . . . . 75.15 110.86 177.036 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.497 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -96.32 -176.07 35.94 Favored Glycine 0 CA--C 1.486 -1.766 0 CA-C-O 116.203 -2.443 . . . . 61.23 114.066 -172.311 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.5 tt -97.17 22.62 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.749 0 CA-C-N 120.211 2.006 . . . . 75.11 111.389 174.768 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.0 p -124.14 128.19 48.89 Favored 'General case' 0 C--N 1.362 1.132 0 CA-C-N 120.348 1.431 . . . . 73.32 111.137 -175.402 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 86.8 m . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 73.34 111.121 -179.974 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.555 2.565 0 CA-C-O 115.466 -2.852 . . . . 64.34 118.899 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.71 173.15 42.7 Favored Glycine 0 C--N 1.378 2.9 0 CA-C-N 124.032 3.916 . . . . 64.33 111.158 -172.03 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -82.6 50.0 3.26 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 CA-C-N 122.519 3.16 . . . . 64.43 115.791 -176.116 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 61.5 mt -154.6 -155.08 0.55 Allowed 'General case' 0 C--N 1.357 0.917 0 CA-C-O 115.852 -2.023 . . . . 74.32 106.205 -178.785 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.89 90.02 3.13 Favored 'General case' 0 C--N 1.359 1.007 0 CA-C-N 121.81 2.096 . . . . 64.31 111.061 -175.69 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.2 -14.79 0.54 Allowed Glycine 0 C--N 1.353 1.482 0 O-C-N 118.816 -2.427 . . . . 72.53 117.927 170.729 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.415 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 8.9 pt-20 -129.5 173.51 10.51 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-N 121.708 2.754 . . . . 75.32 104.921 179.188 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -56.15 -35.77 67.54 Favored 'General case' 0 C--O 1.218 -0.582 0 CA-C-O 117.018 -1.468 . . . . 74.5 110.723 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -110.55 64.02 0.61 Allowed 'General case' 0 C--N 1.36 1.054 0 CA-C-N 120.692 1.587 . . . . 73.13 112.47 -173.098 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.91 96.45 0.01 OUTLIER Glycine 0 C--N 1.356 1.692 0 CA-C-O 116.349 -2.362 . . . . 53.22 108.795 175.567 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.415 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -101.62 -173.9 28.25 Favored Glycine 0 C--N 1.363 2.068 0 CA-C-O 115.079 -3.067 . . . . 41.32 113.557 -174.686 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.5 tt -96.12 25.39 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.361 1.104 0 CA-C-N 120.192 1.996 . . . . 60.13 111.271 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.63 124.3 44.0 Favored 'General case' 0 C--N 1.364 1.238 0 CA-C-N 122.03 2.196 . . . . 73.23 111.112 -175.269 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 73.31 111.15 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 1.536 0 CA-C-O 116.544 -2.253 . . . . 65.11 117.875 . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.46 171.88 37.55 Favored Glycine 0 C--N 1.359 1.815 0 CA-C-N 123.891 3.846 . . . . 75.12 111.398 -169.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -80.2 45.75 2.05 Favored 'Trans proline' 0 C--N 1.353 0.786 0 CA-C-N 122.298 3.049 . . . . 74.33 116.304 -177.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.419 ' N ' ' O ' ' A' ' 11' ' ' GLY . 56.9 mt -150.71 -154.01 0.52 Allowed 'General case' 0 C--N 1.352 0.711 0 N-CA-C 105.848 -1.908 . . . . 75.42 105.848 -178.472 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -126.26 90.21 3.14 Favored 'General case' 0 C--N 1.361 1.069 0 C-N-CA 126.044 1.738 . . . . 73.12 111.131 -176.077 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -139.81 -17.61 0.48 Allowed Glycine 0 C--N 1.349 1.254 0 O-C-N 118.487 -2.633 . . . . 70.44 116.627 172.608 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 7' ' ' GLU . . . . . 0.424 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 8.6 pt-20 -127.7 176.98 7.12 Favored 'General case' 0 C--N 1.359 1.003 0 CA-C-N 121.64 2.72 . . . . 54.52 104.967 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -59.06 -35.96 74.23 Favored 'General case' 0 C--O 1.22 -0.46 0 CA-C-O 117.67 -1.157 . . . . 72.02 111.04 179.578 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 4.9 mmt -110.16 63.2 0.6 Allowed 'General case' 0 C--N 1.36 1.051 0 CA-C-N 119.86 1.209 . . . . 73.42 110.861 -173.321 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 62.81 96.61 0.01 OUTLIER Glycine 0 C--N 1.356 1.647 0 CA-C-O 116.073 -2.515 . . . . 52.01 109.63 175.807 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.424 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -99.38 -174.4 31.27 Favored Glycine 0 N--CA 1.49 2.239 0 CA-C-O 115.942 -2.588 . . . . 63.12 113.422 -176.036 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.0 tt -97.11 25.39 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.985 0 CA-C-N 119.73 1.765 . . . . 75.43 111.085 179.689 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.9 p -120.87 124.57 45.32 Favored 'General case' 0 C--N 1.363 1.174 0 CA-C-N 120.861 1.664 . . . . 64.45 111.149 -176.073 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 13.7 t . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 70.33 111.162 179.998 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.059 0 CA-C-O 116.268 -2.407 . . . . 74.23 117.296 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -148.92 174.97 28.39 Favored Glycine 0 C--N 1.35 1.309 0 CA-C-N 123.358 3.579 . . . . 45.22 111.926 -170.716 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_endo -79.35 44.27 1.66 Allowed 'Trans proline' 0 C--N 1.362 1.282 0 CA-C-N 121.616 2.708 . . . . 64.44 116.046 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.465 ' N ' ' O ' ' A' ' 11' ' ' GLY . 34.2 mt -150.41 -156.3 0.71 Allowed 'General case' 0 C--O 1.218 -0.589 0 N-CA-C 105.89 -1.893 . . . . 63.05 105.89 -175.732 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.49 101.53 7.38 Favored 'General case' 0 C--N 1.355 0.828 0 C-N-CA 125.219 1.407 . . . . 60.21 111.14 -176.289 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -150.11 -33.93 0.04 OUTLIER Glycine 0 C--N 1.351 1.416 0 O-C-N 120.087 -1.633 . . . . 60.1 117.166 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -118.71 -179.43 3.8 Favored 'General case' 0 C--N 1.353 0.725 0 N-CA-C 104.503 -2.406 . . . . 74.34 104.503 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.79 -30.11 71.11 Favored 'General case' 0 C--N 1.347 0.471 0 CA-C-O 117.575 -1.203 . . . . 75.42 111.558 179.735 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 94.5 mtp -111.02 59.32 0.61 Allowed 'General case' 0 C--N 1.359 1.018 0 CA-C-N 119.866 1.212 . . . . 65.3 110.863 -176.133 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.49 103.89 0.02 OUTLIER Glycine 0 C--N 1.353 1.524 0 CA-C-O 117.464 -1.742 . . . . 63.42 109.969 176.28 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.465 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -100.34 -176.53 30.15 Favored Glycine 0 CA--C 1.491 -1.468 0 CA-C-O 115.877 -2.624 . . . . 70.4 112.362 -172.594 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.6 tt -97.39 24.07 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.853 0 CA-C-N 120.343 2.071 . . . . 71.4 111.469 176.533 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -123.58 125.68 45.29 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 119.675 1.125 . . . . 75.34 111.157 -176.041 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 15.1 t . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 73.52 111.173 179.983 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.838 0 CA-C-O 114.936 -3.147 . . . . 51.44 118.198 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -152.62 175.45 31.2 Favored Glycine 0 C--N 1.35 1.313 0 CA-C-N 123.461 3.631 . . . . 63.21 111.5 -172.949 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -80.53 46.68 2.32 Favored 'Trans proline' 0 C--N 1.364 1.391 0 CA-C-N 120.911 2.356 . . . . 75.12 114.731 -178.357 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 4' ' ' LEU . . . . . 0.626 HD22 HG23 ' A' ' 14' ' ' THR . 37.5 mt -151.31 -156.55 0.72 Allowed 'General case' 0 C--N 1.352 0.684 0 N-CA-C 106.819 -1.549 . . . . 74.14 106.819 -177.713 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.18 102.6 8.04 Favored 'General case' 0 C--N 1.362 1.13 0 CA-C-N 120.776 1.625 . . . . 75.14 111.066 -176.904 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -151.77 -34.71 0.03 OUTLIER Glycine 0 C--N 1.357 1.737 0 CA-C-O 117.177 -1.901 . . . . 61.23 116.915 179.236 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -117.46 178.05 4.52 Favored 'General case' 0 CA--C 1.506 -0.712 0 N-CA-C 105.792 -1.929 . . . . 63.11 105.792 177.774 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -61.18 -30.9 70.69 Favored 'General case' 0 C--O 1.22 -0.482 0 CA-C-O 117.662 -1.161 . . . . 72.25 111.415 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 20.9 mmt -110.33 58.51 0.61 Allowed 'General case' 0 C--N 1.359 0.991 0 CA-C-N 119.647 1.112 . . . . 73.35 113.021 -176.14 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 65.97 106.53 0.01 OUTLIER Glycine 0 C--N 1.353 1.528 0 CA-C-O 117.213 -1.881 . . . . 73.54 109.986 178.063 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -102.68 -174.78 26.98 Favored Glycine 0 CA--C 1.489 -1.593 0 CA-C-O 116.138 -2.479 . . . . 73.54 112.368 -172.376 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.4 tt -96.99 22.77 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.846 0 CA-C-N 120.256 2.028 . . . . 64.15 111.192 175.79 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -124.32 125.77 44.9 Favored 'General case' 0 C--N 1.359 0.981 0 CA-C-N 120.888 1.676 . . . . 74.44 111.153 -175.259 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' THR . . . . . 0.626 HG23 HD22 ' A' ' 4' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.257 0 CA-C-N 116.217 -0.447 . . . . 73.14 111.141 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.371 0 CA-C-O 116.573 -2.237 . . . . 42.210000000000001 116.846 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.26 175.36 34.71 Favored Glycine 0 C--N 1.363 2.072 1 CA-C-N 124.782 4.291 . . . . 72.340000000000003 112.099 -170.691 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.53 49.53 3.22 Favored 'Trans proline' 0 C--N 1.352 0.717 0 CA-C-N 122.479 3.139 . . . . 72.219999999999999 115.659 -178.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.419 ' N ' ' O ' ' A' ' 11' ' ' GLY . 37.8 mt -155.56 -156.16 0.62 Allowed 'General case' 0 C--N 1.358 0.965 0 CA-C-O 115.436 -2.221 . . . . 70.129999999999995 106.832 -177.04 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.03 105.49 9.61 Favored 'General case' 0 C--N 1.352 0.685 0 CA-C-N 122.06 2.209 . . . . 52.109999999999999 111.102 -175.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.14 -36.66 0.02 OUTLIER Glycine 0 C--N 1.373 2.632 0 N-CA-C 118.406 2.122 . . . . 43.32 118.406 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -116.31 177.4 4.7 Favored 'General case' 0 C--N 1.349 0.584 0 N-CA-C 105.474 -2.047 . . . . 75.040000000000006 105.474 176.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 7.4 tt0 -58.67 -32.48 69.14 Favored 'General case' 0 C--N 1.348 0.536 0 CA-C-O 117.931 -1.033 . . . . 50.439999999999998 111.816 179.275 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 6.1 mmt -109.63 57.49 0.61 Allowed 'General case' 0 C--N 1.359 0.986 0 CA-C-N 119.924 1.238 . . . . 60.439999999999998 111.655 -172.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 67.88 108.16 0.02 OUTLIER Glycine 0 C--N 1.358 1.767 0 CA-C-O 115.998 -2.557 . . . . 73.430000000000007 109.962 177.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -107.91 -174.18 22.09 Favored Glycine 0 C--N 1.354 1.572 0 CA-C-N 121.505 2.653 . . . . 53.140000000000001 111.198 -170.319 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 8.7 tt -96.42 22.66 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.735 0 CA-C-N 120.412 2.106 . . . . 75.340000000000003 111.022 176.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -124.56 125.69 44.6 Favored 'General case' 0 C--N 1.365 1.271 0 CA-C-N 121.171 1.805 . . . . 64.540000000000006 111.138 -174.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 7.0 t . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 64.510000000000005 111.091 -179.985 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 1.636 0 N-CA-C 120.158 2.823 . . . . 55.409999999999997 120.158 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -156.48 174.22 34.25 Favored Glycine 0 C--N 1.348 1.218 1 CA-C-N 124.817 4.308 . . . . 51.43 111.191 -173.437 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -79.94 44.55 1.74 Allowed 'Trans proline' 0 C--N 1.369 1.636 0 CA-C-N 122.054 2.927 . . . . 62.350000000000001 115.017 -177.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.44 ' N ' ' O ' ' A' ' 11' ' ' GLY . 43.3 mt -148.96 -154.5 0.56 Allowed 'General case' 0 C--N 1.354 0.788 0 N-CA-C 106.477 -1.675 . . . . 65.010000000000005 106.477 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.97 88.58 2.91 Favored 'General case' 0 C--N 1.362 1.142 0 C-N-CA 125.91 1.684 . . . . 72.409999999999997 111.151 -176.558 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -138.31 -14.78 0.7 Allowed Glycine 0 CA--C 1.528 0.845 0 O-C-N 118.724 -2.485 . . . . 71.450000000000003 117.305 171.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -129.39 175.67 8.57 Favored 'General case' 0 C--N 1.359 0.984 0 CA-C-N 121.372 2.586 . . . . 75.200000000000003 106.236 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -58.57 -36.95 74.75 Favored 'General case' 0 C--O 1.219 -0.546 0 CA-C-O 117.807 -1.092 . . . . 73.349999999999994 110.944 178.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 78.3 mtm -109.16 66.83 0.64 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 119.551 1.069 . . . . 63.210000000000001 111.396 -175.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 60.67 91.13 0.02 OUTLIER Glycine 0 C--N 1.352 1.448 0 CA-C-O 116.599 -2.223 . . . . 62.310000000000002 110.041 173.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.44 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -92.22 -174.34 42.09 Favored Glycine 0 C--O 1.201 -1.948 0 CA-C-O 116.204 -2.442 . . . . 74.319999999999993 115.091 -177.263 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.8 tt -96.84 24.06 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.371 1.538 0 CA-C-N 118.645 1.222 . . . . 73.310000000000002 111.257 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.4 p -120.57 124.44 45.32 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-N 120.744 1.611 . . . . 70.219999999999999 111.151 -174.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 15.4 t . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.244 -0.435 . . . . 75.329999999999998 111.153 179.978 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 1.782 0 N-CA-C 119.205 2.442 . . . . 61.200000000000003 119.205 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -158.72 175.25 35.78 Favored Glycine 0 C--N 1.354 1.571 1 CA-C-N 125.813 4.807 . . . . 74.319999999999993 109.764 -174.026 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -80.31 45.18 1.9 Allowed 'Trans proline' 0 C--N 1.351 0.71 0 CA-C-N 121.097 2.449 . . . . 74.200000000000003 115.504 -176.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.441 ' N ' ' O ' ' A' ' 11' ' ' GLY . 47.6 mt -149.95 -154.48 0.56 Allowed 'General case' 0 C--N 1.36 1.022 0 CA-C-O 116.467 -1.73 . . . . 74.140000000000001 107.017 -179.019 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.97 88.86 2.96 Favored 'General case' 0 C--N 1.354 0.778 0 C-N-CA 125.674 1.59 . . . . 62.219999999999999 111.108 -176.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -138.8 -14.58 0.66 Allowed Glycine 0 CA--C 1.529 0.909 0 O-C-N 118.698 -2.501 . . . . 63.299999999999997 117.271 171.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -129.13 174.96 9.09 Favored 'General case' 0 C--N 1.352 0.69 0 CA-C-N 121.04 2.42 . . . . 53.32 105.74 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -58.65 -35.13 72.04 Favored 'General case' 0 C--O 1.219 -0.525 0 CA-C-O 117.682 -1.151 . . . . 71.230000000000004 110.731 179.306 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 3.6 mmt -109.76 63.23 0.6 Allowed 'General case' 0 C--N 1.355 0.816 0 CA-C-N 119.419 1.008 . . . . 70.239999999999995 111.656 -174.077 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.67 91.17 0.02 OUTLIER Glycine 0 C--N 1.352 1.421 0 CA-C-O 116.567 -2.241 . . . . 62.310000000000002 110.093 175.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.441 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -92.87 -175.06 41.21 Favored Glycine 0 N--CA 1.491 2.34 0 CA-C-O 115.617 -2.768 . . . . 65.200000000000003 115.052 -177.006 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 12.1 tt -96.13 24.38 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.844 0 CA-C-N 120.124 1.962 . . . . 64.209999999999994 111.051 -179.481 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.4 p -120.66 124.59 45.59 Favored 'General case' 0 C--N 1.359 1.01 0 CA-C-N 121.346 1.885 . . . . 61.210000000000001 111.132 -175.328 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.5 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.249 -0.432 . . . . 71.040000000000006 111.139 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.703 0 CA-C-O 116.506 -2.274 . . . . 24.149999999999999 117.844 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -145.03 178.63 22.69 Favored Glycine 0 C--N 1.368 2.359 0 CA-C-N 123.347 3.574 . . . . 64.019999999999996 110.995 -174.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -79.38 44.62 1.74 Allowed 'Trans proline' 0 C--N 1.357 1.011 0 CA-C-N 121.78 2.79 . . . . 70.040000000000006 116.375 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.732 HD22 HG23 ' A' ' 14' ' ' THR . 39.3 mt -149.24 -156.34 0.71 Allowed 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 106.381 -1.711 . . . . 72.420000000000002 106.381 -176.203 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.19 100.92 7.1 Favored 'General case' 0 C--N 1.353 0.721 0 C-N-CA 125.079 1.352 . . . . 71.219999999999999 111.095 -176.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -149.53 -32.04 0.05 OUTLIER Glycine 0 C--N 1.347 1.151 0 O-C-N 119.299 -2.125 . . . . 51.020000000000003 116.776 178.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -119.67 179.22 4.3 Favored 'General case' 0 C--N 1.357 0.904 0 N-CA-C 104.743 -2.318 . . . . 64.510000000000005 104.743 178.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -64.12 -29.82 70.93 Favored 'General case' 0 C--N 1.349 0.558 0 CA-C-O 117.382 -1.294 . . . . 65.420000000000002 111.664 178.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 66.3 mmm -110.6 59.29 0.61 Allowed 'General case' 0 C--N 1.357 0.92 0 CA-C-N 119.597 1.089 . . . . 73.230000000000004 110.555 -176.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 65.99 98.74 0.02 OUTLIER Glycine 0 C--N 1.354 1.56 0 CA-C-O 117.978 -1.456 . . . . 64.439999999999998 110.428 174.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.452 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -94.2 -177.58 38.98 Favored Glycine 0 CA--C 1.491 -1.447 0 CA-C-O 115.598 -2.779 . . . . 63.299999999999997 113.183 -171.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.7 tt -97.58 24.85 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.992 0 CA-C-N 120.726 2.263 . . . . 65.310000000000002 111.289 175.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.2 p -124.16 125.83 45.12 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.593 1.088 . . . . 45.350000000000001 111.113 -176.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.732 HG23 HD22 ' A' ' 4' ' ' LEU . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.181 -0.463 . . . . 70.0 111.121 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.172 0 N-CA-C 120.027 2.771 . . . . 70.109999999999999 120.027 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -150.56 178.68 27.85 Favored Glycine 0 C--N 1.366 2.204 0 CA-C-N 124.069 3.935 . . . . 31.149999999999999 112.598 -175.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -81.29 49.62 3.27 Favored 'Trans proline' 0 N--CA 1.449 -1.118 1 CA-C-N 124.298 4.049 . . . . 74.420000000000002 116.208 -178.046 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.449 ' N ' ' O ' ' A' ' 11' ' ' GLY . 59.6 mt -154.01 -157.17 0.75 Allowed 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 116.703 -1.617 . . . . 51.43 106.91 -176.206 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.13 104.71 9.36 Favored 'General case' 0 C--N 1.358 0.976 0 CA-C-N 121.612 2.005 . . . . 71.530000000000001 111.095 -176.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.15 -35.78 0.02 OUTLIER Glycine 0 C--N 1.369 2.367 0 N-CA-C 117.599 1.8 . . . . 74.510000000000005 117.599 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -116.02 177.38 4.7 Favored 'General case' 0 C--N 1.354 0.799 0 N-CA-C 105.755 -1.942 . . . . 74.010000000000005 105.755 175.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -57.17 -33.51 67.52 Favored 'General case' 0 C--N 1.35 0.589 0 CA-C-O 117.926 -1.035 . . . . 42.439999999999998 111.424 178.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 1.8 mmm -110.15 60.72 0.6 Allowed 'General case' 0 C--N 1.354 0.776 0 CA-C-N 119.044 0.838 . . . . 72.299999999999997 112.352 -174.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.53 102.84 0.02 OUTLIER Glycine 0 C--N 1.355 1.631 0 N-CA-C 108.991 -1.644 . . . . 73.109999999999999 108.991 174.36 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -100.9 -174.2 29.19 Favored Glycine 0 C--O 1.207 -1.561 0 CA-C-O 115.912 -2.605 . . . . 73.420000000000002 112.941 -170.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 8.1 tt -96.99 22.48 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.364 1.209 0 CA-C-N 120.012 1.906 . . . . 64.439999999999998 111.669 175.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.4 p -124.48 125.75 44.75 Favored 'General case' 0 C--N 1.364 1.222 0 CA-C-N 120.079 1.308 . . . . 75.549999999999997 111.152 -174.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.1 t . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 71.140000000000001 111.112 -179.956 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.557 2.672 0 CA-C-O 115.318 -2.935 . . . . 62.530000000000001 118.803 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.53 173.12 42.59 Favored Glycine 0 C--N 1.379 2.927 0 CA-C-N 124.147 3.973 . . . . 61.25 111.039 -172.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -81.89 50.58 3.52 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 CA-C-N 122.573 3.186 . . . . 73.109999999999999 115.64 -176.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.648 HD22 HG23 ' A' ' 14' ' ' THR . 71.9 mt -155.61 -156.77 0.67 Allowed 'General case' 0 C--O 1.211 -0.938 0 CA-C-O 115.785 -2.055 . . . . 75.450000000000003 106.362 -177.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.0 91.31 3.41 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 121.798 2.09 . . . . 63.399999999999999 111.093 -176.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -141.87 -14.95 0.39 Allowed Glycine 0 C--N 1.353 1.498 0 O-C-N 119.064 -2.273 . . . . 52.5 118.422 169.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.419 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 10.0 pt-20 -128.24 175.02 8.78 Favored 'General case' 0 C--N 1.353 0.748 0 CA-C-N 121.466 2.633 . . . . 61.329999999999998 104.441 178.788 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -62.49 -30.62 71.4 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 116.886 -1.531 . . . . 74.209999999999994 110.57 -177.029 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 44.0 mtm -111.98 65.26 0.63 Allowed 'General case' 0 C--N 1.359 1.02 0 CA-C-N 120.622 1.555 . . . . 74.519999999999996 112.007 -177.22 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.71 96.66 0.01 OUTLIER Glycine 0 C--N 1.357 1.736 0 CA-C-O 116.346 -2.363 . . . . 72.409999999999997 109.365 174.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.419 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -101.62 -172.87 28.13 Favored Glycine 0 C--N 1.364 2.135 0 CA-C-O 114.722 -3.265 . . . . 72.420000000000002 113.858 -174.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.5 tt -96.96 25.26 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.361 1.105 0 CA-C-N 120.305 2.052 . . . . 75.319999999999993 111.233 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -122.11 124.56 44.19 Favored 'General case' 0 C--N 1.366 1.301 0 CA-C-N 122.138 2.244 . . . . 65.420000000000002 111.123 -174.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.648 HG23 HD22 ' A' ' 4' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.194 -0.457 . . . . 63.329999999999998 111.156 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.554 2.477 0 CA-C-O 115.442 -2.865 . . . . 55.25 118.881 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.71 173.11 42.7 Favored Glycine 0 C--N 1.377 2.84 0 CA-C-N 124.144 3.972 . . . . 74.140000000000001 111.205 -171.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -82.69 49.62 3.14 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 CA-C-N 122.639 3.22 . . . . 70.140000000000001 115.828 -176.041 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.9 mt -154.44 -154.89 0.54 Allowed 'General case' 0 C--N 1.357 0.929 0 CA-C-O 115.744 -2.074 . . . . 64.319999999999993 106.317 -178.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.84 89.88 3.11 Favored 'General case' 0 C--N 1.358 0.969 0 CA-C-N 121.782 2.083 . . . . 62.020000000000003 111.108 -175.532 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.02 -14.6 0.56 Allowed Glycine 0 C--N 1.353 1.503 0 O-C-N 118.84 -2.413 . . . . 55.509999999999998 117.936 170.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.414 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 9.0 pt-20 -129.64 173.45 10.6 Favored 'General case' 0 C--N 1.355 0.83 0 CA-C-N 121.705 2.753 . . . . 74.0 104.999 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -56.84 -35.07 68.4 Favored 'General case' 0 C--O 1.217 -0.622 0 CA-C-O 117.282 -1.342 . . . . 72.530000000000001 111.132 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 7.7 mmt -110.28 64.0 0.61 Allowed 'General case' 0 C--N 1.36 1.042 0 CA-C-N 120.456 1.48 . . . . 71.540000000000006 111.598 -173.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.12 96.82 0.01 OUTLIER Glycine 0 C--N 1.356 1.66 0 CA-C-O 116.42 -2.322 . . . . 63.539999999999999 109.439 175.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.414 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -101.84 -173.86 27.96 Favored Glycine 0 C--N 1.364 2.087 0 CA-C-O 115.14 -3.033 . . . . 73.209999999999994 113.721 -174.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.9 tt -96.3 25.43 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.051 0 CA-C-N 120.245 2.023 . . . . 52.509999999999998 111.281 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -121.38 124.43 44.51 Favored 'General case' 0 C--N 1.364 1.233 0 CA-C-N 122.018 2.19 . . . . 52.32 111.162 -175.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.2 m . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.455 . . . . 53.32 111.145 179.99 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.556 2.655 0 CA-C-O 115.298 -2.946 . . . . 61.200000000000003 118.832 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.01 173.07 42.88 Favored Glycine 0 C--N 1.379 2.928 0 CA-C-N 124.08 3.94 . . . . 63.100000000000001 111.15 -172.043 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -82.61 50.21 3.33 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 CA-C-N 122.665 3.233 . . . . 63.140000000000001 115.71 -175.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.5 mt -154.9 -155.35 0.57 Allowed 'General case' 0 C--N 1.357 0.902 0 CA-C-O 115.891 -2.004 . . . . 73.109999999999999 106.266 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.61 89.84 3.11 Favored 'General case' 0 C--N 1.359 1.019 0 CA-C-N 121.687 2.039 . . . . 70.510000000000005 111.103 -175.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.2 -14.19 0.56 Allowed Glycine 0 C--N 1.355 1.609 0 O-C-N 118.944 -2.347 . . . . 73.319999999999993 117.947 170.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.419 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 10.1 pt-20 -130.39 174.66 9.64 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 121.708 2.754 . . . . 63.520000000000003 104.996 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -61.61 -30.59 70.79 Favored 'General case' 0 C--O 1.218 -0.567 0 CA-C-O 116.923 -1.513 . . . . 72.040000000000006 110.722 -177.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 8.1 mmt -112.01 64.8 0.63 Allowed 'General case' 0 C--N 1.359 1.003 0 CA-C-N 120.598 1.545 . . . . 63.329999999999998 111.561 -176.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 60.87 96.95 0.01 OUTLIER Glycine 0 C--N 1.356 1.674 0 CA-C-O 116.516 -2.269 . . . . 31.329999999999998 109.752 174.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.419 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -102.24 -173.82 27.45 Favored Glycine 0 C--N 1.364 2.107 0 CA-C-O 115.062 -3.077 . . . . 74.129999999999995 113.799 -174.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.7 tt -96.14 24.96 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.053 0 CA-C-N 120.261 2.031 . . . . 54.450000000000003 111.475 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -121.24 124.8 45.54 Favored 'General case' 0 C--N 1.365 1.24 0 CA-C-N 121.913 2.142 . . . . 71.5 111.167 -175.084 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.9 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 53.420000000000002 111.115 -179.988 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.556 2.648 0 CA-C-O 115.264 -2.965 . . . . 52.210000000000001 118.753 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.88 172.82 42.75 Favored Glycine 0 C--N 1.379 2.934 0 CA-C-N 124.085 3.942 . . . . 54.310000000000002 111.125 -172.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -82.09 50.07 3.34 Favored 'Trans proline' 0 N--CA 1.454 -0.839 0 CA-C-N 122.581 3.191 . . . . 73.040000000000006 115.908 -176.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.8 mt -154.64 -154.95 0.54 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-O 115.918 -1.992 . . . . 45.100000000000001 106.114 -178.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.93 91.18 3.33 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 121.731 2.06 . . . . 74.230000000000004 111.143 -175.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -141.33 -15.37 0.43 Allowed Glycine 0 C--N 1.353 1.484 0 O-C-N 119.039 -2.288 . . . . 61.109999999999999 118.209 170.248 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.415 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 9.3 pt-20 -128.36 174.01 9.69 Favored 'General case' 0 C--N 1.354 0.771 0 CA-C-N 121.47 2.635 . . . . 75.540000000000006 104.739 179.063 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -58.77 -33.7 70.6 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-O 116.905 -1.522 . . . . 74.010000000000005 110.886 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 33.4 mmm -111.24 65.09 0.62 Allowed 'General case' 0 C--N 1.359 1.009 0 CA-C-N 120.885 1.675 . . . . 64.120000000000005 111.751 -174.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.42 97.04 0.01 OUTLIER Glycine 0 C--N 1.358 1.769 0 CA-C-O 116.26 -2.411 . . . . 64.239999999999995 109.569 174.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.415 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -102.34 -173.88 27.33 Favored Glycine 0 C--N 1.364 2.133 0 CA-C-O 114.978 -3.123 . . . . 74.310000000000002 113.682 -174.152 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.4 tt -96.24 25.13 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.362 1.111 0 CA-C-N 120.279 2.039 . . . . 72.540000000000006 111.291 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.67 124.62 44.7 Favored 'General case' 0 C--N 1.365 1.247 0 CA-C-N 121.907 2.14 . . . . 54.100000000000001 111.174 -174.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.253 -0.43 . . . . 75.049999999999997 111.113 -179.929 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 1.414 0 CA-C-O 116.708 -2.162 . . . . 73.400000000000006 117.815 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.27 171.94 37.4 Favored Glycine 0 C--N 1.36 1.88 0 CA-C-N 123.808 3.804 . . . . 74.439999999999998 111.459 -170.25 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -79.84 45.33 1.92 Allowed 'Trans proline' 0 C--N 1.354 0.845 0 CA-C-N 122.395 3.098 . . . . 71.420000000000002 116.185 -178.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.622 HD22 HG23 ' A' ' 14' ' ' THR . 48.3 mt -150.69 -155.16 0.6 Allowed 'General case' 0 C--N 1.352 0.677 0 N-CA-C 106.015 -1.846 . . . . 73.329999999999998 106.015 -176.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.6 90.87 3.29 Favored 'General case' 0 C--N 1.359 1.02 0 C-N-CA 125.689 1.596 . . . . 74.420000000000002 111.149 -176.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.54 -17.69 0.42 Allowed Glycine 0 C--N 1.349 1.252 0 O-C-N 118.544 -2.597 . . . . 65.230000000000004 116.774 172.52 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.43 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 8.2 pt-20 -127.92 177.71 6.67 Favored 'General case' 0 C--N 1.36 1.031 0 CA-C-N 121.571 2.685 . . . . 71.129999999999995 104.481 179.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -63.51 -32.07 73.41 Favored 'General case' 0 C--O 1.219 -0.552 0 CA-C-O 117.062 -1.447 . . . . 73.530000000000001 110.937 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 15.9 mtt -110.6 64.53 0.61 Allowed 'General case' 0 C--N 1.361 1.099 0 CA-C-N 120.435 1.471 . . . . 63.039999999999999 111.942 -177.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 63.15 96.76 0.01 OUTLIER Glycine 0 C--N 1.356 1.686 0 CA-C-O 115.958 -2.579 . . . . 54.130000000000003 109.059 174.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.43 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -99.4 -174.04 31.19 Favored Glycine 0 N--CA 1.488 2.147 0 CA-C-O 115.509 -2.828 . . . . 75.25 113.301 -175.331 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.1 tt -97.21 25.46 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.022 0 CA-C-N 119.869 1.834 . . . . 64.239999999999995 111.002 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.52 124.79 45.25 Favored 'General case' 0 C--N 1.363 1.176 0 CA-C-N 121.149 1.795 . . . . 61.25 111.123 -175.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.622 HG23 HD22 ' A' ' 4' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 53.049999999999997 111.139 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.141 0 CA-C-O 116.095 -2.503 . . . . 63.420000000000002 119.231 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -149.4 177.05 27.84 Favored Glycine 0 C--N 1.366 2.244 0 CA-C-N 123.074 3.437 . . . . 75.209999999999994 110.915 -174.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -80.19 46.88 2.36 Favored 'Trans proline' 0 C--N 1.349 0.588 0 CA-C-N 122.272 3.036 . . . . 54.130000000000003 115.267 -178.174 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.497 ' N ' ' O ' ' A' ' 11' ' ' GLY . 54.9 mt -150.81 -156.08 0.68 Allowed 'General case' 0 C--N 1.349 0.544 0 CA-C-O 117.032 -1.461 . . . . 71.439999999999998 108.092 -178.036 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -122.54 102.94 8.37 Favored 'General case' 0 C--N 1.369 1.453 0 CA-C-N 121.042 1.747 . . . . 71.310000000000002 111.089 -177.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -153.3 -33.9 0.03 OUTLIER Glycine 0 C--N 1.349 1.304 0 N-CA-C 117.622 1.809 . . . . 53.109999999999999 117.622 179.479 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -116.11 177.64 4.61 Favored 'General case' 0 C--N 1.351 0.66 0 CA-C-N 119.141 1.47 . . . . 74.120000000000005 107.524 174.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -60.29 -31.44 70.25 Favored 'General case' 0 C--N 1.349 0.544 0 CA-C-O 117.816 -1.088 . . . . 63.299999999999997 110.93 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 31.4 mmm -110.05 58.45 0.61 Allowed 'General case' 0 C--N 1.359 1.004 0 CA-C-N 119.389 0.995 . . . . 71.439999999999998 111.969 -173.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.09 101.14 0.02 OUTLIER Glycine 0 C--N 1.356 1.655 0 CA-C-O 117.08 -1.956 . . . . 75.150000000000006 110.86 177.036 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.497 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -96.32 -176.07 35.94 Favored Glycine 0 CA--C 1.486 -1.766 0 CA-C-O 116.203 -2.443 . . . . 61.229999999999997 114.066 -172.311 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.5 tt -97.17 22.62 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.749 0 CA-C-N 120.211 2.006 . . . . 75.109999999999999 111.389 174.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.0 p -124.14 128.19 48.89 Favored 'General case' 0 C--N 1.362 1.132 0 CA-C-N 120.348 1.431 . . . . 73.319999999999993 111.137 -175.402 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 86.8 m . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 73.340000000000003 111.121 -179.974 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.555 2.565 0 CA-C-O 115.466 -2.852 . . . . 64.340000000000003 118.899 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.71 173.15 42.7 Favored Glycine 0 C--N 1.378 2.9 0 CA-C-N 124.032 3.916 . . . . 64.329999999999998 111.158 -172.03 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -82.6 50.0 3.26 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 CA-C-N 122.519 3.16 . . . . 64.430000000000007 115.791 -176.116 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 61.5 mt -154.6 -155.08 0.55 Allowed 'General case' 0 C--N 1.357 0.917 0 CA-C-O 115.852 -2.023 . . . . 74.319999999999993 106.205 -178.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.89 90.02 3.13 Favored 'General case' 0 C--N 1.359 1.007 0 CA-C-N 121.81 2.096 . . . . 64.310000000000002 111.061 -175.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.2 -14.79 0.54 Allowed Glycine 0 C--N 1.353 1.482 0 O-C-N 118.816 -2.427 . . . . 72.530000000000001 117.927 170.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.415 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 8.9 pt-20 -129.5 173.51 10.51 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-N 121.708 2.754 . . . . 75.319999999999993 104.921 179.188 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -56.15 -35.77 67.54 Favored 'General case' 0 C--O 1.218 -0.582 0 CA-C-O 117.018 -1.468 . . . . 74.5 110.723 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -110.55 64.02 0.61 Allowed 'General case' 0 C--N 1.36 1.054 0 CA-C-N 120.692 1.587 . . . . 73.129999999999995 112.47 -173.098 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.91 96.45 0.01 OUTLIER Glycine 0 C--N 1.356 1.692 0 CA-C-O 116.349 -2.362 . . . . 53.219999999999999 108.795 175.567 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.415 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -101.62 -173.9 28.25 Favored Glycine 0 C--N 1.363 2.068 0 CA-C-O 115.079 -3.067 . . . . 41.32 113.557 -174.686 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.5 tt -96.12 25.39 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.361 1.104 0 CA-C-N 120.192 1.996 . . . . 60.130000000000003 111.271 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.63 124.3 44.0 Favored 'General case' 0 C--N 1.364 1.238 0 CA-C-N 122.03 2.196 . . . . 73.230000000000004 111.112 -175.269 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 73.310000000000002 111.15 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 1.536 0 CA-C-O 116.544 -2.253 . . . . 65.109999999999999 117.875 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.46 171.88 37.55 Favored Glycine 0 C--N 1.359 1.815 0 CA-C-N 123.891 3.846 . . . . 75.120000000000005 111.398 -169.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -80.2 45.75 2.05 Favored 'Trans proline' 0 C--N 1.353 0.786 0 CA-C-N 122.298 3.049 . . . . 74.329999999999998 116.304 -177.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.419 ' N ' ' O ' ' A' ' 11' ' ' GLY . 56.9 mt -150.71 -154.01 0.52 Allowed 'General case' 0 C--N 1.352 0.711 0 N-CA-C 105.848 -1.908 . . . . 75.420000000000002 105.848 -178.472 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -126.26 90.21 3.14 Favored 'General case' 0 C--N 1.361 1.069 0 C-N-CA 126.044 1.738 . . . . 73.120000000000005 111.131 -176.077 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -139.81 -17.61 0.48 Allowed Glycine 0 C--N 1.349 1.254 0 O-C-N 118.487 -2.633 . . . . 70.439999999999998 116.627 172.608 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . 0.424 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 8.6 pt-20 -127.7 176.98 7.12 Favored 'General case' 0 C--N 1.359 1.003 0 CA-C-N 121.64 2.72 . . . . 54.520000000000003 104.967 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -59.06 -35.96 74.23 Favored 'General case' 0 C--O 1.22 -0.46 0 CA-C-O 117.67 -1.157 . . . . 72.019999999999996 111.04 179.578 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 4.9 mmt -110.16 63.2 0.6 Allowed 'General case' 0 C--N 1.36 1.051 0 CA-C-N 119.86 1.209 . . . . 73.420000000000002 110.861 -173.321 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 62.81 96.61 0.01 OUTLIER Glycine 0 C--N 1.356 1.647 0 CA-C-O 116.073 -2.515 . . . . 52.009999999999998 109.63 175.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.424 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -99.38 -174.4 31.27 Favored Glycine 0 N--CA 1.49 2.239 0 CA-C-O 115.942 -2.588 . . . . 63.119999999999997 113.422 -176.036 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.0 tt -97.11 25.39 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.985 0 CA-C-N 119.73 1.765 . . . . 75.430000000000007 111.085 179.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.9 p -120.87 124.57 45.32 Favored 'General case' 0 C--N 1.363 1.174 0 CA-C-N 120.861 1.664 . . . . 64.450000000000003 111.149 -176.073 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 13.7 t . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 70.329999999999998 111.162 179.998 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.059 0 CA-C-O 116.268 -2.407 . . . . 74.230000000000004 117.296 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -148.92 174.97 28.39 Favored Glycine 0 C--N 1.35 1.309 0 CA-C-N 123.358 3.579 . . . . 45.219999999999999 111.926 -170.716 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_endo -79.35 44.27 1.66 Allowed 'Trans proline' 0 C--N 1.362 1.282 0 CA-C-N 121.616 2.708 . . . . 64.439999999999998 116.046 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.465 ' N ' ' O ' ' A' ' 11' ' ' GLY . 34.2 mt -150.41 -156.3 0.71 Allowed 'General case' 0 C--O 1.218 -0.589 0 N-CA-C 105.89 -1.893 . . . . 63.049999999999997 105.89 -175.732 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.49 101.53 7.38 Favored 'General case' 0 C--N 1.355 0.828 0 C-N-CA 125.219 1.407 . . . . 60.210000000000001 111.14 -176.289 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -150.11 -33.93 0.04 OUTLIER Glycine 0 C--N 1.351 1.416 0 O-C-N 120.087 -1.633 . . . . 60.100000000000001 117.166 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -118.71 -179.43 3.8 Favored 'General case' 0 C--N 1.353 0.725 0 N-CA-C 104.503 -2.406 . . . . 74.340000000000003 104.503 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.79 -30.11 71.11 Favored 'General case' 0 C--N 1.347 0.471 0 CA-C-O 117.575 -1.203 . . . . 75.420000000000002 111.558 179.735 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 94.5 mtp -111.02 59.32 0.61 Allowed 'General case' 0 C--N 1.359 1.018 0 CA-C-N 119.866 1.212 . . . . 65.299999999999997 110.863 -176.133 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.49 103.89 0.02 OUTLIER Glycine 0 C--N 1.353 1.524 0 CA-C-O 117.464 -1.742 . . . . 63.420000000000002 109.969 176.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.465 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -100.34 -176.53 30.15 Favored Glycine 0 CA--C 1.491 -1.468 0 CA-C-O 115.877 -2.624 . . . . 70.400000000000006 112.362 -172.594 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.6 tt -97.39 24.07 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.853 0 CA-C-N 120.343 2.071 . . . . 71.400000000000006 111.469 176.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -123.58 125.68 45.29 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 119.675 1.125 . . . . 75.340000000000003 111.157 -176.041 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 15.1 t . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 73.519999999999996 111.173 179.983 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.838 0 CA-C-O 114.936 -3.147 . . . . 51.439999999999998 118.198 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -152.62 175.45 31.2 Favored Glycine 0 C--N 1.35 1.313 0 CA-C-N 123.461 3.631 . . . . 63.210000000000001 111.5 -172.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -80.53 46.68 2.32 Favored 'Trans proline' 0 C--N 1.364 1.391 0 CA-C-N 120.911 2.356 . . . . 75.120000000000005 114.731 -178.357 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' LEU . . . . . 0.626 HD22 HG23 ' A' ' 14' ' ' THR . 37.5 mt -151.31 -156.55 0.72 Allowed 'General case' 0 C--N 1.352 0.684 0 N-CA-C 106.819 -1.549 . . . . 74.140000000000001 106.819 -177.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.18 102.6 8.04 Favored 'General case' 0 C--N 1.362 1.13 0 CA-C-N 120.776 1.625 . . . . 75.140000000000001 111.066 -176.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -151.77 -34.71 0.03 OUTLIER Glycine 0 C--N 1.357 1.737 0 CA-C-O 117.177 -1.901 . . . . 61.229999999999997 116.915 179.236 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -117.46 178.05 4.52 Favored 'General case' 0 CA--C 1.506 -0.712 0 N-CA-C 105.792 -1.929 . . . . 63.109999999999999 105.792 177.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -61.18 -30.9 70.69 Favored 'General case' 0 C--O 1.22 -0.482 0 CA-C-O 117.662 -1.161 . . . . 72.25 111.415 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 20.9 mmt -110.33 58.51 0.61 Allowed 'General case' 0 C--N 1.359 0.991 0 CA-C-N 119.647 1.112 . . . . 73.349999999999994 113.021 -176.14 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 65.97 106.53 0.01 OUTLIER Glycine 0 C--N 1.353 1.528 0 CA-C-O 117.213 -1.881 . . . . 73.540000000000006 109.986 178.063 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -102.68 -174.78 26.98 Favored Glycine 0 CA--C 1.489 -1.593 0 CA-C-O 116.138 -2.479 . . . . 73.540000000000006 112.368 -172.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.4 tt -96.99 22.77 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.846 0 CA-C-N 120.256 2.028 . . . . 64.150000000000006 111.192 175.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -124.32 125.77 44.9 Favored 'General case' 0 C--N 1.359 0.981 0 CA-C-N 120.888 1.676 . . . . 74.439999999999998 111.153 -175.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' THR . . . . . 0.626 HG23 HD22 ' A' ' 4' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.257 0 CA-C-N 116.217 -0.447 . . . . 73.140000000000001 111.141 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.536 1.371 0 CA-C-O 116.573 -2.237 . . . . 42.210000000000001 116.846 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -157.26 175.36 34.71 Favored Glycine 0 C--N 1.363 2.072 1 CA-C-N 124.782 4.291 . . . . 72.340000000000003 112.099 -170.691 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 41.5 Cg_endo -81.53 49.53 3.22 Favored 'Trans proline' 0 C--N 1.352 0.717 0 CA-C-N 122.479 3.139 . . . . 72.219999999999999 115.659 -178.327 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.419 ' N ' ' O ' ' A' ' 11' ' ' GLY . 37.8 mt -155.56 -156.16 0.62 Allowed 'General case' 0 C--N 1.358 0.965 0 CA-C-O 115.436 -2.221 . . . . 70.129999999999995 106.832 -177.04 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.03 105.49 9.61 Favored 'General case' 0 C--N 1.352 0.685 0 CA-C-N 122.06 2.209 . . . . 52.109999999999999 111.102 -175.778 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.14 -36.66 0.02 OUTLIER Glycine 0 C--N 1.373 2.632 0 N-CA-C 118.406 2.122 . . . . 43.32 118.406 -179.084 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.4 pt-20 -116.31 177.4 4.7 Favored 'General case' 0 C--N 1.349 0.584 0 N-CA-C 105.474 -2.047 . . . . 75.040000000000006 105.474 176.075 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 7.4 tt0 -58.67 -32.48 69.14 Favored 'General case' 0 C--N 1.348 0.536 0 CA-C-O 117.931 -1.033 . . . . 50.439999999999998 111.816 179.275 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 6.1 mmt -109.63 57.49 0.61 Allowed 'General case' 0 C--N 1.359 0.986 0 CA-C-N 119.924 1.238 . . . . 60.439999999999998 111.655 -172.59 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 67.88 108.16 0.02 OUTLIER Glycine 0 C--N 1.358 1.767 0 CA-C-O 115.998 -2.557 . . . . 73.430000000000007 109.962 177.869 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.419 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -107.91 -174.18 22.09 Favored Glycine 0 C--N 1.354 1.572 0 CA-C-N 121.505 2.653 . . . . 53.140000000000001 111.198 -170.319 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 8.7 tt -96.42 22.66 0.94 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.735 0 CA-C-N 120.412 2.106 . . . . 75.340000000000003 111.022 176.577 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -124.56 125.69 44.6 Favored 'General case' 0 C--N 1.365 1.271 0 CA-C-N 121.171 1.805 . . . . 64.540000000000006 111.138 -174.653 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 7.0 t . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.227 -0.442 . . . . 64.510000000000005 111.091 -179.985 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.54 1.636 0 N-CA-C 120.158 2.823 . . . . 55.409999999999997 120.158 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -156.48 174.22 34.25 Favored Glycine 0 C--N 1.348 1.218 1 CA-C-N 124.817 4.308 . . . . 51.43 111.191 -173.437 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 68.6 Cg_endo -79.94 44.55 1.74 Allowed 'Trans proline' 0 C--N 1.369 1.636 0 CA-C-N 122.054 2.927 . . . . 62.350000000000001 115.017 -177.36 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.44 ' N ' ' O ' ' A' ' 11' ' ' GLY . 43.3 mt -148.96 -154.5 0.56 Allowed 'General case' 0 C--N 1.354 0.788 0 N-CA-C 106.477 -1.675 . . . . 65.010000000000005 106.477 -178.941 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.97 88.58 2.91 Favored 'General case' 0 C--N 1.362 1.142 0 C-N-CA 125.91 1.684 . . . . 72.409999999999997 111.151 -176.558 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -138.31 -14.78 0.7 Allowed Glycine 0 CA--C 1.528 0.845 0 O-C-N 118.724 -2.485 . . . . 71.450000000000003 117.305 171.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 3.2 pt-20 -129.39 175.67 8.57 Favored 'General case' 0 C--N 1.359 0.984 0 CA-C-N 121.372 2.586 . . . . 75.200000000000003 106.236 179.598 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.8 tp10 -58.57 -36.95 74.75 Favored 'General case' 0 C--O 1.219 -0.546 0 CA-C-O 117.807 -1.092 . . . . 73.349999999999994 110.944 178.798 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 78.3 mtm -109.16 66.83 0.64 Allowed 'General case' 0 C--N 1.356 0.875 0 CA-C-N 119.551 1.069 . . . . 63.210000000000001 111.396 -175.753 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 60.67 91.13 0.02 OUTLIER Glycine 0 C--N 1.352 1.448 0 CA-C-O 116.599 -2.223 . . . . 62.310000000000002 110.041 173.239 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.44 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -92.22 -174.34 42.09 Favored Glycine 0 C--O 1.201 -1.948 0 CA-C-O 116.204 -2.442 . . . . 74.319999999999993 115.091 -177.263 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.8 tt -96.84 24.06 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.371 1.538 0 CA-C-N 118.645 1.222 . . . . 73.310000000000002 111.257 -179.752 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.4 p -120.57 124.44 45.32 Favored 'General case' 0 C--N 1.358 0.939 0 CA-C-N 120.744 1.611 . . . . 70.219999999999999 111.151 -174.86 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 15.4 t . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.244 -0.435 . . . . 75.329999999999998 111.153 179.978 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.543 1.782 0 N-CA-C 119.205 2.442 . . . . 61.200000000000003 119.205 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -158.72 175.25 35.78 Favored Glycine 0 C--N 1.354 1.571 1 CA-C-N 125.813 4.807 . . . . 74.319999999999993 109.764 -174.026 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 64.8 Cg_endo -80.31 45.18 1.9 Allowed 'Trans proline' 0 C--N 1.351 0.71 0 CA-C-N 121.097 2.449 . . . . 74.200000000000003 115.504 -176.902 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.441 ' N ' ' O ' ' A' ' 11' ' ' GLY . 47.6 mt -149.95 -154.48 0.56 Allowed 'General case' 0 C--N 1.36 1.022 0 CA-C-O 116.467 -1.73 . . . . 74.140000000000001 107.017 -179.019 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -124.97 88.86 2.96 Favored 'General case' 0 C--N 1.354 0.778 0 C-N-CA 125.674 1.59 . . . . 62.219999999999999 111.108 -176.203 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -138.8 -14.58 0.66 Allowed Glycine 0 CA--C 1.529 0.909 0 O-C-N 118.698 -2.501 . . . . 63.299999999999997 117.271 171.343 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 3.7 pt-20 -129.13 174.96 9.09 Favored 'General case' 0 C--N 1.352 0.69 0 CA-C-N 121.04 2.42 . . . . 53.32 105.74 179.759 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -58.65 -35.13 72.04 Favored 'General case' 0 C--O 1.219 -0.525 0 CA-C-O 117.682 -1.151 . . . . 71.230000000000004 110.731 179.306 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 3.6 mmt -109.76 63.23 0.6 Allowed 'General case' 0 C--N 1.355 0.816 0 CA-C-N 119.419 1.008 . . . . 70.239999999999995 111.656 -174.077 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.67 91.17 0.02 OUTLIER Glycine 0 C--N 1.352 1.421 0 CA-C-O 116.567 -2.241 . . . . 62.310000000000002 110.093 175.71 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.441 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -92.87 -175.06 41.21 Favored Glycine 0 N--CA 1.491 2.34 0 CA-C-O 115.617 -2.768 . . . . 65.200000000000003 115.052 -177.006 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 12.1 tt -96.13 24.38 0.72 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.844 0 CA-C-N 120.124 1.962 . . . . 64.209999999999994 111.051 -179.481 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.4 p -120.66 124.59 45.59 Favored 'General case' 0 C--N 1.359 1.01 0 CA-C-N 121.346 1.885 . . . . 61.210000000000001 111.132 -175.328 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.5 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.249 -0.432 . . . . 71.040000000000006 111.139 -179.972 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 C--O 1.221 -0.703 0 CA-C-O 116.506 -2.274 . . . . 24.149999999999999 117.844 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -145.03 178.63 22.69 Favored Glycine 0 C--N 1.368 2.359 0 CA-C-N 123.347 3.574 . . . . 64.019999999999996 110.995 -174.826 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 90.1 Cg_endo -79.38 44.62 1.74 Allowed 'Trans proline' 0 C--N 1.357 1.011 0 CA-C-N 121.78 2.79 . . . . 70.040000000000006 116.375 -179.376 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.732 HD22 HG23 ' A' ' 14' ' ' THR . 39.3 mt -149.24 -156.34 0.71 Allowed 'General case' 0 N--CA 1.472 0.653 0 N-CA-C 106.381 -1.711 . . . . 72.420000000000002 106.381 -176.203 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.19 100.92 7.1 Favored 'General case' 0 C--N 1.353 0.721 0 C-N-CA 125.079 1.352 . . . . 71.219999999999999 111.095 -176.758 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -149.53 -32.04 0.05 OUTLIER Glycine 0 C--N 1.347 1.151 0 O-C-N 119.299 -2.125 . . . . 51.020000000000003 116.776 178.939 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 2.2 pt-20 -119.67 179.22 4.3 Favored 'General case' 0 C--N 1.357 0.904 0 N-CA-C 104.743 -2.318 . . . . 64.510000000000005 104.743 178.864 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 13.4 tt0 -64.12 -29.82 70.93 Favored 'General case' 0 C--N 1.349 0.558 0 CA-C-O 117.382 -1.294 . . . . 65.420000000000002 111.664 178.777 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 66.3 mmm -110.6 59.29 0.61 Allowed 'General case' 0 C--N 1.357 0.92 0 CA-C-N 119.597 1.089 . . . . 73.230000000000004 110.555 -176.345 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 65.99 98.74 0.02 OUTLIER Glycine 0 C--N 1.354 1.56 0 CA-C-O 117.978 -1.456 . . . . 64.439999999999998 110.428 174.83 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.452 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -94.2 -177.58 38.98 Favored Glycine 0 CA--C 1.491 -1.447 0 CA-C-O 115.598 -2.779 . . . . 63.299999999999997 113.183 -171.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.7 tt -97.58 24.85 0.79 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.992 0 CA-C-N 120.726 2.263 . . . . 65.310000000000002 111.289 175.63 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.2 p -124.16 125.83 45.12 Favored 'General case' 0 C--N 1.357 0.917 0 CA-C-N 119.593 1.088 . . . . 45.350000000000001 111.113 -176.431 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.732 HG23 HD22 ' A' ' 4' ' ' LEU . 0.3 OUTLIER . . . . . 0 C--N 1.33 -0.278 0 CA-C-N 116.181 -0.463 . . . . 70.0 111.121 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.474 1.172 0 N-CA-C 120.027 2.771 . . . . 70.109999999999999 120.027 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -150.56 178.68 27.85 Favored Glycine 0 C--N 1.366 2.204 0 CA-C-N 124.069 3.935 . . . . 31.149999999999999 112.598 -175.598 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 43.3 Cg_endo -81.29 49.62 3.27 Favored 'Trans proline' 0 N--CA 1.449 -1.118 1 CA-C-N 124.298 4.049 . . . . 74.420000000000002 116.208 -178.046 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.449 ' N ' ' O ' ' A' ' 11' ' ' GLY . 59.6 mt -154.01 -157.17 0.75 Allowed 'General case' 0 N--CA 1.48 1.041 0 CA-C-O 116.703 -1.617 . . . . 51.43 106.91 -176.206 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.13 104.71 9.36 Favored 'General case' 0 C--N 1.358 0.976 0 CA-C-N 121.612 2.005 . . . . 71.530000000000001 111.095 -176.433 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -155.15 -35.78 0.02 OUTLIER Glycine 0 C--N 1.369 2.367 0 N-CA-C 117.599 1.8 . . . . 74.510000000000005 117.599 -179.512 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 8.1 pt-20 -116.02 177.38 4.7 Favored 'General case' 0 C--N 1.354 0.799 0 N-CA-C 105.755 -1.942 . . . . 74.010000000000005 105.755 175.211 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 2.8 tp10 -57.17 -33.51 67.52 Favored 'General case' 0 C--N 1.35 0.589 0 CA-C-O 117.926 -1.035 . . . . 42.439999999999998 111.424 178.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 1.8 mmm -110.15 60.72 0.6 Allowed 'General case' 0 C--N 1.354 0.776 0 CA-C-N 119.044 0.838 . . . . 72.299999999999997 112.352 -174.225 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.53 102.84 0.02 OUTLIER Glycine 0 C--N 1.355 1.631 0 N-CA-C 108.991 -1.644 . . . . 73.109999999999999 108.991 174.36 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.449 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -100.9 -174.2 29.19 Favored Glycine 0 C--O 1.207 -1.561 0 CA-C-O 115.912 -2.605 . . . . 73.420000000000002 112.941 -170.954 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 8.1 tt -96.99 22.48 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.364 1.209 0 CA-C-N 120.012 1.906 . . . . 64.439999999999998 111.669 175.388 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.4 p -124.48 125.75 44.75 Favored 'General case' 0 C--N 1.364 1.222 0 CA-C-N 120.079 1.308 . . . . 75.549999999999997 111.152 -174.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 12.1 t . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.228 -0.442 . . . . 71.140000000000001 111.112 -179.956 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.557 2.672 0 CA-C-O 115.318 -2.935 . . . . 62.530000000000001 118.803 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.53 173.12 42.59 Favored Glycine 0 C--N 1.379 2.927 0 CA-C-N 124.147 3.973 . . . . 61.25 111.039 -172.481 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 42.2 Cg_endo -81.89 50.58 3.52 Favored 'Trans proline' 0 N--CA 1.452 -0.953 0 CA-C-N 122.573 3.186 . . . . 73.109999999999999 115.64 -176.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.648 HD22 HG23 ' A' ' 14' ' ' THR . 71.9 mt -155.61 -156.77 0.67 Allowed 'General case' 0 C--O 1.211 -0.938 0 CA-C-O 115.785 -2.055 . . . . 75.450000000000003 106.362 -177.457 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.0 91.31 3.41 Favored 'General case' 0 C--N 1.359 1.021 0 CA-C-N 121.798 2.09 . . . . 63.399999999999999 111.093 -176.133 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -141.87 -14.95 0.39 Allowed Glycine 0 C--N 1.353 1.498 0 O-C-N 119.064 -2.273 . . . . 52.5 118.422 169.881 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.419 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 10.0 pt-20 -128.24 175.02 8.78 Favored 'General case' 0 C--N 1.353 0.748 0 CA-C-N 121.466 2.633 . . . . 61.329999999999998 104.441 178.788 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 10.3 tt0 -62.49 -30.62 71.4 Favored 'General case' 0 C--O 1.218 -0.589 0 CA-C-O 116.886 -1.531 . . . . 74.209999999999994 110.57 -177.029 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 44.0 mtm -111.98 65.26 0.63 Allowed 'General case' 0 C--N 1.359 1.02 0 CA-C-N 120.622 1.555 . . . . 74.519999999999996 112.007 -177.22 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.71 96.66 0.01 OUTLIER Glycine 0 C--N 1.357 1.736 0 CA-C-O 116.346 -2.363 . . . . 72.409999999999997 109.365 174.338 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.419 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -101.62 -172.87 28.13 Favored Glycine 0 C--N 1.364 2.135 0 CA-C-O 114.722 -3.265 . . . . 72.420000000000002 113.858 -174.197 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.5 tt -96.96 25.26 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.361 1.105 0 CA-C-N 120.305 2.052 . . . . 75.319999999999993 111.233 -179.928 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -122.11 124.56 44.19 Favored 'General case' 0 C--N 1.366 1.301 0 CA-C-N 122.138 2.244 . . . . 65.420000000000002 111.123 -174.757 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.648 HG23 HD22 ' A' ' 4' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.268 0 CA-C-N 116.194 -0.457 . . . . 63.329999999999998 111.156 179.968 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.554 2.477 0 CA-C-O 115.442 -2.865 . . . . 55.25 118.881 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.71 173.11 42.7 Favored Glycine 0 C--N 1.377 2.84 0 CA-C-N 124.144 3.972 . . . . 74.140000000000001 111.205 -171.941 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 41.0 Cg_endo -82.69 49.62 3.14 Favored 'Trans proline' 0 N--CA 1.453 -0.871 0 CA-C-N 122.639 3.22 . . . . 70.140000000000001 115.828 -176.041 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 67.9 mt -154.44 -154.89 0.54 Allowed 'General case' 0 C--N 1.357 0.929 0 CA-C-O 115.744 -2.074 . . . . 64.319999999999993 106.317 -178.821 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.84 89.88 3.11 Favored 'General case' 0 C--N 1.358 0.969 0 CA-C-N 121.782 2.083 . . . . 62.020000000000003 111.108 -175.532 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.02 -14.6 0.56 Allowed Glycine 0 C--N 1.353 1.503 0 O-C-N 118.84 -2.413 . . . . 55.509999999999998 117.936 170.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.414 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 9.0 pt-20 -129.64 173.45 10.6 Favored 'General case' 0 C--N 1.355 0.83 0 CA-C-N 121.705 2.753 . . . . 74.0 104.999 179.192 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 13.0 tt0 -56.84 -35.07 68.4 Favored 'General case' 0 C--O 1.217 -0.622 0 CA-C-O 117.282 -1.342 . . . . 72.530000000000001 111.132 -179.754 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 7.7 mmt -110.28 64.0 0.61 Allowed 'General case' 0 C--N 1.36 1.042 0 CA-C-N 120.456 1.48 . . . . 71.540000000000006 111.598 -173.348 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.12 96.82 0.01 OUTLIER Glycine 0 C--N 1.356 1.66 0 CA-C-O 116.42 -2.322 . . . . 63.539999999999999 109.439 175.633 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.414 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -101.84 -173.86 27.96 Favored Glycine 0 C--N 1.364 2.087 0 CA-C-O 115.14 -3.033 . . . . 73.209999999999994 113.721 -174.933 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.9 tt -96.3 25.43 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.051 0 CA-C-N 120.245 2.023 . . . . 52.509999999999998 111.281 -179.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -121.38 124.43 44.51 Favored 'General case' 0 C--N 1.364 1.233 0 CA-C-N 122.018 2.19 . . . . 52.32 111.162 -175.512 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 2.2 m . . . . . 0 C--N 1.33 -0.272 0 CA-C-N 116.2 -0.455 . . . . 53.32 111.145 179.99 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.556 2.655 0 CA-C-O 115.298 -2.946 . . . . 61.200000000000003 118.832 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -168.01 173.07 42.88 Favored Glycine 0 C--N 1.379 2.928 0 CA-C-N 124.08 3.94 . . . . 63.100000000000001 111.15 -172.043 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.0 Cg_endo -82.61 50.21 3.33 Favored 'Trans proline' 0 N--CA 1.453 -0.857 0 CA-C-N 122.665 3.233 . . . . 63.140000000000001 115.71 -175.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 56.5 mt -154.9 -155.35 0.57 Allowed 'General case' 0 C--N 1.357 0.902 0 CA-C-O 115.891 -2.004 . . . . 73.109999999999999 106.266 -178.558 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.61 89.84 3.11 Favored 'General case' 0 C--N 1.359 1.019 0 CA-C-N 121.687 2.039 . . . . 70.510000000000005 111.103 -175.719 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.2 -14.19 0.56 Allowed Glycine 0 C--N 1.355 1.609 0 O-C-N 118.944 -2.347 . . . . 73.319999999999993 117.947 170.978 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.419 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 10.1 pt-20 -130.39 174.66 9.64 Favored 'General case' 0 N--CA 1.476 0.867 0 CA-C-N 121.708 2.754 . . . . 63.520000000000003 104.996 178.876 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 2.9 tm-20 -61.61 -30.59 70.79 Favored 'General case' 0 C--O 1.218 -0.567 0 CA-C-O 116.923 -1.513 . . . . 72.040000000000006 110.722 -177.551 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 8.1 mmt -112.01 64.8 0.63 Allowed 'General case' 0 C--N 1.359 1.003 0 CA-C-N 120.598 1.545 . . . . 63.329999999999998 111.561 -176.757 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 60.87 96.95 0.01 OUTLIER Glycine 0 C--N 1.356 1.674 0 CA-C-O 116.516 -2.269 . . . . 31.329999999999998 109.752 174.713 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.419 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -102.24 -173.82 27.45 Favored Glycine 0 C--N 1.364 2.107 0 CA-C-O 115.062 -3.077 . . . . 74.129999999999995 113.799 -174.485 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.7 tt -96.14 24.96 0.67 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.053 0 CA-C-N 120.261 2.031 . . . . 54.450000000000003 111.475 -179.51 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.6 p -121.24 124.8 45.54 Favored 'General case' 0 C--N 1.365 1.24 0 CA-C-N 121.913 2.142 . . . . 71.5 111.167 -175.084 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 14.9 t . . . . . 0 C--N 1.33 -0.27 0 CA-C-N 116.206 -0.452 . . . . 53.420000000000002 111.115 -179.988 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.556 2.648 0 CA-C-O 115.264 -2.965 . . . . 52.210000000000001 118.753 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.88 172.82 42.75 Favored Glycine 0 C--N 1.379 2.934 0 CA-C-N 124.085 3.942 . . . . 54.310000000000002 111.125 -172.244 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.8 Cg_endo -82.09 50.07 3.34 Favored 'Trans proline' 0 N--CA 1.454 -0.839 0 CA-C-N 122.581 3.191 . . . . 73.040000000000006 115.908 -176.221 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 54.8 mt -154.64 -154.95 0.54 Allowed 'General case' 0 C--N 1.356 0.873 0 CA-C-O 115.918 -1.992 . . . . 45.100000000000001 106.114 -178.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.93 91.18 3.33 Favored 'General case' 0 C--N 1.359 1.0 0 CA-C-N 121.731 2.06 . . . . 74.230000000000004 111.143 -175.797 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -141.33 -15.37 0.43 Allowed Glycine 0 C--N 1.353 1.484 0 O-C-N 119.039 -2.288 . . . . 61.109999999999999 118.209 170.248 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.415 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 9.3 pt-20 -128.36 174.01 9.69 Favored 'General case' 0 C--N 1.354 0.771 0 CA-C-N 121.47 2.635 . . . . 75.540000000000006 104.739 179.063 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 20.8 tt0 -58.77 -33.7 70.6 Favored 'General case' 0 C--O 1.218 -0.591 0 CA-C-O 116.905 -1.522 . . . . 74.010000000000005 110.886 -179.044 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 33.4 mmm -111.24 65.09 0.62 Allowed 'General case' 0 C--N 1.359 1.009 0 CA-C-N 120.885 1.675 . . . . 64.120000000000005 111.751 -174.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.42 97.04 0.01 OUTLIER Glycine 0 C--N 1.358 1.769 0 CA-C-O 116.26 -2.411 . . . . 64.239999999999995 109.569 174.936 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.415 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -102.34 -173.88 27.33 Favored Glycine 0 C--N 1.364 2.133 0 CA-C-O 114.978 -3.123 . . . . 74.310000000000002 113.682 -174.152 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.4 tt -96.24 25.13 0.66 Allowed 'Isoleucine or valine' 0 C--N 1.362 1.111 0 CA-C-N 120.279 2.039 . . . . 72.540000000000006 111.291 -179.438 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.67 124.62 44.7 Favored 'General case' 0 C--N 1.365 1.247 0 CA-C-N 121.907 2.14 . . . . 54.100000000000001 111.174 -174.961 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 1.1 m . . . . . 0 C--N 1.329 -0.295 0 CA-C-N 116.253 -0.43 . . . . 75.049999999999997 111.113 -179.929 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.537 1.414 0 CA-C-O 116.708 -2.162 . . . . 73.400000000000006 117.815 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.27 171.94 37.4 Favored Glycine 0 C--N 1.36 1.88 0 CA-C-N 123.808 3.804 . . . . 74.439999999999998 111.459 -170.25 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 62.1 Cg_endo -79.84 45.33 1.92 Allowed 'Trans proline' 0 C--N 1.354 0.845 0 CA-C-N 122.395 3.098 . . . . 71.420000000000002 116.185 -178.029 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.622 HD22 HG23 ' A' ' 14' ' ' THR . 48.3 mt -150.69 -155.16 0.6 Allowed 'General case' 0 C--N 1.352 0.677 0 N-CA-C 106.015 -1.846 . . . . 73.329999999999998 106.015 -176.949 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.6 90.87 3.29 Favored 'General case' 0 C--N 1.359 1.02 0 C-N-CA 125.689 1.596 . . . . 74.420000000000002 111.149 -176.719 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.54 -17.69 0.42 Allowed Glycine 0 C--N 1.349 1.252 0 O-C-N 118.544 -2.597 . . . . 65.230000000000004 116.774 172.52 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.43 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 8.2 pt-20 -127.92 177.71 6.67 Favored 'General case' 0 C--N 1.36 1.031 0 CA-C-N 121.571 2.685 . . . . 71.129999999999995 104.481 179.596 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 8.8 tt0 -63.51 -32.07 73.41 Favored 'General case' 0 C--O 1.219 -0.552 0 CA-C-O 117.062 -1.447 . . . . 73.530000000000001 110.937 -179.085 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 15.9 mtt -110.6 64.53 0.61 Allowed 'General case' 0 C--N 1.361 1.099 0 CA-C-N 120.435 1.471 . . . . 63.039999999999999 111.942 -177.776 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 63.15 96.76 0.01 OUTLIER Glycine 0 C--N 1.356 1.686 0 CA-C-O 115.958 -2.579 . . . . 54.130000000000003 109.059 174.66 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.43 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -99.4 -174.04 31.19 Favored Glycine 0 N--CA 1.488 2.147 0 CA-C-O 115.509 -2.828 . . . . 75.25 113.301 -175.331 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.1 tt -97.21 25.46 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.36 1.022 0 CA-C-N 119.869 1.834 . . . . 64.239999999999995 111.002 179.339 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.52 124.79 45.25 Favored 'General case' 0 C--N 1.363 1.176 0 CA-C-N 121.149 1.795 . . . . 61.25 111.123 -175.581 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.622 HG23 HD22 ' A' ' 4' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.329 -0.292 0 CA-C-N 116.169 -0.469 . . . . 53.049999999999997 111.139 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.532 1.141 0 CA-C-O 116.095 -2.503 . . . . 63.420000000000002 119.231 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -149.4 177.05 27.84 Favored Glycine 0 C--N 1.366 2.244 0 CA-C-N 123.074 3.437 . . . . 75.209999999999994 110.915 -174.222 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 68.1 Cg_endo -80.19 46.88 2.36 Favored 'Trans proline' 0 C--N 1.349 0.588 0 CA-C-N 122.272 3.036 . . . . 54.130000000000003 115.267 -178.174 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.497 ' N ' ' O ' ' A' ' 11' ' ' GLY . 54.9 mt -150.81 -156.08 0.68 Allowed 'General case' 0 C--N 1.349 0.544 0 CA-C-O 117.032 -1.461 . . . . 71.439999999999998 108.092 -178.036 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -122.54 102.94 8.37 Favored 'General case' 0 C--N 1.369 1.453 0 CA-C-N 121.042 1.747 . . . . 71.310000000000002 111.089 -177.221 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -153.3 -33.9 0.03 OUTLIER Glycine 0 C--N 1.349 1.304 0 N-CA-C 117.622 1.809 . . . . 53.109999999999999 117.622 179.479 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 4.6 pt-20 -116.11 177.64 4.61 Favored 'General case' 0 C--N 1.351 0.66 0 CA-C-N 119.141 1.47 . . . . 74.120000000000005 107.524 174.966 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 5.0 tt0 -60.29 -31.44 70.25 Favored 'General case' 0 C--N 1.349 0.544 0 CA-C-O 117.816 -1.088 . . . . 63.299999999999997 110.93 179.433 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 31.4 mmm -110.05 58.45 0.61 Allowed 'General case' 0 C--N 1.359 1.004 0 CA-C-N 119.389 0.995 . . . . 71.439999999999998 111.969 -173.677 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.09 101.14 0.02 OUTLIER Glycine 0 C--N 1.356 1.655 0 CA-C-O 117.08 -1.956 . . . . 75.150000000000006 110.86 177.036 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.497 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -96.32 -176.07 35.94 Favored Glycine 0 CA--C 1.486 -1.766 0 CA-C-O 116.203 -2.443 . . . . 61.229999999999997 114.066 -172.311 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.5 tt -97.17 22.62 1.04 Allowed 'Isoleucine or valine' 0 C--N 1.353 0.749 0 CA-C-N 120.211 2.006 . . . . 75.109999999999999 111.389 174.768 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.0 p -124.14 128.19 48.89 Favored 'General case' 0 C--N 1.362 1.132 0 CA-C-N 120.348 1.431 . . . . 73.319999999999993 111.137 -175.402 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 86.8 m . . . . . 0 C--N 1.33 -0.276 0 CA-C-N 116.216 -0.447 . . . . 73.340000000000003 111.121 -179.974 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.555 2.565 0 CA-C-O 115.466 -2.852 . . . . 64.340000000000003 118.899 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -167.71 173.15 42.7 Favored Glycine 0 C--N 1.378 2.9 0 CA-C-N 124.032 3.916 . . . . 64.329999999999998 111.158 -172.03 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 40.5 Cg_endo -82.6 50.0 3.26 Favored 'Trans proline' 0 N--CA 1.453 -0.872 0 CA-C-N 122.519 3.16 . . . . 64.430000000000007 115.791 -176.116 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . . . . . . . . . 61.5 mt -154.6 -155.08 0.55 Allowed 'General case' 0 C--N 1.357 0.917 0 CA-C-O 115.852 -2.023 . . . . 74.319999999999993 106.205 -178.785 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -125.89 90.02 3.13 Favored 'General case' 0 C--N 1.359 1.007 0 CA-C-N 121.81 2.096 . . . . 64.310000000000002 111.061 -175.69 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -140.2 -14.79 0.54 Allowed Glycine 0 C--N 1.353 1.482 0 O-C-N 118.816 -2.427 . . . . 72.530000000000001 117.927 170.729 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.415 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 8.9 pt-20 -129.5 173.51 10.51 Favored 'General case' 0 C--N 1.355 0.833 0 CA-C-N 121.708 2.754 . . . . 75.319999999999993 104.921 179.188 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 24.7 tt0 -56.15 -35.77 67.54 Favored 'General case' 0 C--O 1.218 -0.582 0 CA-C-O 117.018 -1.468 . . . . 74.5 110.723 179.957 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -110.55 64.02 0.61 Allowed 'General case' 0 C--N 1.36 1.054 0 CA-C-N 120.692 1.587 . . . . 73.129999999999995 112.47 -173.098 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 61.91 96.45 0.01 OUTLIER Glycine 0 C--N 1.356 1.692 0 CA-C-O 116.349 -2.362 . . . . 53.219999999999999 108.795 175.567 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.415 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -101.62 -173.9 28.25 Favored Glycine 0 C--N 1.363 2.068 0 CA-C-O 115.079 -3.067 . . . . 41.32 113.557 -174.686 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.5 tt -96.12 25.39 0.64 Allowed 'Isoleucine or valine' 0 C--N 1.361 1.104 0 CA-C-N 120.192 1.996 . . . . 60.130000000000003 111.271 -179.667 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.7 p -121.63 124.3 44.0 Favored 'General case' 0 C--N 1.364 1.238 0 CA-C-N 122.03 2.196 . . . . 73.230000000000004 111.112 -175.269 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.33 -0.274 0 CA-C-N 116.203 -0.453 . . . . 73.310000000000002 111.15 179.981 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 1.536 0 CA-C-O 116.544 -2.253 . . . . 65.109999999999999 117.875 . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -161.46 171.88 37.55 Favored Glycine 0 C--N 1.359 1.815 0 CA-C-N 123.891 3.846 . . . . 75.120000000000005 111.398 -169.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 59.8 Cg_endo -80.2 45.75 2.05 Favored 'Trans proline' 0 C--N 1.353 0.786 0 CA-C-N 122.298 3.049 . . . . 74.329999999999998 116.304 -177.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.419 ' N ' ' O ' ' A' ' 11' ' ' GLY . 56.9 mt -150.71 -154.01 0.52 Allowed 'General case' 0 C--N 1.352 0.711 0 N-CA-C 105.848 -1.908 . . . . 75.420000000000002 105.848 -178.472 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -126.26 90.21 3.14 Favored 'General case' 0 C--N 1.361 1.069 0 C-N-CA 126.044 1.738 . . . . 73.120000000000005 111.131 -176.077 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -139.81 -17.61 0.48 Allowed Glycine 0 C--N 1.349 1.254 0 O-C-N 118.487 -2.633 . . . . 70.439999999999998 116.627 172.608 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . 0.424 ' HG2' ' CA ' ' A' ' 11' ' ' GLY . 8.6 pt-20 -127.7 176.98 7.12 Favored 'General case' 0 C--N 1.359 1.003 0 CA-C-N 121.64 2.72 . . . . 54.520000000000003 104.967 179.528 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -59.06 -35.96 74.23 Favored 'General case' 0 C--O 1.22 -0.46 0 CA-C-O 117.67 -1.157 . . . . 72.019999999999996 111.04 179.578 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 4.9 mmt -110.16 63.2 0.6 Allowed 'General case' 0 C--N 1.36 1.051 0 CA-C-N 119.86 1.209 . . . . 73.420000000000002 110.861 -173.321 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 62.81 96.61 0.01 OUTLIER Glycine 0 C--N 1.356 1.647 0 CA-C-O 116.073 -2.515 . . . . 52.009999999999998 109.63 175.807 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.424 ' CA ' ' HG2' ' A' ' 7' ' ' GLU . . . -99.38 -174.4 31.27 Favored Glycine 0 N--CA 1.49 2.239 0 CA-C-O 115.942 -2.588 . . . . 63.119999999999997 113.422 -176.036 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.0 tt -97.11 25.39 0.7 Allowed 'Isoleucine or valine' 0 C--N 1.359 0.985 0 CA-C-N 119.73 1.765 . . . . 75.430000000000007 111.085 179.689 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 10.9 p -120.87 124.57 45.32 Favored 'General case' 0 C--N 1.363 1.174 0 CA-C-N 120.861 1.664 . . . . 64.450000000000003 111.149 -176.073 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 13.7 t . . . . . 0 C--N 1.329 -0.286 0 CA-C-N 116.197 -0.456 . . . . 70.329999999999998 111.162 179.998 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.531 1.059 0 CA-C-O 116.268 -2.407 . . . . 74.230000000000004 117.296 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -148.92 174.97 28.39 Favored Glycine 0 C--N 1.35 1.309 0 CA-C-N 123.358 3.579 . . . . 45.219999999999999 111.926 -170.716 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 79.9 Cg_endo -79.35 44.27 1.66 Allowed 'Trans proline' 0 C--N 1.362 1.282 0 CA-C-N 121.616 2.708 . . . . 64.439999999999998 116.046 -179.544 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.465 ' N ' ' O ' ' A' ' 11' ' ' GLY . 34.2 mt -150.41 -156.3 0.71 Allowed 'General case' 0 C--O 1.218 -0.589 0 N-CA-C 105.89 -1.893 . . . . 63.049999999999997 105.89 -175.732 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.49 101.53 7.38 Favored 'General case' 0 C--N 1.355 0.828 0 C-N-CA 125.219 1.407 . . . . 60.210000000000001 111.14 -176.289 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -150.11 -33.93 0.04 OUTLIER Glycine 0 C--N 1.351 1.416 0 O-C-N 120.087 -1.633 . . . . 60.100000000000001 117.166 179.708 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 5.0 pt-20 -118.71 -179.43 3.8 Favored 'General case' 0 C--N 1.353 0.725 0 N-CA-C 104.503 -2.406 . . . . 74.340000000000003 104.503 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -64.79 -30.11 71.11 Favored 'General case' 0 C--N 1.347 0.471 0 CA-C-O 117.575 -1.203 . . . . 75.420000000000002 111.558 179.735 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 94.5 mtp -111.02 59.32 0.61 Allowed 'General case' 0 C--N 1.359 1.018 0 CA-C-N 119.866 1.212 . . . . 65.299999999999997 110.863 -176.133 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 66.49 103.89 0.02 OUTLIER Glycine 0 C--N 1.353 1.524 0 CA-C-O 117.464 -1.742 . . . . 63.420000000000002 109.969 176.28 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.465 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -100.34 -176.53 30.15 Favored Glycine 0 CA--C 1.491 -1.468 0 CA-C-O 115.877 -2.624 . . . . 70.400000000000006 112.362 -172.594 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 10.6 tt -97.39 24.07 0.87 Allowed 'Isoleucine or valine' 0 C--N 1.356 0.853 0 CA-C-N 120.343 2.071 . . . . 71.400000000000006 111.469 176.533 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -123.58 125.68 45.29 Favored 'General case' 0 C--N 1.36 1.022 0 CA-C-N 119.675 1.125 . . . . 75.340000000000003 111.157 -176.041 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . . . . . . . . . 15.1 t . . . . . 0 C--N 1.329 -0.308 0 CA-C-N 116.21 -0.45 . . . . 73.519999999999996 111.173 179.983 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' GLY . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.527 0.838 0 CA-C-O 114.936 -3.147 . . . . 51.439999999999998 118.198 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' GLY . . . . . . . . . . . . . . . -152.62 175.45 31.2 Favored Glycine 0 C--N 1.35 1.313 0 CA-C-N 123.461 3.631 . . . . 63.210000000000001 111.5 -172.949 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' PRO . . . . . . . . . . . . . 66.6 Cg_endo -80.53 46.68 2.32 Favored 'Trans proline' 0 C--N 1.364 1.391 0 CA-C-N 120.911 2.356 . . . . 75.120000000000005 114.731 -178.357 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' LEU . . . . . 0.626 HD22 HG23 ' A' ' 14' ' ' THR . 37.5 mt -151.31 -156.55 0.72 Allowed 'General case' 0 C--N 1.352 0.684 0 N-CA-C 106.819 -1.549 . . . . 74.140000000000001 106.819 -177.713 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' ALA . . . . . . . . . . . . . . . -123.18 102.6 8.04 Favored 'General case' 0 C--N 1.362 1.13 0 CA-C-N 120.776 1.625 . . . . 75.140000000000001 111.066 -176.904 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' GLY . . . . . . . . . . . . . . . -151.77 -34.71 0.03 OUTLIER Glycine 0 C--N 1.357 1.737 0 CA-C-O 117.177 -1.901 . . . . 61.229999999999997 116.915 179.236 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' GLU . . . . . . . . . . . . . 7.2 pt-20 -117.46 178.05 4.52 Favored 'General case' 0 CA--C 1.506 -0.712 0 N-CA-C 105.792 -1.929 . . . . 63.109999999999999 105.792 177.774 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' GLU . . . . . . . . . . . . . 12.3 tt0 -61.18 -30.9 70.69 Favored 'General case' 0 C--O 1.22 -0.482 0 CA-C-O 117.662 -1.161 . . . . 72.25 111.415 179.48 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' MET . . . . . . . . . . . . . 20.9 mmt -110.33 58.51 0.61 Allowed 'General case' 0 C--N 1.359 0.991 0 CA-C-N 119.647 1.112 . . . . 73.349999999999994 113.021 -176.14 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . 65.97 106.53 0.01 OUTLIER Glycine 0 C--N 1.353 1.528 0 CA-C-O 117.213 -1.881 . . . . 73.540000000000006 109.986 178.063 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' GLY . . . . . 0.459 ' O ' ' N ' ' A' ' 4' ' ' LEU . . . -102.68 -174.78 26.98 Favored Glycine 0 CA--C 1.489 -1.593 0 CA-C-O 116.138 -2.479 . . . . 73.540000000000006 112.368 -172.376 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' ILE . . . . . . . . . . . . . 9.4 tt -96.99 22.77 0.99 Allowed 'Isoleucine or valine' 0 C--N 1.355 0.846 0 CA-C-N 120.256 2.028 . . . . 64.150000000000006 111.192 175.79 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' THR . . . . . . . . . . . . . 5.3 p -124.32 125.77 44.9 Favored 'General case' 0 C--N 1.359 0.981 0 CA-C-N 120.888 1.676 . . . . 74.439999999999998 111.153 -175.259 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' THR . . . . . 0.626 HG23 HD22 ' A' ' 4' ' ' LEU . 0.2 OUTLIER . . . . . 0 C--N 1.33 -0.257 0 CA-C-N 116.217 -0.447 . . . . 73.140000000000001 111.141 -179.989 . . . . . . . . 2 2 . 1 stop_ save_